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1. Introduction 
Protection against severe clinical disease or mortality after an infection with highly virulent 
viruses is achieved by vaccination. Different approaches were used after the first successful 
vaccination trial by Dr. Jenner against smallpox virus (Rusnock, 2016), not only for human 
diseases, but also for pathogens of livestock.  
In the last decades, the impact of several highly virulent pathogens on livestock could be 
reduced significantly by vaccination, like Rabies (Mähl et al., 2014), Classical swine fever  
(Postel et al., 2017), Foot-and-Mouth Disease (Paton et al., 2009) and others. However, when 
new viruses emerge in a naïve, unprotected host population, the risk for this population is very 
high, as seen with Rabbit hemorrhagic disease virus (RHDV) in European rabbits. 
Detected for the first time in 1984 in China in rabbits imported from Germany the virus 
spread within 10 years rapidly and is now endemic in more than 40 countries worldwide 
where wild populations of European rabbits exist. Moreover, since its emergence several 
RHDV variants appeared (Abrantes et al., 2012). A genetically more different variant was 
found in 2010 in France, named RHDV-2 (Le Gall-Reculé et al., 2013).  
RHDV is a highly contagious viral disease causing a severe hepatitis combined with high 
mortality in European rabbits. It was estimated that in Europe several 100 million rabbits in 
households and an unknown number of wild rabbits died. In Australia and New Zealand, 
where non-native populations of European rabbits exist, up to 95% of all rabbits died after 
initial introduction of RHDV as pest control agent (Abrantes et al., 2012).  
To prevent the fatal outcome of this infectious disease several attempts were made to develop 
a successful vaccine. However, due to the fact that RHDV cannot be cultivated in cell culture, 
mainly inactivated RHDV vaccines prepared from livers of infected rabbits are available with 
the ethical problem that for vaccine production animals have to die from RHDV infection to 
protect others from the same infection. 
In the present thesis the generation and optimization of a recombinant RHDV-2 vaccine, 
based on capsid protein VP60 expressed by recombinant baculoviruses, and the evaluation of 
its protective potential against RHDV-2 infection in rabbits is described and discussed.
2. Literature 
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2. Literature 
2.2.  Emergence, Prevalence and Importance of Rabbit Hemorrhagic Disease 
Rabbit hemorrhagic disease (RHD) is a highly contagious viral infection of domesticated and 
wild European rabbits (Oryctolagus cuniculus). The first outbreak occurred in spring 1984 
when a previously unknown disease killed Angora rabbits imported from Germany in the 
Jiangsu province of the People's Republic of China. Within 9 months several million rabbits 
died by this rabbit viral hemorrhagic disease (Liu et al., 1984; Xu and Chen, 1989; Xu, 1991). 
First, a picornavirus or a parvovirus were suggested to be the causative pathogen (Pu et al., 
1985; Gregg and House, 1989; Xu and Chen, 1989; Xu, 1991). In the late 1980’s/ early 
1990’s the aetiological agent was characterized as a Calicivirus (Granzow et al., 1989; 
Ohlinger et al., 1989; Ohlinger et al., 1990; Parra and Prieto, 1990; Meyers et al., 1991; 
Moussa et al., 1992) and the disease was named RHD caused by RHDV (Granzow et al., 
1996).  
The origin of RHDV is not fully understood. The pathogenic forms of this Calicivirus may 
have evolved from avirulent strains circulating asymptomatically in European rabbits 
(Capucci et al., 1996; Moss et al., 2002; Forrester et al., 2006, 2008; Strive et al., 2010). Moss 
et al. (2002) were able to prove that Caliciviruses were circulating in rabbits in Great Britain 
and most likely also in the rest of Europe at least 30 years before the first outbreak of RHDV 
in China emerged. Moreover, a common ancestor of Rabbit Calicivirus-like viruses (RCV) 
and RHDV circulating over 200 years ago was predicted, which mutated to the virulent 
RHDV strains that emerged in 1984 (Kerr et al., 2009). Another hypothesis postulates 
spillover infections of Caliciviruses found in small mammals close to wild rabbit populations 
(Merchán, et al., 2011; Abrantes et al., 2012; Le Gall-Reculé et al., 2013).  
RHDV does not seem to have evolved from European brown hare syndrome virus (EBHSV) 
(Nowotny et al., 1997), another Calicivirus which occurred for the first time in 1980 in 
Denmark and Sweden (Gavier-Widén and Mörner, 1991) and causes a disease in European 
brown hares similar to RHD in rabbits. This is indicated not only by the limited amino acid 
sequence homology of about 76% between classical RHDV and EBHSV-capsid protein VP60 
(Wirblich et al., 1994) but also by the fact that there is no cross-protection against RHDV in 
animals surviving an EBHSV infection (Lavazza et al., 1996).  
Soon after the epidemics in China and in Korea in 1984 (Liu et al., 1984; Park et al., 1987; 
Xu, 1991) the first outbreak of RHD in Europe was reported in Italy in 1986 (Cancelotti and 
Renzi, 1991). Within the next ten years RHDV became endemic in most European countries. 
Especially for the wild rabbit population on the Iberian Peninsula, where European rabbits 
2. Literature 
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originated, RHDV caused a severe reduction of the population (Argüello et al., 1988; 
Villafuerte et al., 1995; Delibes-Mateos et al., 2007, 2008; Abrantes et al., 2012).  
Already in 1988 RHDV was found in domestic rabbits in North Africa (Morisse et al., 1991). 
Also in 1988, it was introduced into Mexico, from where it was eradicated in 1992 most 
probably due to the absence of a susceptible wild rabbit population (Gregg et al., 1991). 
RHDV was first diagnosed in North America in 2000 followed by a limited number of 
outbreaks. Also in geographically distant regions, such as Cuba, Uruguay and Reunion Island, 
RHDV caused losses in domestic rabbits (Le Gall-Reculé et al., 2003; Farnós et al., 2007). 
The rapid dissemination of RHDV within one decade since the first detection, mainly due to 
the import of rabbits from already affected countries, resulted in the recent situation that 
RHDV is nowadays endemic in most parts of Europe, Asia, and parts of Africa (Cooke, 2002; 
Moss et al., 2002; Abrantes et al., 2012). 
In contrast to the unwanted introduction of RHDV in all other countries, in Australia, where 
the European rabbit is an important ‘pest species’ and a major threat to the endemic wildlife 
(Gibb and Williams, 1994; Fenner, 2010), the Czech RHDV-1 strain V351 was introduced as 
a biocontrol agent on Wardang Island in Spencer Gulf, South Australia in 1991 (Cooke, 
2002). In 1995, despite strict quarantine measures, RHDV escaped from the island (Cooke 
and Fenner, 2002) and spread all over southern Australia within two years (Mutze et al., 
1998). In these areas, RHDV caused an up to 95% reduction of the rabbit populations 
(Abrantes et al., 2012). 
In New Zealand, were it was initially decided not to follow the Australian example, RHDV 
was illegally introduced (as indicated by genetic analysis showing the similarity to the Czech 
V351 strain) with a comparable impact on the population of non-native European rabbits 
(Thompson and Clark, 1997; O’Keefe et. al., 1998). 
Another problem with RHDV was the genetic variability after emergence in 1984. Since then 
several variants have been isolated with virulence ranging from avirulent, inducing no 
mortality but at least partial protection, to highly virulent with up to 100% mortality after 
infection (Capucci et al., 1996, 1998; Le Gall-Reculé et al., 1998, 2003). In 2010, a RHDV 
was isolated in France with only 82,4% nucleotide identity of the capsid protein VP60 gene to 
all known RHDV strains and grouped into the new cluster RHDV-2. The previous strains 
were afterwards grouped into the RHDV-1 cluster (Le Gall-Reculé et al., 2013; see 2.3.4.). 
The morbidity and mortality induced by RHDV is with up to 100% extremely high in 
unvaccinated rabbits. Therefore, the disease has a dramatic direct effect on wild rabbit 
populations with up to 95% decline when first introduced. Since the majority of RHDV 
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infected rabbits die in their burrows underground, RHD is extremely hard to locate in the 
wild. RHD prevalence also varies depending on the season, breeding cycles and geographical 
location with some areas with high morbidity and mortality among its rabbit populations 
followed by calmer periods (Cooke, 2002; Mutze et al., 1998). Two intrinsic factors - 
maternal antibodies transmitted to the young as well as a not yet fully understood resistance of 
young rabbits - may be responsible for reoccurrence of RHDV outbreaks as some rabbits may 
develop immunity against RHDV strains, while others may endure persistent infections. 
However, the immunity is not maintained through the next generation, leaving open the 
possibility of further outbreaks in the population (Cooke et al., 2000; Marques et al., 2012). 
Indirectly, RHDV affects ecosystems in Europe, where wild rabbits are an important food 
source for certain endangered predators, such as Iberian lynx (Lynx pardinus) (Delibes-
Mateos et al., 2007, 2008; Anonymous, 2016). Moreover, used to control excessive numbers 
of wild, non-native European rabbits (Oryctolagus cuniculus) in Australia and New Zealand, 
it may also influence the endemic fauna positively by the subsequent reduction of predator 
populations which formerly hunted rabbits (Anonymous, 2016; Pedler et al., 2016).  
Finally, RHDV causes important economic losses in the rabbit meat and fur industry. Here, in 
the last two decades several 100 million rabbits died after RHDV infection (Abrantes et al., 
2012). These dramatic economical losses highlight the need for the development of vaccines 
against RHDV. 
 
2.3.  The Rabbit Hemorrhagic Disease Virus (RHDV) 
2.3.1. Classification 
First trials to identify the RHD causing viral pathogen were hampered because RHDV cannot 
be cultivated in cell culture. In the beginning the virus was suspected to be a picornavirus (An 
et al., 1988), a parvovirus (Gregg and House, 1989) or a parvo-like virus (Xu, 1991). In the 
early 1990s it was finally identified as a member of the Caliciviridae family (Ohlinger et al. 
1990; Parra and Prieto, 1990; Rodák et al., 1990; Meyers et al., 1991; Abrantes et al., 2012). 
Four genera in the Caliciviridae family are recognized by the International Committee on 
Taxonomy of Viruses (ICTV) at the moment: Lagovirus, Vesivirus, Norovirus and Sapovirus. 
Three more genera are not recognized by the ICTV yet, but are nominated as part of this 
family. These are: Nabovirus or Becovirus (Oliver et al., 2006) Recovirus (Farkas et al., 2008) 
and Valovirus (L’Homme et al., 2009). Caliciviruses cause different diseases like 
gastroenteritis (Norovirus, Sapovirus), hemorrhagic diseases (Lagovirus) and reproductive 
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failures, vesicular lesions and respiratory infections (Vesivirus). Several animal species and 
humans serve as hosts (Abrantes et al., 2012) (Fig. 1). 
 
Fig. 1. Overview over Calicivirus genera (with permission of N.J. Knowles, Pirbright Institute, UK) 
 
Currently, two virus species are assigned to the genus Lagovirus: RHDV and European brown 
hare syndrome virus (EBHSV). EBHSV was first detected in Sweden in the early 1980s 
(Gavier-Widén and Mörner, 1993). This virus is closely related to RHDV but represents a 
distinct species and only hares (Lepus europaeus and Lepus timidus) are susceptible to 
infection. Clinical symptoms, (histo-)pathological alterations, mortality rates, virion 
morphology and antigenicity are similar to RHDV, but there is no cross-species infection and 
cross-species protection (Capucci et al., 1991; Marcato et al., 1991; Chasey et al., 1992; Fuchs 
and Weissenböck, 1992; Wirblich et al., 1994; Lavazza et al., 1996; Abrantes et al., 2012). 
 
2.3.2. Genome organization and replication  
Caliciviruses are non-enveloped single stranded RNA viruses with a genome of positive 
polarity (Granzow et al., 1989). The genome consists of a genomic and subgenomic RNA 
(Meyers et al., 1991; Abrantes et al., 2012). In contrast to other Calicivirus genera, the  
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7437 nt genomic RNA of Lagoviruses encompasses 2 slightly overlapping ORFs, instead of 3 
ORFs as in other Calicivirus genera. ORF1 encodes a polyprotein, which consists of non-
structural proteins (p16, p23, p29, a helicase, RNA-dependent RNA polymerase, VPg and a 
protease) and the major structural capsid protein VP60 (Fig. 2).  
After translation, the polyprotein precursor is cleaved by the viral trypsin-like cysteine 
protease. The helicase and RNA-dependent RNA polymerase are important for viral 
replication, whereas the role of p16, p23 and p29 is not known yet. ORF2 encodes VP10, a 
minor structural protein. The subgenomic RNA is 2,2kb in size and translated into structural 
proteins VP10 and VP60 (Wirblich et al., 1996; Abrantes et al., 2012), the latter used for virus 
assembly. 
 
 
Fig. 2. Genomic organization of RHDV (Abrantes et al., 2012; modified)  
The RHDV genome consists of two slightly overlapping ORFs, ORF1 and ORF2. ORF1 encodes a polyprotein 
which is cleaved by the viral trypsin-like protease (arrows) into non-structural proteins (p16, p23, helicase, p29, 
VPg, protease and RdRp) and the major structural protein VP60. ORF2 encodes the minor structural protein 
VP10. Subgenomic RNA encoding both VP60 and VP10 can be found in the viral particle, too. Both RNA 
species are poly-adenylated at their 3’end with the covalently attached viral protein VPg at the 5’end. 
 
In contrast to other Caliciviruses, VP10 is not necessary for infectivity of RHDV but seems to 
induce apoptosis in host cells for virus release, downregulates VP60 expression and decreases 
the level of genome replication (Liu et al., 2008; Chen et al., 2009). Both, genomic and 
subgenomic RNA have a polyadenylated 3’ terminus. At the 5’ terminus a virus-genome 
linked protein (VPg) is attached (Wirblich et al., 1996; Abrantes et al., 2012) which may play 
a role in translation (Goodfellow et al., 2005; Wang et al., 2013a).  
The first step of viral entry in Calicivirus infections involves recognition of histo-blood group 
antigens (HBGAs) by the P-domain L1 loop of VP60 (see 2.3.3.) (Ruvoën-Clouet et al., 2000; 
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Chen et al., 2011; Wang et al., 2013b). After attachment and internalization into the cell, the 
genomic RNA becomes uncoated and is translated into a polyprotein precursor, which is then 
processed and cleaved by the viral trypsin-like cysteine protease into the non-structural 
proteins and VP60 (Fig. 3). The protease, helicase, RNA-dependent RNA polymerase and 
VPg form a replication complex which synthesizes either antigenomic RNA from genomic 
RNA or subgenomic RNA from antigenomic RNA.  
Antigenomic RNA is also used as template for genomic RNA which can be translated again 
into a polyprotein precursor or becomes packaged in new virus particles. The release mode is 
not fully known yet, but apoptosis seems to be involved (Rohayem et al., 2010; Abrantes et 
al., 2012). 
 
 
Fig. 3. The replication cycle of Caliciviruses (from Abrantes et al., 2012; modified) 
1: Attachment and internalization; 2: Uncoating of viral genome; 3: translation of genomic RNA into polyprotein 
precursor; 4: cleaving into non-structural proteins and VP60 by viral protease; 5: formation of replication 
complex by non-structural proteins; 6: synthesis of antigenomic RNA; 7: antigenomic RNA as template for 
genomic RNA; 8: antigenomic RNA as template for subgenomic RNA; 9: translation of subgenomic RNA into 
structural proteins VP60 and VP10; 10: assembly of structural proteins and packaging of genomic RNA in 
assembled viral protein core; 11: release of mature virions 
 
2.3.3. Viral particles, antigenicity and stability 
RHDV mature virions are spherical, non-enveloped, icosahedral particles of 32-40nm in 
diameter, whose capsid consists of 90 dimers of capsid protein VP60. These dimers form 32 
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cup shaped depressions on the surface which are arranged in a T = 3 icosahedral symmetry 
(hence the family name Caliciviridae as calix means cup in Latin) (Granzow et al., 1989; 
Valícek et al., 1990; Thouvenin et al., 1997; Luque et al., 2012). Each VP60 monomer 
consists of a shell (S) domain and a protruding (P) domain. The S-domain is buried and 
includes the N-terminus. The P-domain is protruding on the surface and encompasses the C-
terminus. Both are connected by a hinge domain. The P-domain (Fig. 4) is subdivided into 
two subdomains: P1 (stem of arch) and P2 (top of arch) (Prasad et al., 1994; Capucci et al., 
1995; Bárcena et al., 2004; Hu et al., 2010; Abrantes et al., 2012). 
 
 
Fig. 4. Crystal structure of RHDV-VP60 P-domain (from Wang et al., 2013b; modified)  
Ribbon representation of the crystal structure of the RHDV-VP60 P-domain. P1 (green) and P2 (pink) sub-
domains are indicated and colored according to their secondary structure elements.  
 
The P2-subdomain is located at the most exposed region of the capsid. The Loop L1 
contributes to host interaction and contains one of the main neutralizing epitopes (Wang et al., 
2013b). Therefore and due to selection pressure resulting from recognition by host antibodies, 
this region displays the greatest genetic and antigenic variation (Capucci et al., 1995; 
Martínez-Torrecuadrada et al., 1998; Bárcena et al., 2004; Abrantes et al., 2012) and tends to 
evolve faster to escape from the selective pressure (Esteves et al., 2008; Kinnear and Linde, 
2010).  
The virus itself is very resistant and remains infectious in the environment for a long time. 
When exposed to normal environmental conditions it can last up to 10 days in dried states. 
While in animal carcasses it can even last for 3 months (Henning et al., 2005). Durability is 
dependent on weather conditions. According to OIE, RHDV is infectious in carcasses for up 
to 20 days at 22°C and in dried states on clothes for at least 3 months at room temperature 
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under experimental conditions. It also survives in organ suspensions > 7 months at 4°C or at 
least 2 days at 60°C in organ suspensions and dried states. Unprotected virus is resistant to 
temperatures of 50°C for 1 hour and also to freeze-thaw cycles. RHDV is stable at pH 4,5-
10,5, but can also survive pH of 3,0. It can be inactivated for example by pH >12,0, formalin 
(1-2%), sodium hydroxide (1%), 0,5% sodium hypochlorite or substituted phenolics (Smíd et 
al., 1991; OIE, Technical Disease Card, 2009; Anonymous, 2016). 
 
2.3.4. Appearance of RHDV variants 
The existence of three main RHDV groups is indicated by genetic and antigenic comparison 
and epidemiological data (OIE, Terrestrial Manual, 2016):  
a) “classical RHDV” (RHDV-1): Virus of genogroups G1–G5, first reported in 1984 in 
China (Liu et al., 1984) and since then spread to other areas in Asia, Africa, Americas, 
Europe and Oceania. Nowadays these viruses are endemic where European rabbits live 
naturally or are domesticated. 
b)  RHDVa/G6: Identified in Europe in 1996 (Capucci et al., 1998; Schirrmeier et al., 1999) 
and currently detected also in Oceania, Asia and Americas. Nucleotide identity of VP60 
between classical RHDV and RHDVa was found to be about 93% (Capucci et al., 1998). 
c) RHDV-2: Emerged in France in 2010 in wild and farmed vaccinated rabbits (Dalton et al., 
2012; Le Gall-Reculé et al., 2011a, 2013), then rapidly spread in Europe, the 
Mediterranean basin (Malta and Tunisia), and also in Australia in 2015. The nucleotide 
identity of VP60 between RHDV-1/RHDVa and RHDV-2 was determined to be 82,4% 
and between EBHSV and RHDV-2 70,4%, confirming that it is indeed a new RHDV 
variant. 
 
The G1-G6 RHDV genogroups of the serotype RHDV-1 do not cluster by regional but by 
temporal appearance or year of emergence. Originally groups G1-G3 were identified. Later 
G1 and G2 disappeared in many regions. G3 turned into G4 and new clusters G5 and G6 
emerged with subtype G6 being a distinct antigenic variant (RHDVa) (Le Gall-Reculé et al., 
1998, 2003).  
RHDV-2 originated of unknown origin and seems not to derive from classical RHDV (Le 
Gall-Reculé et al., 2013). It is classified as a second RHDV serotype (Fig. 5). 
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Fig. 5. Phylogenetic tree derived for RHDV-VP60 gene nucleotide sequences of 127 rabbit lagoviruses 
including 7 RHDV-2 (from Le Gall-Reculé et al., 2013; modified) 
The tree was obtained using the Neighbor-Joining method and was drawn to a scale of nucleotide substitutions 
per site. The percentages greater than 70% of replicate trees in which the associated taxa clustered together in the 
bootstrap test (1000 replicates) are given in italics before each major branch node. The European brown hare 
syndrome virus (EBHSV) strain GD (Z69620) was used as an out-group to root the tree. The names of some 
representative strains from different countries are shown. For RHDV, the genetic groups G1 to G6 according to 
Le Gall-Reculé et al., 2003 and clade 1 to 4, or A to D, according to Kerr et al., 2009 or to Kinnear et al., 2010, 
respectively, are annotated. 
 
After RHDV-2 discovery in north western France in summer of 2010 and its detection in 
samples collected in April 2010 from a rabbitry in western France, further cases appeared in 
southern France in February 2011 and in north eastern Italy in summer 2011. The virus was 
not only found in rabbitries but in wild populations as well (Le Gall-Reculé et al., 2013). 
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Liver samples of rabbits and also cape hares in Sardinia collected between April and October 
2011 (Puggioni et al., 2013) were also tested positive for RHDV-2. In Spain RHDV-2 was 
confirmed after testing of liver samples collected in September 2011 (Dalton et al., 2012). In 
November 2012 RHDV-2 was found in livers of both of the European rabbit subspecies in 
Portugal (Abrantes et al., 2013). In 2014 RHDV-2 cases in Scotland and Wales and in 2014 
England were confirmed (Baily et al., 2014; Westcott et al., 2014). Westcott and Choudhury 
(2015) even traced back the occurrence of RHDV-2 in Great Britain to 2010. In late 2014 
RHDV-2 was detected on the Azores islands and therefore for the first time outside of 
continental Europe (Duarte et al., 2015a, b). In 2015 first cases were described in Australia 
with a strain closely related to another one that is currently present in Portugal and the Azores 
islands (Hall et al., 2015). To date, RHDV-2 continues to spread and seems to replace the 
classical strains of RHDV in some regions, e.g. in the Iberian Peninsula (Dalton et al., 2014), 
Portugal (Lopes et al., 2014a) and France (Le Gall-Reculé et al., 2013). 
First cases in Germany were proved in samples from a rabbitry in North Rhine Westphalia in 
RHDV-1 vaccinated rabbits in 2013 (Fig. 6). 
 
 
Fig. 6. Overview of classical RHDV (RHDV-1) and RHDV-2 cases in Germany in 2016 
Only rabbits examined at FLI- Insel Riems are depicted. (Overview by N. Neumann, kindly provided by  
Dr. P. König, FLI- Insel Riems) 
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In March 2014, it was detected in Rhineland Palatinate and in August outbreaks occurred 
already in middle and eastern parts of Germany (FLI- Insel Riems). By the end of 2016, 
RHDV-2 had spread across Germany and most of the liver samples of deceased rabbits that 
were examined in 2016 at FLI- Insel Riems were tested positive for RHDV-2 (Fig. 6). 
In contrast to full cross-protection between RHDV-1 and RHDVa (Capucci et al., 1998; 
Schirrmeier et al., 1999), only a partial cross-protection between RHDV-1/RHDVa and 
RHDV-2 (Le Gall-Reculé et al., 2013) was found in infection trials.  
In addition to the pathogenic variants of classical RHDV, RHDVa and RHDV-2, there are 
several strains of non-pathogenic rabbit Caliciviruses circulating in the wild rabbit population. 
An Italian non-pathogenic strain isolated in 1996 was called Rabbit Calicivirus (RCV) and 
was the first evidence of non-pathogenic Caliciviruses in rabbits (Capucci et al., 1996). For 
non-pathogenic Caliciviruses the new term rabbit Calicivirus-like viruses (RCV-like) was 
introduced by Kerr et al. (2009). Together with isolates like Ashington (Moss et al., 2002) or 
06-11 (Le Gall-Reculé et al., 2011b), the Italian RCV belongs to a new group of rabbit 
Caliciviruses which is distinct from the RHDV-1/RHDVa group (Strive et al., 2009). Another 
important non-pathogenic strain is the Australian strain RCV-A1 (Strive et al., 2010), which 
is genetically distinct also from other RCVs and forms a separate group (Strive et al., 2009) 
(Fig. 5). Non-lethality has been confirmed for the Italian RCV and RCV-A1, whereas it is 
only assumed for other non-pathogenic Caliciviruses (Le Gall-Reculé et al., 2011b). These 
non-pathogenic RHDV strains are transmitted by the fecal-oral route and have a different 
organ tropism. They do not replicate in the liver but in the intestine of rabbits. However, the 
Italian RCV was also found in liver and spleen in a few rabbits in small amounts (Capucci et 
al., 1996) and the RCV-A1 virus was detected in the liver of one and the spleen of two 
animals after infection (Strive et al., 2009). Rabbits infected with RCV do not display any 
RHD like symptoms. Importantly, RCV is able to induce antibody titers in rabbits which can 
lead to complete cross-protection against classical RHDV infection. However, these RCV 
cannot infect hares and there is no cross-protection between RCV and EBHSV (Capucci et al., 
1996). RCV-A1 induces only a partial cross-protection against classical RHDV (Strive et al., 
2009). The amino acid identity of VP60 of the Italian RCV to the classical RHDV is 91,5%. 
The average nucleotide identity between RCV-A1 and classical RHDV is 78%, and between 
RCV-A1 and EBHSV 71% at the genomic level.  
Some non-pathogenic strains, however, do not induce any protection against classical RHDV, 
for example the strain 06-11 (Le Gall-Reculé et al., 2011b), although the nucleotide identity 
of VP60 between RCV strain 06-11 and classical RHDV is 83% (Le Gall-Reculé et al., 
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2011b). High antibody levels for non-pathogenic, non-protective strains were detected in 
rabbit sera but those animals did not survive a classical RHDV infection (Marchandeau et al., 
2005; Abrantes et al., 2012).  
The pathogenic forms seem to have evolved from non-pathogenic Caliciviruses (Capucci et 
al., 1996; Moss et al., 2002; Forrester et al., 2006; Strive et al., 2010). Moss et al. (2002) 
demonstrated that rabbit Caliciviruses were circulating in Great Britain and most likely also in 
the rest of Europe at least 30 years before the first outbreak of RHDV in China. There seems 
to be a common ancestor of RCV-like viruses and RHDV over 200 years ago and it is 
suggested that virulent RHDV emerged in the early 20th century, as the most plausible 
explanation for the sudden occurrence of pathogenic RHDV (Kerr et al., 2009). Another 
hypothesis for the occurrence of pathogenic rabbit Caliciviruses is a species jump as RHDV 
was found in small mammals (Mus spretus, Apodemus sylvaticus) close to wild rabbit 
populations (Merchán et al., 2011; Abrantes et al., 2012; Le Gall-Reculé et al., 2013). There is 
still a lot unknown regarding the importance of non-pathogenic strains for the variation of 
RHDV (Marchandeau et al., 2005). A current example of ongoing mutual influence of 
different RHDV strains regarding protection against RHDV can be observed in Australia. The 
non-pathogenic Australian strain RCV-A1 induces partial cross-protection against the 
pathogenic Czech RHDV-1 strain V351 that was released in Australia in 1996 in order to 
eradicate rabbit populations therefore interfering with success of this project. However, the 
Korean RHDVa strain named K5 is in turn able to break the protection against RHDV-1 build 
by RCV-A1 which makes it a useful tool for further decimation of rabbits 
(www.pestsmart.org.au).  
 
2.4. Rabbit Hemorrhagic Disease (RHD) 
2.4.1. Susceptibility and transmission 
Wild and domestic European rabbits (Oryctolagus cuniculus) from the age of 9 weeks are 
fully susceptible to classical RHDV and develop severe clinical signs within 20–48h after 
infection (Xu and Chen, 1989). Other lagomorphs like European brown hares (Lepus 
europaeus), cottontails (Sylvilagus floridanus) (Lavazza et al., 2015), black-tailed jackrabbits 
(Lepus californicus) and volcano rabbits (Romerolagus diazzi) seem not to be susceptible to 
classical RHDV (Merchán et al., 2011). However, in dead wild Iberian hares (Lepus 
granatensis) collected during an outbreak in the 1990s classical RHDV-RNA was recently 
detected (Lopes et al., 2014b). In some rodents like wood mice (Apodemus sylvaticus) and 
Algerian mice (Mus spretus), collected in the vicinity of warrens that contained RHDV 
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infected wild rabbits, viral RNA was detected in internal organs (Merchán et al., 2011). No 
evidence of RHDV replication was found in any other mammals tested so far, including rabbit 
predators, although some of those animals did seroconvert (Leighton et al., 1995; Parkes et 
al., 2004; Merchán et al., 2011; Anonymous, 2016).  
The new virus variant RHDV-2 seems to have a broader host range as this virus infects not 
only European rabbits but also Cape hares (Lepus capensis var. mediterraneus) and Italian 
hares (Lepus corsicanus) (Le Gall-Reculé et al., 2013; Puggioni et al., 2013; Camarda et al., 
2014). While initially no evidence was found of infected European brown hares (Puggioni et 
al., 2013) more and more cases were detected recently (Velarde et al., 2016; Hall et al., 2017; 
FLI- Insel Riems), suggesting another species jump. A possible explanation for overcoming 
species barriers could be the genetic variation of the capsid protein VP60 which alters the 
binding to histo-blood group antigens that are discussed to be important entry ways for the 
virus (Le Gall-Reculé et al., 2013; Puggioni et al., 2013). HBGAs are found in the upper 
respiratory tract and intestines of rabbits, and RHDV is able to bind to these receptors. 
Different types of HBGAs were found in rabbits and different virus strains show variable 
affinity to the different HBGAs, suggesting that there is a constant adaptation of the host as 
well as the virus. By changing those attachment factors, e.g. through mutations, individual 
animals or even complete species can become more or less susceptible to the virus (Nyström 
et al., 2011; Le Pendu et al., 2014; Velarde et al., 2016). 
The virus is transmitted mainly orally, but also by the nasal, conjunctival or parenteral route 
by direct contact with live or dead animals, or indirectly by contaminated equipment, food, 
water and clothes as well as insects (Xu and Chen, 1989; Ohlinger et al., 1993; Asgari et al., 
1998). Infectious virus can persist in flies for up to 9 days and already a few virus particles 
can infect rabbits via the conjunctival route. Virus can be deposited via fly spots (oral or anal 
excretions of flies) on vegetation where it is then consumed by rabbits (Asgari et al., 1998). 
RHDV is supposed to be transmitted with most secretions and excretions, e.g. urine, feces and 
respiratory secretions from infected animals and can be shed by surviving animals for at least 
one month after their recovery. Viral RNA has been detected in rabbits for at least 15 weeks 
after infection (Gall et al., 2007; Anonymous, 2016). RHDV remains infectious in carcasses 
for long periods of time and even rabbit fur can contain infectious virus (Xu and Chen, 1989; 
Xu 1991; McColl et al., 2002; Henning et al., 2005). 
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2.4.2. Clinical course and pathology 
The incubation period of RHD usually ranges between 20-48h with rabbits dying in most 
cases within 12-36h after onset of fever, which can rise over 40°C. Four different clinical 
courses are distinguished: peracute, acute, subacute and chronic (Xu and Chen, 1989; 
Abrantes et al., 2012). In the peracute form, animals die suddenly without any clinical signs. 
Sometimes foamy hemorrhagic nasal discharge and vaginal hemorrhages are seen. High fever, 
anorexia, apathy, congestion of the palpebral conjunctiva and death within 48-72h post 
infection are characteristics of the acute form. Also neurological symptoms like opisthotonus, 
excitement, paralysis and ataxia were observed. In the moribund stage tracheitis, dyspnea and 
cyanosis as well as foamy and bloody nasal discharge, lacrimation, ocular hemorrhages and 
epistaxis can be seen. In subacute forms of the disease rabbits display similar, but milder 
clinical symptoms and most animals survive. Characteristically, rabbits surviving the RHDV 
infections develop high RHDV specific antibody titers which confer a long-lasting protection 
from re-infection (Patton, 1989). A low percentage of RHDV infected rabbits develop a 
chronic form of the disease with severe and generalized jaundice, anorexia and lethargy 
(Capucci et al., 1991). Of these chronically infected animals some die within 2 weeks post 
infection (Lavazza and Capucci, 2008), but those that survive develop high RHDV specific 
antibody titers (Capucci et al., 1991; Abrantes et al., 2012). For RHDV-2 similar symptoms, 
but more prolonged courses of the disease are described (Le Gall-Reculé et. al., 2013). 
Mortality rates range from 5-60% (Velarde et al., 2016) in contrast to mortality rates between 
70-100% of RHDV-1. 
Main (histo-)pathological alterations are seen in the liver, lungs, spleen, kidneys and serosal 
surfaces. In the liver an acute necrotizing hepatitis is seen due to apoptosis of liver cells 
induced by the virus (Alonso et al., 1998). It usually appears swollen, yellow/grey to-red, 
fragile and reticulated. Disseminated hepatic necrosis is seen with fatty degeneration. 
Petechial hemorrhages are also seen in the mucosa of gall bladder. Kidneys often are 
enlarged, congested with hyperemia or petechial hemorrhages, (glomerulo-)nephritis can be 
found in some cases. Additionally, hyaline thrombi and hyaline degeneration are seen in 
glomerular capillaries. Splenomegaly due to congestion as well as depletion of lymphocytes 
due to necrosis as characterized by karryorhexis and karyolysis of the lymphocytes and 
reticuloendothelial cells is found. In the lungs hemorrhages, hyperemia and alveolar edema 
are found with presence of macrophages and neutrophils in the airway and alveoli, while in 
the trachea bloody foam and hyperemia of the mucous membrane are seen. Hemorrhages and 
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congestions can also be observed in other organs, like brain, thymus and heart (Xu and Chen, 
1989; Marcato et al., 1991; Park et al., 1995; Abrantes et al., 2012).  
 
2.4.3. Pathogenesis 
After entry, the virus presumably attaches to HBGA receptors in the upper respiratory and 
digestive tract (Nyström et al., 2011). The main target cells are hepatocytes. In animals older 
than 9 weeks, virus antigen was found in the liver already from 12h pi to 24h pi, mainly in 
periportal areas. During a massive rise of antigen amounts over the next 24h, symptoms of 
apoptosis begin (Prieto et al., 2000).  
Already in an early infection stage, viral antigen is found in neutrophils surrounding infected 
hepatocytes. Antigen is also detected in Kupffer cells, circulating monocytes, lymphocytes 
and macrophages in the red and white pulp of the spleen, lung macrophages, glomerular 
mesangial cells of the kidneys and lymphocytes in the thymus and lymph nodes (Ramiro-
Ibáñez et al., 1999; Prieto et al., 2000; Kimura et al., 2001). However, it remains unclear 
whether replication takes place in these cells (Prieto et al., 2000) but the possibility was 
discussed in another study (Kimura et al., 2001). It is suggested, that macrophages and 
circulating monocytes play an important role in virus dissemination in the body (Ramiro-
Ibáñez et al., 1999; Kimura et al., 2001). 
In the end, animals die from acute liver failure and disseminated intravascular coagulation 
(DIC) which leads to total organ failure (Ueda et al., 1992; Park et al., 1995). Liver failure 
results as virus induces apoptosis in hepatocytes (Vallejo et al., 2014; Trzeciak-Ryczek et al., 
2015). After apoptosis there is little to no regeneration of liver tissue which leads to loss of 
function and an increase of liver enzymes can be seen in the blood (AST, ALT, bilirubin,  
γ-GT, AP, LDH) (Ferreira et al., 2006; Trzeciak-Ryczek et al., 2015). Bilirubin rises already 
18h pi, AST and ALT from 24-36h. AST values of > 6000 IU/l result in death in the next 6h. 
Hypoglycemia, probably due to damage of mitochondria during apoptosis, is also an 
important finding which is assumed to be responsible for seizures before death (Ferreira et al., 
2006). In the terminal phase of the disease a decrease of thrombocytes, leukocytes, fibrinogen, 
antithrombin, coagulation factors V, VII, X and an increase of fibrin is observed. Additionally 
a prolonged activated partial thromboplastin time and prothrombin time can be measured 
(Plassiart et al., 1992; Ueda et al., 1992). Severe leukopenia is explained by cytotoxic effects 
of the virus to white blood cells, the migration of cells to the liver and reduced production of 
white blood cells due to a cytopathic effect of the virus to the bone marrow (Ferreira et al., 
2006). DIC means a wide spread activation of the coagulation system in the body. The 
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internal and external coagulation pathway is activated which leads to an increased coagulation 
rate in the whole body. This results in formation of blood clots in small blood vessels and 
therefore organ failure and consequently in the consumption of thrombocytes and coagulation 
factors which in turn leads to heavy bleeding. DIC can be caused by many reasons, for 
example through trauma, bacterial or viral infections, intoxication etc. In RHDV-infected 
animals, DIC was already observed between 24h and 30h after infection. Its pathogenesis 
remains unclear (Trzeciak-Ryczek et al., 2015) and there have been many suppositions made 
about it. It is concluded that DIC appears together with liver necrosis, because rabbits with 
mild hepatitis do not develop DIC, whereas rabbits with heavy acute necrotizing hepatitis do 
(Plassiart et al., 1992). DIC seems to be caused by liver dysfunction, which leads to activation 
of the external coagulation pathway by tissue thromboplastin (external pathway) or activation 
of coagulation factors in serum (internal pathway) due to endothelium damage, to reduced 
formation of coagulation factors in the liver, a reduced clearing of coagulation factors because 
of liver and spleen damage and a reduction of coagulation inhibitors leading to increased 
coagulation (Plassiart et al., 1992; Ueda et al., 1992; Park et al., 1997). It is unknown, whether 
the endothelium is damaged by the virus itself, by antigen-antibody complexes or because of 
aggregation of infected monocytes at the endothelium (Park et al., 1997; Ramiro-Ibáñez et al., 
1999). 
 
2.4.4. Age dependent resistance 
Rabbits younger than 9 weeks display a not yet fully understood resistance against a RHDV 
infection which seems to be independent of maternal antibodies, but involves the innate 
immune system. They do not exhibit any clinical symptoms (Mikami et al., 1999; Marques et 
al., 2012, 2014). After infection at an early age, rabbits achieve a long-term resistance like 
surviving adult rabbits (Ferreira et al., 2005; Marques et al., 2012). In 2 week old rabbits, 
aggregates of macrophages, lymphocytes and heterophils in the liver increase from 24h pi. 
Near these aggregates necrotic hepatocytes are detected. Similar findings are seen in 4 week 
old rabbits but with more severity suggesting that 4 week old rabbits become already more 
susceptible than younger animals. RHDV-antigen is only found in hepatocytes and 
macrophages in the liver in these young rabbits, and in contrast to adult rabbits only a few are 
infected (Mikami et al., 1999). Also, the number of thrombocytes and coagulation factors do 
not change and liver enzymes ALT and AST increase only slightly (Ferreira et al., 2004). 
From 24h pi large numbers of heterophils are found in the liver of 4 week old rabbits whereas 
from 48h pi mostly B- and T-cell lymphocytes as well as liver macrophages are detected with 
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most hepatocytes being intact. At that time of the infection in fully susceptible animals, large 
amounts of heterophils and damaged hepatocytes are usually found (Ferreira et al., 2005; 
Marques et al., 2012). While adult rabbits display leukopenia with severe decrease not only of 
heterophils but also of lymphocytes in the final stage of the disease, young rabbits show only 
a transient decrease of heterophils (Ferreira et al., 2004, 2006). The resistance of young 
animals seems to be based on innate immune mechanisms in early immune response with 
activation of pro- and anti-inflammatory cytokines and IFNα (Ferreira et al., 2005; Marques et 
al., 2012). When immuno-suppressed, young rabbits infected with RHDV show the same 
clinical symptoms and pathological alterations as adult rabbits as well as an increase of 
cytokines and heterophils in the liver (Marques et al., 2014). With increasing age rabbits 
become more susceptible to a RHDV-1/RHDVa infection. The reasons for the increasing 
susceptibility are still unknown. It could be connected to a change in molecular structures on 
the surface of hepatocytes or changes in HBGA patterns which are also made responsible for 
differences in susceptibility of different species as was mentioned earlier (Ferreira et al., 
2005; Nyström et al., 2011; Abrantes et al., 2012). The new variant RHDV-2 infects and kills 
young rabbits from the age of 4 weeks, sometimes even younger (Dalton et al., 2012). The 
basis for this early susceptibility to this virus variant is also still unknown.  
 
2.5. Control of Rabbit Hemorrhagic Disease 
2.5.1. Treatment  
No treatment is available to cure infected rabbits once clinical symptoms appear. A 
metaphylactic passive immunization is useful only for animals with subclinical or no clinical 
signs to gain protection for a short time (Abrantes et al., 2012).  
 
2.5.2. Protection by sanitation and hygiene management 
For control of RHDV a proper hygiene management and vaccination are the most important 
tools. To limit distribution and prevent disease, especially in the rabbit industry, biosecurity 
measures such as sanitation, disinfection and quarantine are highly recommended. These 
measures are even more important in countries with circulating RHDV in wild rabbits where 
eradication cannot be achieved, while RHDV-free countries could place restrictions on 
importation of rabbits and rabbit products. A strict hygiene management can help to prevent 
spreading of the virus among the animals. Before integrating new animals in consisting 
groups, quarantine is recommended. Correct hygiene management of RHDV outbreaks is 
dependent on the epidemiological situation of the region in which they occur. In order to 
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determine the right management measure, viral evolution in the field should be monitored to 
detect new genetic and antigenic variants early (Argüello- Villares, 1991; Abrantes et al., 
2012; Le Gall-Reculé et al., 2013; Anonymous, 2016).  
 
2.5.3. Protection by vaccination 
Vaccines are supposed to protect organisms against diseases by stimulation of a specific anti-
pathogen immune response (Aoshi et al., 2011). There are two principle forms of vaccination: 
passive and active. For passive immunization pathogen-specific, neutralizing antibodies 
(immunoglobulin preparations from animals of the same species) are applied to provide a 
“lent” immunity. This form is mainly used as metaphylactic treatment when a naїve host is 
infected by pathogens causing severe diseases like rabies (Both et al., 2012). 
Active immunization is achieved by vaccines composed of either attenuated live or 
inactivated pathogens. Conventional live attenuated vaccines contain former virulent agents 
that are attenuated in vitro either by a mutagenic agent or by different culture conditions or 
they contain non-pathogenic field strains. Live vaccines induce a long-lasting immune 
response by mimicking a natural infection. The problem with attenuated vaccines is the 
possibility of reversion to virulence by passaging in the host.  
Conventional killed vaccines contain inactivated pathogens or only immunogenic parts of 
them. The induced immune response is usually short-lived. To maintain a protective immune 
status, multiple doses and booster immunizations are frequently necessary. However, the 
advantage of these vaccines is that the antigen cannot replicate or reverse to virulence. 
Additionally, they can be stored easily in a freeze-dried state and refrigeration like for live 
vaccines is not necessary (Babiuk, 2002).  
 
2.5.3.1. Conventional vaccines against RHDV 
Vaccines against the classical variants RHDV/RHDVa are usually made of liver material of 
infected rabbits followed by chemical inactivation of the virus (Argüello-Villares, 1991; Smíd 
et al., 1991). An exception is the recombinant vaccine “Nobivac Myxo-RHD” (Intervet 
International BV, Netherlands) which contains a myxoma virus vector that expresses  
RHDV-1-VP60. Examples of liver-derived vaccines against RHDV licensed in Germany are 
shown in table 1. 
In September 2016, the first liver-derived vaccine against the new variant RHDV-2 was 
introduced into the European market (Eravac, Laboratorios Hipra S.A., E) followed by a 
second in March 2017 (Filavac VHD K C+V, FILAVIE, F Roussay) which covers RHDV-1 
2. Literature 
 
20 
 
and RHDV-2. Further liver-derived RHDV-2 vaccines are available with only national 
authorization in Spain (Novarvilap, Ovejero Laboratorio; Cunipravac RHD variant, Hipra, 
veterinary faculty Utrecht) (StIKoVet, FLI, state 28.06.2016 + 08.05.2017). 
The RHDV-1 vaccine “CUNIVAK RHD” provides an early long-lasting protection against 
RHDV-1. Moreover, a partial cross-protection against RHDV-2 was seen in rabbits after 
prime-boost vaccination 7 days after a second vaccination. This cross-protection lasts for 3 
months as well as for 6 months as 89,5% and 83,3% of prime-boost vaccinated rabbits 
survived a challenge with RHDV-2 (Dr. H. Schirrmeier, FLI- Insel Riems, personal 
communication; Dr. M. Müller, IDT, personal communication). 
 
Tab. 1. Overview of liver-derived vaccines against RHDV licensed in Germany (PEI, state 12.07.2017) 
vaccine containing virus strains manufacturer 
date of  
accession 
accession 
number 
Lapimed  
RHD 
classical RHDV strain AG88,  
inactivated 
Merial GmbH 08.04.1995 499a/91 
Dercunimix 
myxoma virus strain SG3, attenuated 
classical RHDV strain AG88, inactivated 
Merial GmbH 20.12.2001 PEI.V.01945.01.1 
RIKA-  
VACC  
RHD 
classical RHDV strain  
Eisenhüttenstadt, inactivated 
Ecuphar AG 04.09.2003 200a/91 
CUNIVAK 
RHD 
classical RHDV strain 
Eisenhüttenstadt, inactivated 
IDT Biologika  
GmbH 
11.05.2004 206a/92 
RIKA- 
VACC Duo 
myxoma virus strain CAMP V-219, 
attenuated 
classical RHDV strain CAMP V-351, 
inactivated 
Ecuphar NV 12.06.2008 PEI.V.03071.01.1 
CUNIVAK 
COMBO 
myxoma virus strain CAMP V-219, 
attenuated 
classical RHDV strain CAMP V-351, 
inactivated 
IDT Biologika  
GmbH 
05.08.2009 PEI.V.07962.01.1 
Eravac RHDV-2 strain V-1037, inactivated 
Laboratorios  
Hipra S.A., E 
26.09.2016 EU/2/16/199 
Filavac  
VHD  
K C+V 
RHDV-1 strain IM.507 SC.2011, 
inactivated 
RHDV-2 strain LP.SV.2012,  
inactivated 
FILAVIE, F  
Roussay 
13.03.2017 PEI.V.11900.01.1 
 
2.5.3.2. Recombinant vaccines  
There is a growing interest in the use of molecular methods to obtain novel safe and efficient 
vaccines. The goal is to avoid the risks associated with live vaccines but to maintain the 
efficient induction of an immune response by a biologically active agent that can replicate in 
the host. Specific genes can be deleted, which results in reduced risks of reversion. This 
concept is used in so called marker vaccines that also allow differentiation between organisms 
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infected with wild type or vaccine virus. Another possibility is to use modified viruses as 
vectors for other pathogens, therefore allowing immunization against more than one pathogen 
(Babiuk, 2002). For RHDV this approach was used for the recombinant vaccine “Nobivac 
Myxo-RHD” (Intervet International BV, Netherlands, source PEI, state 12.07.2017) in which 
a myxoma virus vector expresses RHDV-1-VP60 and induces protection against both 
myxomatosis and classical RHDV.  
Another type of genetically engineered vaccines are sub-unit vaccines. They contain single 
proteins or peptides which are derived from infectious virus material or produced in 
recombinant expression vector systems (Babiuk, 2002). Single proteins have the disadvantage 
of being less immunogenic than vaccines containing the whole virus particle, therefore being 
more expensive in manufacturing because higher amounts of antigenic protein is needed than 
in conventional vaccines (Noad and Roy, 2003). Special kinds of sub-unit vaccines are Virus 
like particle (VLP) vaccines (Noad and Roy, 2003). VLPs are virus particles that lack viral 
genome. They are not infectious but because of their similarity to infectious particles by 
structure and antigenicity, they have the ability to induce a strong immune response. 
Structural proteins can assemble spontaneously to VLPs with their immunogenic potential 
being higher than that of non-assembled proteins. That is also the reason why less antigen is 
needed than in classical sub-unit vaccines. VLPs can induce not only a humoral but also a 
cellular immune response (Grgagic and Anderson, 2006; Chen and Lai, 2013). Processing of 
VLPs by dendritic cells can lead to activation of the innate and adaptive immune system 
(Grgagic and Anderson, 2006; Chen and Lai, 2013). VLPs taken up by antigen presenting 
cells can be presented by MHC class II molecules after processing. This leads to activation of 
dendritic cells, abundant cytokine release and stimulation of CD4+ T-cells. VLPs are also 
presented by MHC class I molecules by antigen presenting cells, after their processing in the 
cytosol, leading to activation of cytotoxic CD8+ T-cells (Kushnir et al., 2012; Chen and Lai, 
2013). Due to their size, VLPs can spread easily to lymph nodes where even more T-cells can 
interact with them. Some VLP types are shown to induce maturation of dendritic cells which 
in turn produce cytokines and activate CD8+ T-cells (Chen and Lai, 2013). VLPs induce also 
B-cell responses with generation of memory B-cells leading to high antibody titers and long-
lasting immune responses (Chen and Lai, 2013). Because of this great immunogenic potential, 
VLPs are explored for use in many different fields for diagnostic, prophylactic or therapeutic 
use like vaccines, gene therapy or immunotherapy (Kushnir et al., 2012). 
VLPs for vaccine development are often generated by using different expression systems like 
baculoviruses, yeast, Escherichia coli or Vaccinia virus (Noad and Roy, 2003). Presently, 
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different vaccines based on VLPs are commercially used. In veterinary medicine, for 
example, two VLP based vaccines against porcine circovirus type 2 are on the market: 
Ingelvac CircoFLEX®, Boehringer Ingelheim and Porcilis PCV, Intervet International B.V., 
Netherlands/MSD (Crisci et al., 2012; van Oers et al., 2015; PEI, state of 15.02.2017). 
For the development of RHDV-1 vaccines based on the recombinant capsid protein VP60, 
different heterologous expression systems and recombinant viruses (Bertagnoli et al., 1996a, 
b; Fischer et al., 1997; Bárcena et al., 2000; Fernández et al., 2011; Rohde et al., 2011) were 
established. As expression systems served Escherichia coli (Boga et al., 1994; Guo et al, 
2016), cultured insect cells (Laurent et al., 1994; Marín et al., 1995; Nagesha et al., 1995; 
Plana-Duran et al., 1996; Gromadzka et al., 2006; López-Vidal et al., 2015), yeast (Farnós et 
al., 2005), plants (Castañón et al., 1999; Mischkofsky et al., 2009) and insect larvae (Pérez-
Filgueira et al., 2007). The immunogenic potential of recombinant VP60 by induction of a 
protective humoral immune response was proven in different studies. However, low 
production costs, high yields and the potential of scaling up need to be taken into 
consideration when aiming for commercial use (Abrantes et al., 2012).  
 
2.6. Recombinant baculoviruses  
2.6.1. Baculovirus       
Baculoviruses are DNA viruses of the family Baculoviridae with about 700 known members. 
Their natural hosts are insects mainly of the order Lepidoptera to which butterflies and moths 
belong. They cannot infect and replicate in mammalian cells but can be internalized by 
vertebrate cells. 
Baculoviruses are divided into four genera: α-, β-, γ- and δ-baculovirus. They are rod shaped, 
enveloped viruses, of about 30-60 x 250-300nm in size, and contain a circular double stranded 
DNA with a genome of 80-180kb (Airenne et al., 2013). 
There are two virus forms, BV (budded virus) and ODV (occlusion-derived virus). ODV is 
surrounded by a so-called occlusion body which is composed of polyhedrin and is the viral 
form which can persist in the environment. After ingestion by insects, the polyhedrin 
occlusion body dissolves and the virus then infects intestinal cells by direct fusion with the 
cell membranes of the midgut. The DNA genome is replicated and transcribed in the nucleus. 
After translation and assembly of nucleocapsids, the BV form leaves the cell by budding at 
the plasma membrane. This budded virus is infectious and can infect more cells in the same 
host. Very late in the infection progress, the nucleocapsids bind to the membrane of the 
nucleus and are embedded in the polyhedrin matrix (ODV form). These virus forms are 
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released again into the environment after cell death and can endure for years before infecting 
a new host (Hu, 2005; Airenne et al., 2013; Clem and Passarelli, 2013). ODV forms of β-
baculoviruses only contain one virion per occlusion body whereas α-, γ- and δ-baculoviruses 
contain several virions in their occlusion bodies reflected by the former name 
Polyhedroviruses (Airenne et al., 2013). 
The most widely used baculovirus is the Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV) which is 25 x 260nm in size and has a genome of 134kb. It 
belongs to the genus α-baculovirus and its genome has been sequenced. Since they only infect 
insect cells, baculoviruses can be handled at low bio safety levels (Airenne et al., 2013). 
Genome expression in AcNMPV is under temporal control (Rohel and Faulkner, 1984) with 
(immediate) early, (delayed) early, late and very late promotors for different phases of gene 
expression. In the very late phase, proteins polyhedrin and P10 are expressed under two 
strong promotors, the polyhedrin promotor and the P10 promotor, respectively. Both proteins 
are non-essential, thus these two promotors are widely used in baculovirus expression systems 
for directing expression of foreign proteins (van Oers et al., 2015).  
 
2.6.2. Baculovirus expression system 
Because of their large DNA genome which can be modified easily, and convenient laboratory 
handling characteristics, protein expression systems based on baculoviruses as vectors were 
developed in the 1980’s. The first protein that was produced by recombinant baculoviruses 
was human IFN-β, expressed under control of the polyhedrin promotor (Smith et al., 1983). 
Since then the baculovirus expression system has been developed further and has become an 
important tool for protein expression. In 1993, the nowadays widely used “bacmid system” 
was developed (Luckow et al., 1993). It uses a bacterial artificial chromosome (“bac”) that 
carries the entire AcMNPV genome sequence with which recombinant baculoviral genomes 
are generated in Escherichia coli faster to develop recombinant baculoviruses or expression 
vectors more effectively (van Oers et al., 2015). A well-known commercially used 
baculovirus expression system that uses this technique is the Bac-to-Bac® System by Life 
Technologies (Fig. 7). 
 
2. Literature 
 
24 
 
 
Fig. 7. Overview of generation of recombinant baculoviruses with Baculovirus Expression System 
“Invitrogen Bac-to-Bac®” by Life Technologies (with permission of Life Technologies/ Thermo Fisher 
Scientific) 
Upper row from left to right: cloning of gene of interest from donor plasmid into a recombinant donor 
plasmid; transformation of purified plasmid DNA into DH10BacTM E.coli cells containing Bacmid DNA; 
Transposition of gene of interest into Bacmid DNA of E.coli and antibiotic selection of E.coli containing 
recombinant Bacmid DNA  
Lower row from right to left: Isolation of recombinant Bacmid DNA; transfection of insect cells with 
recombinant Bacmid DNA; generation of recombinant baculoviruses; determination of viral titer, recombinant 
gene expression or viral amplification 
 
Insect cell lines used for infection by recombinant baculoviruses are often SF9 and SF21 cells, 
derived from ovarian tissue of Spodoptera frugiperda, or BTI-TN-5B1-4 cells (High V; 
Invitrogen), derived from ovarian tissue of Trichoplusia ni (Hu, 2005). 
Protein expression by baculoviruses in insect cells has many advantages. Proteins can be 
produced in large amounts and, since baculoviruses can only infect some cells of Lepidoptera 
species, they provide no risk to mammalians (Noad and Roy, 2003).  
However, not only insect cells are suitable for protein expression by recombinant 
baculoviruses, but also mammalian cells. Hofmann et al. (1995) transduced successfully 
mammalian cells (human hepatocytes) with modified baculoviruses that expressed proteins 
under a cytomegalovirus (CMV) immediate early promotor, while Boyce and Bucher (1996) 
did the same in different types of mammalian cells under a Rous sarcoma virus (RSV) long 
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terminal repeat (LTR) promoter-β galactosidase (β-gal) gene cassette. Shoji et al. (1997) 
developed the strong CAG(GS) enhancer/promotor element, which consists of the CMV 
immediate early enhancer promotor, the chicken β-actin promoter and a rabbit β-globin 
polyadenylation signal, for transduction. Transduction of mammalian cells with recombinant 
baculoviruses is called “BacMam” system.  
 
2.6.3. Recombinant baculovirus based vaccines 
Protein expressed by recombinant baculoviruses are used as vaccines commercially, for 
example, Porcilis Pesti (Intervet International BV, Netherlands), against Classical swine fever 
containing E2- glycoprotein of CSFV (van Oers et al., 2015; PEI, state 15.02.2017). A 
recombinant baculovirus-derived vaccine for use in humans, Cervarix (GlaxoSmithKline 
Biologicals S.A.) is directed against human papilloma virus. Many more vaccine candidates 
containing protein expressed by baculovirus expression system are in clinical tests (Vicente et 
al., 2011; van Oers et al., 2015). 
Beside other advantages mentioned earlier (2.6.2), live baculoviruses are supposed to have an 
immunogenic effect in the vaccinated organism by inducing interferon α (Gronowski et al., 
1999). This could be an asset in induction of immune responses by recombinant baculovirus 
vaccines. 
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3. Aims of the thesis 
Development of effective vaccines was a major breakthrough to protect rabbits from RHD in 
the early 1990’s (Argüello-Villares, 1991), which was however accompanied with the death 
of thousands of rabbits needed to produce the vaccines from infected rabbit livers. With the 
appearance of the new virus variant RHDV-2 among rabbit populations and due to the 
insufficient protection of available vaccines, it was necessary to develop new ones that protect 
rabbits against the fatal outcome of RHDV-2 infection.  
 
Therefore, the aims of this thesis were  
a) to develop a recombinant baculovirus-derived RHDV-2-VP60 vaccine to replace the 
ethically questionable conventional vaccine production from liver preparations of 
infected rabbits, 
b) to optimize the recombinant baculovirus vaccine to combine high production yields, 
easy and effective purification with a good antigenicity based on the self-assembly of 
the structural protein VP60 of RHDV-2 into VLPs  
c) to establish an effective immunization protocol to induce a protective long-lasting 
immunity with a minimal dose early after a single immunization, 
d) to analyze the onset and duration of immunity against RHDV-2 and cross-protective 
capacity against classical RHDV (RHDV-1) of the induced immunity and  
e) to characterize the humoral and cellular immune response against RHDV-2 in rabbits 
immunized with the newly established recombinant vaccine in comparison with a 
conventional RHDV-2 vaccine. 
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4. Material 
4.1. Cell lines 
Sf9 Insect cell line from ovary tissue of the moth Spodoptera frugiperda  
High V Insect cell line from ovary tissue of the moth Trichoplusia ni 
RK13  Rabbit kidney cell line 
 
All cell lines were obtained from Collection of Cell Lines in Veterinary Medicine (CCLV) 
FLI, Insel Riems. 
 
4.2. Virus strains 
Recombinant baculoviruses: 
BacMam-ieGFP  recombinant baculovirus, expresses GFP under control of 
the HCMV major ie promotor, FLI 
CO107 Baculo-p10GFP  recombinant baculovirus, expresses GFP under control of 
the baculoviral P10 promotor, FLI 
 
The following recombinant baculoviruses were generated in this study (6.1): 
 
BacBacVP60-2/BHV1  recombinant baculovirus, expressing VP60 of RHDV-2 
with the codon usage of BHV-1 under control of the 
promotor P10 and GFP under control of the promotor 
HCMVie in insect cells 
BacBacVP60-2/AcMNPV recombinant baculovirus, expressing VP60 of RHDV-2 
with the codon usage of AcMNPV under control of the 
promotor P10 and GFP under control of the promotor 
HCMVie in insect cells  
BacMamVP60-2/BHV1 recombinant baculovirus, expressing VP60 of RHDV-2 
with the codon usage of BHV-1 under control of the 
hybrid promotor CAG(GS) and GFP under control of the 
polyhedrin promotor in mammalian cells 
BacMamVP60-2/AcMNPV recombinant baculovirus, expressing VP60 of RHDV-2 
with the codon usage of AcMNPV under control of the 
hybrid promotor CAG(GS) and GFP under control of the 
polyhedrin promotor in mammalian cells 
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RHDV challenge viruses 
RHDV-2 strain “Werne” wild type virus prepared from the liver of a RHDV-2 
“Werne” infected rabbit (FLI) 
RHDV-1 strain “Eisenhüttenstadt” wild type virus prepared from the liver of a RHDV-1 
“Eisenhüttenstadt” infected rabbit (FLI) 
 
4.3. Media and solutions for cell cultivation 
ZB5         ZB12 
5,32 g Hank’s Salts        2,7 g lactalbumine-hydrolysate 
4,76 g Earle’s Salts           3,75 g Leibovitz L15 (Gibco) 
1,25 g NaHCO3          1,26 g NaHCO3 
0,12 g Na-pyruvate       15 mg phenol red 
10 ml nonessential amino acids (NEAS)   75 ml Hank’s salts 
100 ml fetal calf serum (FCS)           
ad 1 l aqua dest.        
100 U/ml penicillinG          
100 µg/ml streptomycin         
pH 7,2 
 
ZB15        trypsin solution 
46,12 g Grace´s Insect powder medium (Serva)  32,0 g NaCl  
3,3 g lactalbumine-hydrolysate (Difco)     0,8 g KCl  
3,3 g yeast extract (NeoLab)      10 g trypsin  
ad 900 ml aqua dest.      5 g EDTA  
100 ml fetal calf serum (FCS)      0,8 g KH2PO4   
100 U/ml penicillinG         4,6 g NaH2HPO4 x 2H2O 
100 µg/ml streptomycin        64 mg phenol red   
pH 6,5          pH 7,2 – 7,4 
        ad 1 l aqua dest. 
 
High V medium 
Insectomed SF express-medium   
(Biochrome) 
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Media ZB5, ZB15 and ZB12 were received as complete preparations from CCLV FLI, Insel 
Riems. 
 
4.4. Bacteria 
C600  Escherichia coli Genotyp: F– supE44 thi-1 thr-1 leuB6 LacY1 tonA21 
Lambda- hsdR-hsdM+ (FLI) 
DH10Bac™ Escherichia coli Genotype: F– mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 
lacX74 recA1 endA1 araD139 (ara, leu)7697 galU galK – rpsL nupG 
/pMON14272 / pMON7124 (Invitrogen) 
 
All bacteria were incubated in LB-medium while shaking or on LB agar plates at 37°C. 
 
4.5. Media and solutions for bacterial cultures     
LB-Medium      LB+-Medium 
10 g bacto- tryptone     LB-Medium with  
5 g yeast extract     10 mM KCl  
8 g NaCl      20 mM MgSO4 
ad 1 l aqua dest. 
 
SOC-Medium      SOA-Medium 
10 ml SOA-medium     10 g peptone 140 
100 µl 1M MgSO4     2,5 g yeast extract 
100 µl 1M MgCl2     1 ml 5M NaCl 
200 µl 1M Glucose     1,25 ml 1M KCl 
ad 500 ml aqua dest.     ad 500 ml aqua dest. 
 
selection medium 
markers for selection were added in following concentrations: 
 
ampicillin 100 µg/ml       
gentamicin 7 µg/ml       
kanamycin 50 µg/ml 
tetracycline 10 µg/ml 
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LB-agar 
LB-medium with 1,5 % agar and selection markers in the following concentrations: 
 
ampicillin 100 µg/ml      IPTG 40 µg/ml 
gentamicin 7 µg/ml     X-Gal 100 µg/ml in dimethylformamid 
kanamycin 50 µg/ml      
tetracycline 10 µg/ml 
 
4.6. Plasmids 
The following two plasmids were generated by GeneArt (Regensburg, Germany) using the  
provided sequences of RHDV-2-VP60 of strain 10-05 (GenBank accession no. FR819781; 
Suppl. 7) (this study): 
 
14ABWG4P_RHDV-2_VP60_ vector containing the synthetic ORF encoding  
BHV1_Cod_pMK-RQ  RHDV-2-VP60 with the BHV-1 codon usage  
 
14ABWG6P_RHDV-2_VP60_ vector containing the synthetic ORF encoding  
ACNPHV_pMK-RQ RHDV-2-VP60 with the AcMNPV codon usage 
 
pFBD-P10Uhis-ieGFP  cloning vector for gene integration of the P10 
promoter controlled expression cassettes into the 
baculovirus genome, contains a GFP expression 
cassette controlled by the major ie promotor of 
HCMV (FLI) 
 
pCAGGS-PHGFP  cloning vector for gene integration of hybrid 
CAG(GS) promotor controlled expression 
cassettes into the baculovirus genome, contains a 
GFP expression cassette controlled by the 
baculoviral polyhedrin promotor for GFP 
expression (FLI) 
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The following plasmids were generated using the above mentioned vectors (this study):  
 
pFBD_RHDV-2_VP60_BHV_Cod  vector coding for viral VP60 protein of RHDV-2 
with BHV-1 codon usage under control of the 
promotor P10, derived from cloning vector 
pFBD-P10Uhis-ieGFP 
 
pFBD_RHDV-2_VP60_AcMNPV  vector coding for viral VP60 protein of RHDV-2 
with AcMNPV codon usage under control of the 
promotor P10, derived from cloning vector 
pFBD-P10Uhis-ieGFP 
 
pMBCAGGS-RHDV-2_VP60 vector coding for viral VP60 protein of RHDV-2  
_BHV1_Cod with BHV-1 codon usage under control of the 
hybrid promotor CAG(GS), derived from cloning 
vector pCAGGS-PHGFP 
 
pMBCAGGS-RHDV-2_VP60 vector coding for viral VP60 protein of RHDV-2  
_AcMNPV with AcMNPV codon usage under control of the 
hybrid promotor CAG(GS), derived from cloning 
vector pCAGGS-PHGFP 
 
4.7. Antibiotics 
ampicillin      Serva 
gentamicin      Sigma 
kanamycin      Sigma 
penicillin G      Biochrom 
streptomycin      Biochrom 
tetracycline      Sigma 
 
4.8. Enzymes, nucleic acids, DNA/ protein size markers 
alkaline phosphatase     Roche 
calf intestinal phosphatase (20 U/µl)   Roche 
DNA Polymerase I, Large (Klenow) Fragment New England BioLabs 
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DNA-size marker “1kb-ladder”   Invitrogen 
dNTP Mix 10 mM     Promega 
internal control RNA (IC-RNA)   FLI 
lysozyme      Sigma 
prestaind protein ladder    Thermo Scientific  
protein size marker Page RulerTM     
protein kinase K     Roche 
restriction enzymes      Biolabs 
RNase A      Sigma 
T4-DNA-Ligase     Roche 
 
4.9. Sera and purified antigen 
fetal calf serum (FCS)    Invitrogen 
horse serum       Biochrom 
purified RHDV-1 antigen     FLI 
purified RHDV-2 antigen FLI 
rabbit normal serum     FLI 
rabbit serum RHDV-1 positive    FLI 
rabbit serum RHDV-2 positive    FLI 
 
4.10. Antibodies 
goat α-rabbit IgG, peroxidase-conjugated    Dianova 
αGFP IgG, polyclonal rabbit serum   FLI 
αVP60_1 IgG, polyclonal rabbit-ab    FLI 
DYLight 488 conjugated anti-mouse IgG1   Rockland 
R-Phycoerythrin –conjugated anti-mouse IgM  Jackson Immuno Research 
R-Phycoerythrin –conjugated anti-mouse IgG2a Jackson Immuno Research 
 
4.11. Chemicals and bioreagents 
1,4-Dithiothreitol (DTT)    Roche 
2-mercaptoethanol        MP Biomedicals 
agar       Difco 
agarose      Invitrogen 
ATP       Sigma 
bacto tryptone      Invitrogen 
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binary ethylenimin      Sigma 
bovine serum albumin (BSA)   NEB 
bromophenol blue     Serva 
cesium chloride     Invitrogen 
EDTA       Sigma 
EGTA       Sigma 
ethidium bromide     Serva 
FuGENE® HD     Roche 
IPTG       Roche 
o-Phenylenediamine dihydrochloride   Sigma 
(OPD, 4 mg/tbl)      
Pancoll animal, density 1,077 g/ml   Pan-Biotech 
PEG       Sigma 
ROX (1:200 in 10 mM Tris-HCl pH 8)   Invitrogen 
SDS       Serva 
sucrose      Serva 
TEMED      Roth 
tris       Invitrogen 
trypsin (powder)     Difco 
Tween 20      Sigma 
X-Gal       Invitrogen  
yeast-extract      Difco 
 
4.12. Kits 
ClarityTM Western ECL Substrate    Bio-Rad  
Ingezim RHDV DAS R.17.RHD.K2   Ingenasa 
Plasmid Midi Kit     QIAGEN 
QIAamp Viral RNA Mini Kit    Qiagen 
SuperScriptTM III One-Step RT-PCR System  Invitrogen 
with Platinum® Taq DNA Polymerase   
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4.13. Buffers and solutions 
Buffers used in different methods: 
10x PBS        PBS+ 
80 g NaCl         140 mM NaCl          
2 g KCl        2,7 mM KCl      
11,5 g Na2HPO4 x H2O      8 mM Na2HPO4   
2 g KH2PO4         1,5 mM KH2PO4  
ad 1 l aqua dest.       0,9 mM CaCl2 x 2H2O   
pH 7,4            0,5 mM MgSO4   
pH 7,4       
 
Buffers used for DNA preparation and cloning: 
10x TA      50x TA (for DNA-agarose gels)  
330 mM tris         2 M tris      
660 mM potassium acetate       0,05 M Na-acetate   
100 mM magnesium acetate       pH 7,8 with glacial acetic acid   
1 mg/ml BSA           
5 mM DTT                
pH 7,9 with acetic acid    
 
DNA-marker           sample buffer (for DNA-marker)   
30 µl 1kb ladder (1000 µg/ml)      40 % sucrose  
40 µl 10x TA           0,05 % bromophenol blue  
330 µl aqua dest.           0,1 % SDS  
100 µl sample buffer      1 mM EDTA  
heat for 10min at 56°C 
 
TE buffer 
10 mM tris pH 7,5 
1 mM EDTA pH 7,5 
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Buffers used for purification of plasmid DNA: 
Solution I      Solution II 
10 mM EDTA, pH 8,0        0,2 M NaOH  
20 mM tris, pH 8,0         1 % SDS  
50 mM glucose       
2 mg/ml lysozyme       
 
Solution III    
3 M Na-acetate pH 4,8 
 
Buffers and solutions used for SDS-PAGE: 
SDS 10 % separating gel    SDS 4,5 % stacking gel     
9,6 ml 30 % acrylamide / 0,8 %  3 ml 30 % acrylamide/ 0,8 % 
bisacrylamide bisacrylamide  
7,5 ml 4x Lower Tris         5 ml 4x Lower Tris     
12,9 ml aqua dest.           12 ml aqua dest.   
60 µl 10 % ammonium peroxodisulfate  60 µl 10 % ammonium peroxodisulfate   
30 µl TEMED           60 µl TEMED    
 
4x Lower Tris      4x Upper Tris  
1,5 M tris-HCl pH 8,8        0,5 M tris-HCl pH 6,8  
0,4 % SDS           0,4 % SDS 
 
4x protein lysis buffer     10x running buffer  
40 % sucrose       144 g/l glycine       
12 % SDS       30 g/l tris       
62,5 mM 4x Upper Tris     10 g/l SDS       
0,025 % bromophenol blue  
ad 100 ml aqua dest.   
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Buffers used for Western Blot: 
transfer buffer      washing buffer I     
1,514 g tris           1x PBS with 0,3 % Tween 20     
7,21 g glycine   
0,5 g SDS            washing buffer II 
100 ml 30 % methanol         1x PBS with 0,1 % Tween 20 
ad 500 ml aqua dest.    
 
Buffers and solutions used for VLP purification: 
40 % sucrose       1 M tris-HCl        
40 g D+ - sucrose      60,57 g tris       
ad 100 ml 0,2 M tris-HCl    ad 500 ml aqua dest.     
       pH 6,8 with concentrated HCl    
 
CsCl solution 
4,2 g CsCl in 10 ml PBS end volume   
 
Buffers used for antigen purification: 
TEN buffer   
20 mM tris 
1 mM EDTA  
150 mM NaCl  
pH 7,6 
 
Buffers and solutions used for antibody-ELISA: 
Coating buffer Tris-NaCl washing buffer 
2,422 g tris 1x PBS with 0,05 % Tween 20 
8,766 g NaCl       
ad 1 l aqua dest. 
pH 7,6 
 
 
 
 
4. Material 
 
 
37 
 
substrate buffer  
solution A: solution B: 
0,1 M citric acid ad 100 ml aqua dest.  0,2 M Na2HPO4 x 2H2O ad 100 ml aqua 
dest. 
substrate solution 
2,43 ml solution A 
2,57 ml solution B 
5 ml aqua dest. 
 
1 tablet OPD is dissolved in 10 ml substrate solution, add 15 µl 30% H2O2 immediately  
before use.   
 
Buffer used for hemagglutination test: 
0,15 M Isotonic phosphate buffer (IP)  
8,28 g NaCl  
1,19 g Na2HPO4 x 2H2O  
0,2 g KH2PO4  
ad 1000 ml aqua dest.   
 
Real time RT-PCR Mastermix: 
Mastermix RT-PCR RHDV-2   Mastermix RT-PCR RHDV-1 
2,4 µl RNAse free water     2,4 µl RNAse free water  
12,5 µl Rxn Mix (2x)     12,5 µl Rxn Mix (2x) 
1,0 µl SS III RT/ Platinum Taq Mix    1,0 µl SS III RT/ Platinum Taq Mix 
2,0 µl RHDV-2 Mix      2,0 µl RHDV-1 Mix 
2,0 µl IC-Mix      2,0 µl IC-Mix 
0,1 µl ROX      0,1 µl ROX 
 
Buffer used for flow cytometric analysis (FACS): 
FACS buffer 
1x PBS with 0,01% 1mM EDTA 
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4.14. Primers and probes  
All primers and probes (Tab. 2) were obtained from Eurofins Genomics (Germany) and used 
in concentrations of 100pmol/µl. 
 
Tab. 2. Primers and probes used for real time RT-PCR 
 
4.15. Monoclonal antibodies 
Tab. 3. Monoclonal antibodies specific for leukocyte differentiation markers used for FACS analysis 
clone antigen expressing leukocytes isotype reference 
RTH2A not defined T-cells G1 Davis et al., 2008 
RTH26A isoform of CD5 T-cells G2a Kotani et al., 1993 
RTH1A CD4 Thelper cells, monocytes G1 Jacobson et al., 1993 
ISC27A CD8 Tcytotoxic cell G2a Davis et al., 2008 
ISC29E CD8 Tcytotoxic cell G1 Davis et al., 2008 
 
4.16. Equipment and devices 
agarose gel apparatus       FLI 
BioPhotometer      Eppendorf  
electrophoresis power supply    Pharmacia Biotech  
ELISA microplate reader Spectra   Tecan 
ELISA microplate washer HydroFlex    Tecan 
Eppendorf Thermomixer 5436     Eppendorf  
 
Primer/Probe Mix Sequence 5' - 3' reference 
RHDV-specific qRT-PCR 
  
RHDV-1 Mix 
 
Gall et al., 2007 
vp60-7_forward primer ACYTGACTGAACTYATTGACG 
 
vp60-8_reverse primer TCAGACATAAGAAAAGCCATTGG 
 
vp60-9_FAM probe 
FAM-CCAARAGCACRCTCGTGTTCAACCT- 
TAMRA  
   
RHDV-2 Mix 
 
unpublished 
FRA-korr-forward primer ACTTGTCAGACCTTGTTGACA 
 
FRA-reverse primer TCAGACATAAGAAAAGCCATTAG 
 
FRA _v2-FAM probe 
FAM-CCACAAGCACGCTTGTGTACAACTTG- 
BHQ1  
   
IC-specific qRT-PCR 
  
IC-Mix 
 
Hoffmann et al., 2006 
EGFP12-F primer TCGAGGGCGACACCCTG 
 
EGFP10-R primer CTTGTACAGCTCGTCCATGC 
 
EFGP-Hex probe HEX-AGCACCCAGTCCGCCCTGAGCA-BHQ1 
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fluorescence microscope Eclipse Ti-S  Nikon 
with digital camera             
gyratory shaker Duomax 1030    Heidolph 
incubator for bacterial cultures    Heraeus  
incubator MAX Q 8000       Thermo Scientific  
light microscope     Leitz    
Microm HM 340E     Microm International 
Mini Protean Tetra System       Bio-Rad  
multichannel pipettes, pipettes   Eppendorf, Gilson  
polarizing light microscope Zeiss Axio Scope.A1 Zeiss    
qPCR system MX3005P     Stratagene  
Tissue Lyser II      Qiagen 
Tissue processor Leica ASP 300S   Leica Biosystems 
Trans-Blot®-SD Semi-Dry Transfer Cell    Bio-Rad  
ultrasound waterbath     Branson   
UV-Transilluminator        Herolab  
VersaDoc™ Imaging System       Bio-Rad  
vortex mixer      Bachofer  
water jacketed CO2 incubator for cell culture Forma Scientific  
 
Centrifuges  
centrifuge 5415R        Eppendorf  
centrifuge 5430R        Eppendorf  
centrifuge 5810R     Eppendorf 
centrifuge Rotina 420R      Hettich  
J2-HS Centrifuge         Beckman  
Minifuge 4400 GL     Heraeus Christ 
Optima™ LE-80K Ultracentrifuge     Beckman  
Optima™ Max-XP Ultracentrifuge     Beckman  
Wifug centrifuge     Lab Centrifuges 
 
4.17. Consumables 
96 well U-bottom microplates    Greiner 
BD Microtainer® Blood Collection Tubes  Becton, Dickinson 
cell culture plates + flasks    Greiner, Costar® 
4. Material 
 
 
40 
 
cellulose chromatography paper 3MM  Whatman® 
centrifuge tubes     Beckman 
EDTA pretreated tubes, 1,6mg EDTA/ml blood Sarstedt 
FACS tubes      Becton Dickinson 
filter paper        Schleicher Schuell 
medium binding 96well ELISA plates   Greiner 
Microlon® 200 96W Microplate      
N-ACHROPLAN objectives    Zeiss 
needles Sterican® 21G and 24G   Braun  
nitrocellulose membrane 0,2 µm    Whatman® Protran®   
PCR plates 96well with Flat Cap Strips  Kisker Biotech 
reaction tubes      Eppendorf  
self-adhesive PCR aluminium foil seal  SLG Süd-Laborbedarf Gauting 
stainless steel beads, 5mm     Qiagen 
syringes        Braun  
tubes 2.0 ml, sterile, DNA-, DNase-, RNase  Biozym 
and Pyrogen free       
tubes, black cap, 12ml    Greiner 
 
4.18. Software 
Chemiluminescence: QuantityOne   Bio-Rad 
ELISA microplate washer software:   
Hydrocontrol 4.1     Tecan 
ELISA reading software: E.A.S.Y win  Herolab GmbH 
qRT-PCR: MxPro     Stratagene   
FACS: CellQuestPro      Becton Dickinson 
 
4.19. Animals 
Rabbits, hybrids “Zimmermannkaninchen” (“ZI-KA”) from a commercial rabbit farm 
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5. Methods  
5.1. Generation of recombinant baculoviruses  
5.1.1. Purification of plasmids coding for RHDV-2-VP60 ORFs  
Two plasmids containing the open reading frames for VP60 of RHDV-2 were synthesized by 
GeneArt (Regensburg, Germany) based on the codon usages of autographa californica 
multiple nucleopolyhedrovirus (CU AcMNPV) and bovine herpesvirus 1 (CU BHV-1), 
respectively. The sequences of the respective ORFs were deduced from the RHDV-2-VP60 
amino acid sequence (Le Gall-Reculé et al., 2013, GenBank accession number FR819781 
RHDV; see supplementary data) and designed using the codon usage tables available at 
http://www.kazusa.or.jp/codon/.  
In a first step, the plasmids were purified from 200µl E.coli suspended in 50ml LB medium + 
kanamycin cultivated overnight using the Qiagen Plasmid Midi Kit. Briefly, bacterial cells 
were pelleted by centrifugation with a Heraeus Christ centrifuge at 4°C with 3000rpm for 
30min. The pellet was resuspended in 4ml buffer P1 and P2 each and incubated at room 
temperature for 5min before adding 4ml buffer P3 and incubation on ice for 15min. 
Centrifugation was performed at 4°C with 15000rpm for 30min using a JA17 rotor of a J2-HS 
centrifuge. A Qiagen tip was equilibrated with 4ml QBT buffer. The supernatant was added to 
the Qiagen tip and the tip was washed with 10ml QC buffer twice afterwards. DNA was 
eluated with 5ml QF buffer and then aliquoted into 1ml samples. DNA was precipitated at 
room temperature by adding of 0,7ml isopropanol followed by centrifugation at 4°C with 
14000rpm for 15min with an Eppendorf centrifuge. Pellets were washed with 1ml 70% 
ethanol and centrifuged at 4°C with 14000rpm for 5min. After drying of the pellets at 56°C, 
DNA was resuspended in 125µl TE buffer.  
 
5.1.2. Preparation of transfer vectors  
pFBD-P10Uhis-ieGFP (kindly provided by C. Klopfleisch) and pCAGGS-PHGFP were used 
as transfer vectors. Both transfer vectors contain a GFP expression cassette which facilitates 
isolation and titer determination of the respective baculovirus recombinants (Keil et al., 2009). 
Transfer vector pFBD-P10Uhis-ieGFP was cleaved with SmaI while transfer vector 
pCAGGS-PHGFP was cleaved with EcoRI. 5µg DNA was cleaved with 2U of the respective 
restriction enzyme per µg DNA in a final volume of 100µl containing 10µl 10x reaction 
buffers NEB2 (EcoR1) or Cut Smart (SmaI), respectively. The reaction mixture with EcoR1 
was incubated for 1,5 hours at 37°C, while the one with SmaI was incubated at 25°C for the 
same time. Cleavage was controlled by agarose gel electrophoresis. 
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5.1.3. Cleavage of plasmids by restriction enzymes 
In the provided plasmids the synthetic open reading frames for RHDV-2-VP60 were flanked 
by EcoRI cleavage sites to facilitate isolation of the respective ORFs. 5µg of each plasmids 
DNA were cleaved with 10U EcoRI in a final volume of 50µl containing 5µl  
10x reaction buffers NEB2 or 10xTA, respectively. The reaction mixtures were incubated for 
1,5 hours at 37°C. Correct cleavage was controlled by agarose gel electrophoresis. 
 
5.1.4. Blunt ending of sticky ends with Klenow enzyme 
Cleavage with restriction enzyme SmaI results in blunt ends at the restriction sites. Because 
cleavage with EcoR1 results in 5’ overhanging ends of the DNA fragments (sticky ends), the 
synthetic ORFs of RHDV-2-VP60 meant to be integrated into the transfer vector  
pFBD-P10Uhis-ieGFP, cleaved with SmaI, had to be blunt ended by the Klenow fragment of 
the E.coli DNA polymerase I which lacks the 5‘ to 3‘ exonuclease activity and refills 
overhanging 5‘ ends by DNA polymerase activity. 5µg of DNA was resuspended with 5µl  
10x TA buffer and 42µl aqua dest. Then 2µl dNTP-Mix (10mM) and 5U Klenow polymerase 
were added. After incubation for 30min at room temperature the reaction was stopped by 
adding 1µl EDTA (0,5M, pH 7,5). 
 
5.1.5. Dephosphorylation of cleaved transfer vectors  
To avoid religation of the linearized vectors, calf intestinal phosphatase (CIP) was used to 
dephosphorylate their 5‘ends. After mixing of 5µg appropriately cleaved vector DNA with 
25µl 10x phosphatase buffer and aqua dest. ad 250µl, 1µl CIP (20U/µl) was added and then 
incubated at 37°C for 30min. After a second addition of 1µl CIP, the mixture was incubated 
for further 30min at 56°C. 50µl 60mM EGTA was added, followed by incubation at 65°C for 
15min to stop the reaction. The phosphatase was digested by incubation for 30min at 56°C 
with 30µl 10% SDS and 1µl protein kinase K (10mg/ml).  
 
5.1.6. Cleaning of transfer vector DNA  
Following dephosphorylation, the 330µl vector DNA solution was mixed 1:1 v/v with phenol 
and centrifuged at 14000rpm in an Eppendorf centrifuge for 2min at room temperature. The 
upper phase was then mixed 1:1 (v/v) with 50% phenol/ 50% chloroform- isoamylalcohol 
(24:1). After thorough mixing, the upper phase was added to 1ml chloroform- isoamylalcohol 
(24:1) and mixed again. After adding of 1/10 volume 3M Na- acetate (pH 7) and 2.5 to 3 
volumes 100% ethanol, the DNA was precipitated by incubation at -80°C for 30min and 
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harvested by centrifugation with 14000rpm for 15min at room temperature with an Eppendorf 
centrifuge. The pellet was washed with 1ml 70% ethanol and centrifuged again with 
14000rpm for 5min at room temperature. After drying, the pellet was resuspended in TE 
buffer by incubation at 56°C for 5min and shaking at room temperature for 15min afterwards. 
Recovery of DNA was controlled by agarose gel electrophoresis using 1µl of each sample. 
 
5.1.7. Purification of DNA by phenol extraction of agarose gels 
The respective DNA preparations were size separated by agarose gel electrophoresis in 
presence of ethidium bromide. DNA fragments were visualized by long wave UV light and 
excised. After mincing the gel slices in an Eppendorf tube with a glass rod, an equal amount 
of phenol was added. After mixing, the samples were frozen in liquid nitrogen for 20sec and 
centrifuged immediately afterwards with 14000rpm for 30min at room temperature with an 
Eppendorf centrifuge. The upper phase was added to 1ml of chloroform- isomylalcohol (24:1) 
followed by mixing and centrifuged as above for 2min. The upper phase transferred into a 
new reaction tube and 1/10 volume 3M Na- acetate (pH7) and 2.5 to 3 volumes 100% ethanol 
were added. After incubation at -80°C for 30min, precipitated DNA was pelleted by 
centrifugation with 14000rpm at room temperature for 15min. The pellet was washed with 
1ml 70% ethanol and centrifuged with 14000rpm at room temperature for 5min. The pellet 
was then dried at 56°C and resuspended in 50µl TE buffer by incubation at 56°C for 5min and 
shaking at room temperature for 15min. 1µl of each sample was size separated by agarose gel 
electrophoresis to control recovery. 
 
5.1.8. Ligation 
For ligation, a ligation buffer was prepared, consisting of 5µl of each 10x TA buffer, ATP 
(10mM), DTT (100mM) and BSA (500µg/ml). Because blunt ends do not ligate as easily as 
sticky ends, blunt ended inserts were used in a ratio of 2:1 (µg/µg) with vector pFBD-
P10Uhis-ieGFP whereas inserts with sticky ends, meant for vector pCAGGS-PHGFP, were 
used 1:1. As controls, vector DNAs alone were treated accordingly. To each reaction mixture 
1µl T4-DNA-ligase was added with a concentration of 1U/µl for blunt end ligation and 
0,1U/µl for sticky end ligation and filled with aqua dest. ad 50µl. The reaction mixture was 
incubated at 37°C for 5min, followed by incubation at 25°C for 1 hour and at 4°C overnight. 
As ligation control, 5µl of each sample were size separated by agarose gel electrophoresis.  
 
 
5. Methods 
 
 
44 
 
5.1.9. Transformation and transposition 
5.1.9.1. Transformation  
10µl of each ligation mixture was incubated with 50µl transformation competent E.coli C600 
on ice for 20min, at 42°C for 2min and again on ice for 5min. Afterwards 200µl LB+ medium 
were added, followed by incubation for 1 hour at 37°C. Since the cloning vectors encode 
ampicillin resistance, the mixture was plated on LB-agar plates with ampicillin with 100µg/ml 
ampicillin and incubated at 30°C overnight. The next day, colonies were picked and 
cultivated in 3ml LB medium with 100µg/ml ampicillin overnight at 37°C and shaking at 
300rpm. Clones containing transfer vectors with the respective RHDV-2-VP60 ORF in the 
correct orientation were identified by restriction enzyme cleavage of rapid-test plasmid DNA. 
 
5.1.9.2. Transposition  
1µl of bacterial plasmid DNA was incubated with 100µl transformation competent DH10Bac 
E.coli on ice for 20min, at 42°C for 2min and again on ice for 5min. After adding 900µl  
SOC-medium, incubation for 4 hours at 37°C and shaking at 300rpm using an Eppendorf 
thermomixer 5432 followed. A dilution series till 10-3 with 1ml of the bacterial suspension in 
SOC medium was incubated at 37°C and 300rpm overnight. The next day, 500µl dilutions till 
10-5 were created from the 10-3 dilution. After further incubation at 37°C and 300rpm for  
2 hours using an Eppendorf thermomixer, 200µl of dilutions 10-3 to 10-5 were plated on agar 
plates containing IPTG, X-Gal and antibiotics gentamycin, kanamycin and tetracycline. The 
plates were incubated at 37°C and at room temperature afterwards for 24 hours each time. 
After that time blue-stained and unstained (white) colonies could be differentiated on the 
plates. 4 white colonies that harbour baculovirus bacmid DNA with the target sequences from 
the transfer plasmids, were picked and each colony was incubated at 37°C overnight in 3ml  
LB selection medium.  
 
5.1.10. Isolation of nucleic acids 
5.1.10.1. Rapid-test, small scale purification of plasmid DNA and baculovirus bacmid 
DNA 
After transformation of the ligation mixture and after transposition, 1ml of overnight bacterial 
cultures was centrifuged with 7000rpm for 30sec at room temperature with an Eppendorf 
centrifuge. The pellet was then shaken shortly at room temperature with an Eppendorf mixer 
5432 before adding of 100µl solution I. After thorough mixing 100µl solution II was added 
and agitated shortly before adding 150µl of solution III. After incubation for 60min on ice, a 
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centrifugation at 14000rpm at room temperature was performed. Supernatant was then mixed 
with 1ml 100% ethanol and incubated at -70°C for 15min. After another centrifugation step at 
14000rpm and room temperature for 10min, the pellet was washed with 1ml 70% ethanol and 
centrifuged again with 14000rpm at room temperature for 5min. The pellet was then dried at 
56°C and resuspended in 40µl TE buffer with RNase A (50µg/ml) at 56°C for 5min and 
shaking at room temperature for 15min.  
For DNA prepared after transposition, RNase incubation was done at 37°C for 30min. 
Baculoviral bacmid DNA concentration was measured by spectrophotometry and regarded as 
pure when a 260nm/280nm ratio of approximately 2,0 was obtained. 
For identification of E.coli clones containing the envisaged plasmid, 10µl bacterial plasmid 
DNA was added to 2,5µl NEB 3 buffer, 0,3µl NcoI and 12,2µl aqua dest. and incubated at 
37°C for 1 hour. Cleavage products were analyzed by agarose gel electrophoresis.  
 
5.1.10.2. Purification of bacterial plasmid DNA by Qiagen Plasmid Midi-Kit 
To obtain larger quantities of pure plasmid DNA, 1µl plasmid DNA was added to 50µl 
transformation competent E.coli 600, treated as described above (3.1.9.1.)  incubated at 37°C 
for 1 hour in 1ml LB medium and then in LB medium with ampicillin with 100 µg/ml 
overnight at 37°C while shaking at 300rpm. DNA was purified with a Qiagen Plasmid Midi 
Kit according to the manufacturer’s protocol. Purified plasmid DNA was resuspended in 
125µl TE buffer. The DNA concentration was determined by spectrophotometry. For 
verification of the identity, 500ng plasmid DNA were cleaved with 0,5µl NcoI, 2,5µl buffer 
NEB3 and aqua dest. ad 25µl at 37°C for 1 hour, followed by an agarose gel electrophoresis 
with 90V. 
 
5.1.11. Photometric measurement of DNA concentration 
Concentration of DNA was measured with a photometer at absorption of 260nm or 280nm in 
a dilution of 1:100 with aqua dest. 260nm is correlated to 50µg/ml dsDNA. 
 
5.1.12. Cell cultures 
5.1.12.1. Cultivation of insect cell lines 
SF9 (Spodoptera frugiperda) cells were cultivated in Grace’s supplemented insect cell 
medium with 10% FCS, 100U penicillin per ml, and 100µg streptomycin per ml (ZB15).  
High V cells were cultivated in Insectomed SF express-medium (Biochrome) (High V 
medium). Both cell lines were kept at 27°C in humidified atmosphere containing 2,5% CO2. 
5. Methods 
 
 
46 
 
Every 3-4 days the cells were passed. Old medium was removed, fresh medium was added, 
then cells were detached by hitting the bottom of the flasks and split in a ratio of 1:4 into new 
flasks. 
 
5.1.12.2. Cultivation of rabbit kidney cell line  
RK13 (rabbit kidney) cells were cultivated in MEM (Earl’s and Hank’s salts 1:1) 
supplemented with non-essential amino acids, 10% FCS, 100U penicillin per ml and 100µg  
streptomycin per ml (ZB5) at 37°C in humidified atmosphere with 2,5% or 5% CO2. Cells 
were passed every 3-4 days. At first old medium was removed and cells were detached by 
trypsination at 37°C. Cells were then centrifuged for 2min at 500xg at room temperature. The 
pellet was washed once with medium ZB5 and centrifuged again. Cells were split in a ratio 
1:4 into new flasks.  
 
5.1.13. Transfection of recombinant bacmid DNA in High V cells 
Circa 106 High V cells were seeded in a 6well plate with 2ml per well High V medium and 
incubated at 27°C for 1 hour. A transfection mix with 5µg DNA, 6µl FugeneR HD and aqua 
dest. ad 100µl was prepared and incubated at room temperature for 40min before diluting it 
with 900µl High V medium. After washing the cells with High V medium, 1ml of the same 
medium was added. The diluted transfection mix was then carefully dropped on the cells and 
incubation for 5 hours at 27°C followed. Afterwards the culture supernatant was removed and 
replaced by 2ml High V medium with 100 U penicillin/ml and 100 µg streptomycin/ml per 
well before incubation at 27°C for 3 days. Then cells and supernatants were collected and 
frozen at -80°C. Replication of baculoviruses could be detected by GFP autofluorescence and 
cell lysis. 
 
5.1.14. Isolation of recombinant baculoviruses by plaque assay 
Into each well of 6 well plates circa 106 SF9 cells/well were seeded in 2ml ZB15 medium and 
incubated for 30min. A dilution series of the transfected High V cells supernatants from 100 
till 10-2 was prepared and 100µl of each dilution was pipetted into the 6 wells. After 
incubation for 1 hour at 27°C, supernatants were removed and cultures were overlaid with an 
agarose overlay. After incubation at 27°C for 3 days, autofluorescent plaques were detected 
with the fluorescence microscope due to GFP expression of the recombinant baculoviruses in 
the insect cells. Cells within plaques were picked and resuspended in 1ml of ZB15 medium 
each. After shaking for 30min at room temperature with 600rpm, each plaque was transferred 
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into flasks with 105 SF9 cells. After 5-7 days at 27°C, supernatants were frozen at -80°C in 
2ml Eppendorf tubes.  
 
5.1.15. Cultivation and titration of recombinant baculoviruses by endpoint dilution assay 
For cultivation of baculovirus recombinants, SF9 cells were infected with an MOI of 0,1 and 
incubated for 7 days at 27°C. Infection progress was monitored by GFP autofluorescence and 
cell lysis. Cells and supernatants were harvested and aliquoted at -80°C. 
For titration, supernatants of each picked plaque or aliquoted cell suspensions were diluted 
from 10-1 to 10-8 in ZB15 medium after thawing and treating by ultrasound (40W, 20sec). 
100µl virus dilution was pipetted into the wells of a 96well plate in quadruplicate. Then 6x104  
SF9 cells/well were added. After 5-7 days at 27°C, the number of autofluorescence positive 
wells were counted and virus titers were calculated as endpoint dilution assay TCID50:  
 
TCID50= D(n/p+0,5) x 1/sample volume (ml)   D=dilution factor 
        n= number of positive wells 
        p= number of parallel values 
 
5.2. Infection and transduction of cells with recombinant baculoviruses 
5.2.1. Infection of SF9 cells with recombinant baculoviruses 
For RHDV-2-VP60 production or generation of recombinant baculoviruses, SF9 cells were 
infected in suspension with ZB15 medium at the MOIs and for the times given in the results 
section and seeded into appropriate cell culture plates or flasks. At the indicated times the 
cells were detached and pelleted at 300g for 2 to 10min. Cell pellets were washed once with 
PBS. For protein analyses cells were lysed with lysis buffer directly and stored at -20°C until 
use. For further processing, cell pellets were adjusted to yield a 20% (weight per volume) 
suspension with PBS and stored at -80°C until further processing. 
 
5.2.2. Transduction of RK13 cells with recombinant baculoviruses  
For RHDV-2-VP60 production confluent RK13 cell cultures were trypsinized, washed with 
ZB5 and cells were seeded into appropriate cell culture vessels and transduced 24h later with 
the respective recombinant baculoviruses. Before transduction, cells were washed once with 
PBS+ (with calcium and magnesium). Recombinant baculoviruses were added in PBS+ at the 
MOIs and for the times given in the results section. Cells were incubated at 26°C either by 
shaking on a gyratory shaker with 300rpm for 5 hours or by shaking for 1,5 hours with 
300rpm followed by 1 hour of centrifugation at 600g. After transduction, the inoculum was 
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replaced by cell culture medium ZB5 containing 5mM butyrate for 24 hours to increase gene 
expression and the cells were incubated at 37°C. If applicable, further incubation continued in 
normal culture medium ZB5 at 37°C. At the indicated times, cells were either lysed directly in 
lysis buffer and stored at -20°C for protein analyses or, for further processing, they were 
detached by trypsinization, pelleted at 300g for 2 to 10min, washed with PBS, adjusted to 
yield a 20% (weight per volume) suspension with PBS and stored at -80°C until use.  
 
5.3. Gel electrophoresis 
5.3.1. Agarose gel electrophoresis 
The appropriate amount of agarose was melted by boiling in water. After cooling to 56°C,  
TA buffer to a 1x final concentration and 0.1 µg/ml ethidium bromide (in 20mM Tris pH 8,0) 
were added. The mixture was poured into gel electrophoresis chambers of different sizes. 
After the gel had solidified, running buffer, which consisted of 1x TA buffer with 0,1 µg/ml 
ethidium bromide, was added. Electrophoresis was done at 90V- 135V, depending on the gel 
size. As molecular weight standard an 1kb DNA ladder was used. DNA fragments were 
visualized by UV light at 256nm or 366nm and documented by photography. 
 
5.3.2. SDS-polyacrylamide gel electrophoresis 
Protein samples were separated by discontinuous SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE). They consisted of a 10% separating gel and a 4,5% stacking gel mounted into a 
vertical gel electrophoresis chamber (Mini Protean® Tetra Cell, Bio-Rad). Once the gels were 
solidified, 1x running buffer was added. Protein samples were thawed and treated with 
ultrasound (ultrasonic waterbath, Branson) for 2x 20sec at 40W. If not already done at time of 
harvesting, samples were then mixed with sample buffer. After adding of 4%  
2-mercaptoethanol, incubation at 85°C for 5min and short centrifugation, 20µl of samples 
were loaded into the wells of the stacking gel. 6µl of Prestained Protein Marker Page RulerTM 
served as size marker. Electrophoresis was done at 200V for 45min.  
 
5.4. Western Blot 
5.4.1. Transfer of protein samples to nitro cellulose membrane 
After separation of the protein samples by SDS-polyacrylamide gel electrophoresis, proteins 
were transferred onto a nitro cellulose membrane (Whatman®). In a semi dry western blot 
apparatus (Trans-Blot®-SD Semi-Dry Transfer Cell, Bio-Rad) 3 layers of Whatman® 3MM 
paper, which were soaked with transfer buffer, were placed. On top of those, the wet nitro- 
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cellulose membrane followed by the polyacrylamide gel and three more soaked layers of 
Whatman® 3MM papers were laid. Transfer was done at 20V for 45min. 
 
5.4.2. Chemiluminescence 
The nitro cellulose membrane was washed with PBS after blotting and then incubated in PBS 
with 6% skim milk powder for 60min and incubated at 4°C overnight afterwards. The next 
day the membrane was washed once with PBS/0,1% Tween20 and then incubated with 
antibodies αVP60_1 IgG (1:10000) or αGFP IgG (1:50000) in PBS/0,1% Tween20 for 1 hour 
by shaking at room temperature in the dark. After incubation it was washed 3 times with 
PBS/0,3% Tween20 and then incubated for 15min again by shaking at room temperature in 
the dark. 3 more washing steps were performed with PBS/0,1% Tween20, followed by 
incubation for 5min as described. Anti-rabbit IgG POD conjugate was diluted 1:20000 in 
PBS/0,1% Tween20 and added to the membrane. After incubating for 1 hour, the washing 
steps were repeated as describe above. Chemiluminescent substrates (ClarityTM Western ECL 
Substrate, Bio-Rad) were added as recommended by the supplier and chemiluminescent 
signals were recorded by a Bio-Rad VersaDocTM Imaging System, using the software 
QuantityOne. 
 
5.5. VLP purification 
For VLP purification after transduction, RK13 cells in T162 flasks were incubated with the 
respective recombinant baculoviruses at an MOI of 25 in 20ml PBS+ on a gyratory shaker at 
26°C with 300rpm for 5 hours. The inoculum was replaced by culture medium ZB5 with 
5mM butyrate and cells were incubated at 37°C and 5% CO2 for 24h. The medium was then 
replaced by normal cell culture medium and cells were harvested by trypsinization and low 
speed centrifugation 1 day later. The pellets were washed once with PBS and resuspended in 
PBS to yield a 20% weight per volume suspension. 
For VLP purification from SF9 cells, cultures in T162 flasks were infected with the respective 
recombinant baculoviruses at an MOI of 1 and harvested 3 days pi. After harvesting and low 
speed centrifugation, the cells were resuspended in PBS to yield a 20% weight per volume 
suspension. 
After one freeze (-80°C)/ thaw cycle the suspensions were sonicated twice for 20 seconds in 
Branson ultrasonic water bath at 40W. Cell debris was removed by centrifugation with 
5000rpm at 4°C for 30 minutes using a Heraeus Christ Minifuge. The supernatants were 
extracted with one third volume of chloroform by vortexing for 2 minutes and centrifuging 
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again with 5000rpm at 4°C for 30min. The aqueous phase was laid on a 20% sucrose cushion 
made in 0,2M Tris-HCl, pH 6,8 and centrifuged with 30000rpm at 4°C for 2 hours using a 
Beckman SW 32 rotor. The pellet was resuspended in 3,5ml CsCl2 solution and centrifuged in 
a Beckman SW 60 rotor with 48000rpm for 65h at 20°C. The visible band with accumulated 
VLPs was aspired and dissolved in PBS. VLPs were pelleted with a Beckman SW 32 rotor 
with 30000rpm at 4°C for 2h and resuspended in 400µl PBS for examination by electron 
microscopy.  
 
5.6. Transmission electron microscopy 
VLP samples were analyzed by Dr. K. Franzke, Head of the laboratory for Electron 
Microscopy at FLI- Insel Riems. For transmission electron microscopy the purified particles 
were adsorbed to formvar-coated nickel grids for 7min, stained with 1 % phosphotungstic 
acid (pH 6.0) and analyzed with a FEI Tecnai- 12 Spirit transmission electron microscope at 
an accelerating voltage of 80kV. 
 
5.7. Evaluation of viral load 
5.7.1. Liver homogenate  
To determine the viral load in rabbit liver tissue after challenge with RHDV-2 different 
methods were used comparatively.  
About 200mg liver samples were homogenized after adding 1,5ml of medium ZB12 using 
Qiagen Tissue Lyser II for 2 minutes at 30HZ. The lysed tissue suspension was then 
centrifuged with 14000rpm with an Eppendorf centrifuge at 4°C for 5 minutes and 
supernatant was immediately used or stored at -80°C until further analysis.  
 
5.7.2. RNA purification 
RNA was purified from the liver supernatant samples using the QIAamp Viral RNA Mini Kit 
(Qiagen) according to manufacturer’s protocol. For each sample 5µl of an internal process 
control RNA (“IC-RNA”; Hoffmann et. al, 2006; kindly provided by Dr. G. Strebelow, FLI- 
Insel Riems) was added as internal purification efficancy control. For up to 6 samples a 
sample of RNAse free water as RNA isolation control was additionally purified. Purified 
RNA was stored at -80°C until further use. 
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5.7.3. Quantitative real time RT-PCR 
To verify the presence of RHDV-RNA in liver supernatant samples, 5µl of purified RNA 
were analyzed by an established and validated qRT-PCR method (Gall et.al. 2007) using the 
SuperScriptTM III One-Step RT-PCR System with Platinum® Taq DNA Polymerase 
(Invitrogen). A no template control (“NTC”) with RNase free water served as negative 
control, purified RHDV-2 RNA at a previously determined threshold cycle value (ct) of 33 or 
standard RHDV-1 RNA with 2x106 copies/µl served as positive control (“PC”). The primer/ 
probe mix “RHDV-2 Mix” was used to detect RHDV-2 RNA in the liver samples, the 
primer/probe mix “RHDV-1 Mix” to detect RHDV-1 RNA and the primer/probe mix “IC-
Mix” for the validation of IC-RNA (Tab. 2). As reference dye ROX was used. To 20µl of 
master mix, 5µl sample were added. Preparation of the master mix and adding of samples 
were performed on ice. After reverse transcription for 30min at 50°C, the inactivation of the 
reverse transcriptase and activation of the taq polymerase was done for 2min at 94°C. The 
PCR consisted of 42 cycles with denaturation for 30sec at 94°C, annealing for 45sec at 55°C 
and elongation for 45sec at 68°C. The real time RT-PCR was analyzed using the real time 
PCR cycler MX3005P and the software program “MxPro” measuring the channels FAM 
(liver samples, “NTC” and “PC”), HEX (“IC”) and ROX (reference dye).  
 
5.7.4. Antigen-ELISA 
For the determination of the RHDV-2-VP60 antigen content in liver samples the commercial 
ELISA Kit “Ingezim RHDV DAS R.17.RHD.K2” (Ingenasa, Spain) was used according to 
manufacturer’s protocol. Briefly, 100µl of each liver sample in duplicates were incubated for 
1h at 37°C in coated 96 well plates and washed 3 times with washing buffer. Then 100µl 
conjugate was added to each well and incubated for 1h at room temperature. After another 3 
washing steps, 100µl substrate solution was added to each well and incubated for 5min at 
room temperature. The reaction was stopped with 100µl/well stop solution. Positive and 
negative controls samples provided within the kit served as internal controls. A liver sample 
from a rabbit infected with RHDV-2 “Werne” with a predetermined RHDV-2 antigen content 
served as external positive control. Absorbance was measured at 450nm with an ELISA 
reader (Spectra, Tecan) and E.A.S.Y Win software. 
 
5.7.5. Hemagglutination assay (HA)  
The hemagglutination assay (HA) was performed according to OIE standard procedure. In a 
96well plate (U-shaped) 50µl of isotonic phosphate buffer were added per well. Then 50µl of 
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each liver supernatant sample were titrated in two-fold steps and incubated with 50µl/well of 
a 1% dilution of blood group 0 human erythrocytes in isotonic phosphate buffer at 4°C for 
90min. A RHDV-2 strain “Werne” liver homogenate with predetermined titer was used as 
positive control and isotonic phosphate buffer as negative control. All samples were run in 
duplicates. The HA titer was expressed as the value of the highest dilution resulting in 
complete hemagglutination assessed by visual observation. 
 
5.8. Purification of RHDV-2 antigen for antibody-ELISA 
A 10% suspension of ground infectious RHDV-2 liver material in medium ZB12 was 
centrifuged with 3000rpm at 4°C for 30min with a Heraeus Christ centrifuge. Supernatant was 
then extracted with 15% chloroform by shaking the mixture with 220rpm at room 
temperature. After adding of 4% binary ethylenimin to the supernatant, incubation at 4°C 
overnight followed. The next day 20% Na-thiosulfate was added and another centrifugation 
step at 4°C with 3000rpm for 30min was performed. Supernatant was precipitated with 10% 
PEG over 2 hours at room temperature and then incubated at 4°C overnight. After 
centrifugation at 4°C with 4000rpm for 50min the pellet was resuspended 1/20 volume TEN 
buffer (pH 7,5) and incubated at 4°C overnight. After centrifugation with 4000rpm at 4°C for 
20min, supernatant was ultracentrifuged on a 17% sucrose/TEN cushion with a ratio of 4:1. 
Ultracentrifugation was performed using a Beckman SW 32 rotor with 25000rpm at 4°C for 
2h. After drying, the pellet was resuspended in 5ml TEN buffer and stored at -80°C. The 
concentration of purified antigen was determined using reference sera. 
 
5.9. Generation of RHDV-2 challenge virus 
A 10% suspension of ground infectious RHDV-2 liver material in medium ZB12 was 
centrifuged with 3000rpm at 4°C for 10min with a Heraeus centrifuge. Supernatants were 
then lyophilized in aliquots of 1ml. The titer of the challenge virus was determined by 
hemagglutination assay. 
 
5.10. Measurement of RHDV specific serum antibodies  
Serum samples from all trials were analyzed in an indirect ELISA for the presence of  
RHDV-1 or RHDV-2 specific antibodies. 96well ELISA plates (Microlon® 200 96W 
Microplate, Greiner, Germany) were coated with 100 µl/well of purified RHDV-1 or  
RHDV-2 antigen respectively in coating buffer Tris-NaCl at 4°C overnight. After 3 times 
washing with PBS/0,05% Tween20 using a microplate washer (HydroFlex Tecan) the rabbit 
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sera were two-fold diluted in PBS/0,05% Tween20 with 5 % horse serum. 100µl/well were 
shaken for a short time and then incubated for 1 hour at 37°C. After further 3 times washing 
as described 100µl anti-rabbit IgG POD conjugate diluted 1:20000 in PBS/0,05% Tween20 + 
5% horse serum were added per well. Plates were shaken for a short time and again incubated 
at 37°C for 1 hour. After three more washing steps 100µl/well substrate solution was added 
and incubated for 30 minutes at room temperature in the dark. The reaction was stopped by 
adding 50µl 4M H2SO4 per well and absorbance at 492nm was measured with an ELISA 
reader (Spectra, Tecan) and E.A.S.Y Win Software. 
 
5.11. Flow cytometric analysis (FACS) 
FACS analysis of EDTA blood samples were performed by the laboratory of Dr. B. Köllner at 
the FLI- Insel Riems. Blood leukocytes were prepared by density gradient centrifugation. 1ml 
of EDTA blood was diluted 1:4 v/v with PBS, 0,01% 1mM EDTA. The cell suspensions were 
laid on 3 ml of Pancoll (1,077g/ml) and centrifuged for 30min with 1800rpm in an Eppendorf 
centrifuge. The cells at the interface were collected, resuspended with PBS, 0,01% 1mM 
EDTA, centrifuged again for 6min with 1600rpm and resuspended in 2ml of PBS, 0,01% 
EDTA. 2 x 105 cells/well were then incubated in a U-bottom 96well plate with combinations 
of different monoclonal antibodies specific for leukocyte differentiation markers (Tab. 3) at 
4°C for 30min. Plates were again centrifuged with 1000rpm for 3min with an Eppendorf 
centrifuge and supernatants were then discarded. After washing with 100µl/well PBS, 0,01% 
1mM EDTA the labelled cells were incubated with 50µl/well isotype specific fluorochrome 
(FITC or PE) antibody conjugates for 30min at 4°C. Another centrifugation with 1000rpm for 
3min was performed. After discarding of supernatants, cells were washed with 100µl/well 
PBS, 0,01% 1mM EDTA once. After final washing the cells were resuspended in 300µl PBS, 
0,01% 1mM EDTA and analyzed in FACScalibur (Becton Dickinson). 
 
5.12. Generation of vaccine candidates 
SF9 cells were seeded and immediately infected with the respective recombinant baculovirus 
stocks at an MOI of 1 and incubated for 72h at 27°C, 2,7 % CO2 in T162 flasks. After 3 days 
the cells were detached and centrifuged with 1500rpm for 20min at 4°C with a Heraeus Christ 
centrifuge. The pellets were frozen at -80°C till further processing. After thawing, the pellets 
were resuspended in PBS, pooled and sonicated for 5x 20 seconds at 40W with a Branson 
ultrasonic water bath for disintegration of cells. 
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RK13 cells were seeded in T75 flasks. After 24 hours they were transduced with the 
respective recombinant baculoviruses at an MOI of 25 and then incubated in 10 ml PBS+ on a 
gyratory shaker with 300rpm at 26°C for 5 hours. The inoculum was replaced by culture 
medium ZB5 with 5 mM butyrate and cells were incubated at 37°C and 5% CO2 for 24h. The 
medium was then replaced by cell culture medium ZB5 and cells were harvested by 
trypsinization, low speed centrifugation and washing with PBS 1 day later. The pellets were 
resuspended in PBS, pooled and frozen at -80°C till further processing. After thawing, the 
cells were treated with ultrasound for 5x 20 seconds at 40W for disintegration of cells. 
The recombinant vaccine candidates derived from SF9 were designated as “recRHDV2-vacc; 
BacBac-A” or “recRHDV2-vacc”. The recombinant vaccine candidate derived from RK13 
cells was named “recRHDV2-vacc; BacMam-A”. 
The recombinant vaccine candidates were used in comparison to a conventionally prepared 
vaccine using a liver homogenate from RHDV-2 (strain “Werne”) infected rabbits inactivated 
with BEI (referred to as “convRHDV2-vacc”; kindly provided by Dr. H. Schirrmeier, FLI- 
Insel Riems). 
As a negative control preparation, SF9 cells were infected with recombinant baculovirus 
CO107 Baculop10GFP (kindly provided by C. Klopfleisch) at an MOI of 1. This recombinant 
expresses GFP but not VP60 (referred to as “recbacGFP-vacc”). Infected SF9 cells were 
processed the same way as for the “recRHDV2-vacc” vaccine. 
Hemagglutination activity of rec-RHDV-2-VLPs in the obtained vaccine stocks was 
determined by hemagglutination assay and amount of RHDV-2-VP60 protein was confirmed 
using an indirect ELISA Kit (Ingenasa). 
The candidate vaccine preparations were mixed with aluminum hydroxide following the 
standard operation procedure for the proprietary RHDV-1 vaccine “Cunivak RHD” by IDT 
Biologika (Riems, Germany) 
 
5.13. Animal experiments 
All animal trials received prior approval from the Federal state Ethical Committee for Animal 
Experimentation (LALLF-7221.3-1-025/15) and were performed following the acquirements 
of the EU directive 2010/63 and the EG recommendation 2007/526/ and the German animal 
welfare act. 
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5.13.1. Animals 
For all trials 10-20 weeks old mix breed “Zimmermann”- rabbits from a commercial rabbit 
farm were used and randomly distributed into the groups. All rabbits were vaccinated twice 
against Pasteurella multocida before. The different trials started earliest 7 days after arrival of 
the rabbits to ensure that the animals were healthy and adapted to the housing conditions. All 
animals were clinically examined and the absence of antibodies against RHDV-2 was verified 
in an ELISA as described above.  
The rabbits were fed with commercial rabbit food (ssniff-Spezialdiäten GmbH, Germany) and 
water ad libitum. 
 
5.13.2. Blood sampling of rabbits  
From all rabbits 1ml blood was sampled within 36 or 72 hours after vaccination or challenge 
infection from ear veins into EDTA pretreated tubes (Sarstedt) for isolation of leukocytes and 
200µl blood was sampled in weekly or monthly time intervals before and after vaccination 
into non-treated tubes for serum collection (Becton, Dickinson). 
 
5.13.3. Immunization of rabbits  
For trials, groups of 4, 8 or 10 animals were used. Vaccination was done into the musculus 
quadriceps femoris of the left hind leg with 1ml of the recombinant vaccines “recRHDV2-
vacc; BacBac-A”, “recRHDV2-vacc; BacMam-A”, as well as “convRHDV2-vacc” and 0,5ml 
of the commercial vaccine “Cunivak RHD” (recommended dose for RHDV-1 protection by 
manufacturer) for trial 1 to test immunogenic properties of VLPs.  In the following trials, 
rabbits were vaccinated with 0,5ml of the “recRHDV2-vacc” or the “convRHDV2-vacc”. 
Respective HU contents for every trial are specified in the results section. A group of 4 non-
vaccinated rabbits served as negative control group in each trial. Additionally, a group of 9 
rabbits was vaccinated with 0,5ml of the “recbacGFP-vacc”. After vaccination, the animals 
were observed and checked for clinical signs. 
 
5.13.4. Challenge infection 
The challenge infection in all trials was done by injection into musculus quadriceps femoris of 
the left hind leg with 2560 HUs of challenge virus RHDV-2 strain “Werne” or RHDV-1 strain 
“Eisenhüttenstadt”. After challenge, the health status of all rabbits was monitored at least 
twice a day and rectal body temperature was taken twice a day over two weeks. 
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Blood was sampled as described until the rabbits were euthanized in a moribund stage or died. 
14 days after challenge all remaining animals were euthanized in accordance with animal 
welfare and blood and organ samples were taken and prepared for further analysis. 
 
5.13.5. Pathological observation and organ sampling  
Postmortem macroscopic and histopathological analysis was performed by Dr. R. Ulrich at 
FLI- Insel Riems. All rabbits underwent complete necropsy under biosafety level 2 conditions 
according to FLI internal standard guidelines. Samples from heart, lung, spleen, liver, kidney, 
intestine and brain were fixed in 10% neutral buffered formalin, embedded in paraffin wax 
using a Leica ASP 300S fully enclosed tissue processor (Leica Biosystems, Nussloch, 
Germany), sectioned at 2-4µm thickness using a Microm HM 340E electronic rotary 
microtome, mounted on glass slides, and stained with hematoxylin and eosin (Mulisch and 
Welsch, 2010). Histopathological changes were assessed using a Zeiss Axio Scope.A1 
microscope equipped with 5x, 10x, 20x, and 40x N-ACHROPLAN objectives. A selection of 
macroscopic and/or light microscopic morphological changes frequently occurring in RHD 
were recorded as being present (1) or not (0) in a spreadsheet for evaluation (Suppl. 1-6). 
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6. Results 
6.1. Generation of recombinant baculoviruses 
In order to obtain high yields of recombinant RHDV-2-VP60, two expression cassettes within 
the baculovirus transfer plasmids were constructed. In both, the sequence of RHDV-2-VP60 
was optimized based on the codon usage (CU) of AcMNPV or glycoprotein B of bovine 
herpesvirus 1. These two RHDV-2-VP60 open reading frames had a nucleotide sequence 
identity of 76.2% among each other and 74.5% (BHV-1-CU) and 74.6% (AcMNPV-CU) 
identity to the authentic RHDV-2-VP60 sequence (GenBank accession number FR819781). 
Both synthetic RHDV-2-VP60 ORFs were inserted into transfer vectors pFBD-P10Uhis-
ieGFP and pCAGGS-PHGFP. This approach resulted in four different recombinant plasmids: 
(1) pFBD_RHDV-2_VP60_AcMNPV, (2) pFBD_RHDV-2_VP60_BHV1, (3) pMBCAGGS-
RHDV-2_VP60_AcMNPV and (4) pMBCAGGS-RHDV-2_VP60_BHV1. The expression of 
recombinant RHDV-2-VP60 in the first two plasmids is controlled by the very late 
baculoviral P10 promotor for use in insect cells whereas gene expression in the second two 
plasmids is controlled by the hybrid CAG(GS) enhancer/promotor element for use in 
mammalian cells. GFP expression cassettes controlled by HCMVie promotor in plasmids 
pFBD_RHDV-2_VP60_AcMNPV and pFBD_RHDV-2_VP60_BHV1 or by the baculoviral 
polyhedrin promotor in plasmids pMBCAGGS-RHDV-2_VP60_AcMNPV and 
pMBCAGGS-RHDV-2_VP60_BHV1 were used to facilitate isolation and titer determination 
of the respective baculovirus recombinants in insect cells (Fig. 8). 
 
 
Fig. 8. Diagram of the arrangement of expression cassettes within the baculovirus transfer plasmids  
Only relevant details are depicted (not to scale) 
PPH: polyhedrin promoter; PP10: p10 promoter; PHCMVie: human cytomegalovirus immediate-early 
enhancer/promoter; PCAGGS: CAG(GS) enhancer/promotor element   
Arrows indicate the transcription directions of the respective genes. Positions of relevant restriction enzyme 
cleavage sites are indicated. 
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After transposition of the GFP and RHDV-2-VP60 expression cassettes into the baculovirus 
bacmid DNA contained in E.coli, recombinant baculovirus DNA was isolated and used for 
transfection of High V cells. Two recombinant baculoviruses for infection of insect cells 
named BacBacVP60-2/AcMNPV (further referred to as BacBac-A) and BacBacVP60-
2/BHV1 (further referred to as BacBac-B) and two for transduction of mammalian cells 
designated BacMamVP60-2/AcMNPV (further referred to as BacMam-A) and 
BacMamVP60-2/BHV1 (further referred to as BacMam-B) were generated and propagated on 
SF9 cells for further characterization. The resulting virus stocks reached TCID50 titers of  
1,8 x 109 for both „BacBac“ stocks and TCID50 titers of 3,2 x 109 for both „BacMam“ stocks. 
 
6.2. RHDV-2-VP60 expression levels were significantly influenced by the used 
promotors but only slightly by the codon usage of synthetic VP60 
The resulting expression of RHDV-2-VP60 analyzed after infection of insect or transduction 
of vertebrate cells using the above described four recombinant baculoviruses (BacBac-A or -
B; BacMam-A, -B) respectively is shown in figure 9. The expression kinetics in infected 
insect-derived SF9 cells indicated an increase over time which was shown also for kinetics in 
transduced rabbit kidney-derived RK13 cells but with a slight decrease from day 5 after 
transduction. After infection of SF9 cells using BacBac-A or BacBac-B at an MOI of 1 a 
comparable expression level of the RHDV-2-VP60 was determined by immunoblotting.  
 
 
Fig. 9. Comparative kinetics of RHDV-2-VP60 expression  
Left:  after infection of insect-derived SF9 cells with BacBac-A (CU AcMNPV) or BacBac-B (CU BHV-1), 
MOI 1 or  
Right: after transduction of rabbit kidney-derived RK13 cells with BacMam-A (CU AcMNPV) or BacMam-B 
(CU BHV-1), MOI 25.  
Numbers above western blot bands represent the days after infection or transduction, respectively. 
Non-infected SF9 or non-transduced RK13 cells showed no signals in Western Blots (not shown). 
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This was also true after transduction of RK13 cells with BacMam-A or BacMam-B, both at an 
MOI of 25 (Fig. 9). 
Protein expression was found to be dependent on the amount of recombinant baculovirus with 
MOI 0,1 to 1 in SF9 cells and MOI 5 to 25 in RK13 cells (Fig. 10). 
 
 
Fig. 10. Comparative kinetics of RHDV-2-VP60 expression dependent on MOI of recombinant 
baculoviruses  
Left: 3 days after infection of insect-derived SF9 cells with BacBac-A (CU AcMNPV) or BacBac-B (CU 
BHV-1) or 
Right: 1 day after transduction of rabbit kidney-derived RK13 cells using BacMam-A (CU AcMNPV) or 
BacMam-B (CU BHV-1) 
 
To verify the kinetics of RHDV-2-VP60 protein expression in mammalian cells, RK13 cells 
were also transduced with BacMam-A together with a different recombinant baculovirus 
which expresses only GFP (BacMam-ieGFP) as a second indicator for target protein content 
progression (Fig. 11). The GFP autofluorescence images indicate that GFP content increases 
until 72h after transduction (p.a.tr.) (Fig. 11A) and then appears to remain largely unchanged 
until day 6 after transduction when a slight decrease was seen and confirmed by 
immunoblotting (Fig. 11B).  
Similar findings were seen after infection of SF9 cells with BacBac-A. Due to baculoviral 
GFP activity in insect cells, no second indicator was needed. Like for RK13 cells GFP 
autofluorescence increases steadily until at least 90h post infection (data not shown). The 
same applies to the recombinant RHDV-2-VP60, from day 3 post infection degradation bands 
are occurring, though (Fig. 9 + 10). Non-infected SF9 or non-transduced RK13 cells showed 
no signals in Western Blots (not shown). 
Previous experiments with GFP expressing “BacBac-recombinants” indicated that SF9 cells 
became successively fragile during progression of the infection at an MOI of 1 which results 
in leakage of soluble proteins into the extracellular media during cell harvest (data not 
shown). 
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Fig. 11. Time course of RHDV-2-VP60 protein progression in rabbit kidney-derived RK13 cells 
Incubation for more than 3 days after transduction (d.a.tr.) does not improve RHDV-2-VP60 protein expression 
levels.  
RK13 cells were transduced with BacMam-A (CU AcMNPV), MOI of 25 together with BacMam-ieGFP,  
MOI of 10.  
A) GFP after transduction determined by autofluorescence.  
B) Protein expression estimated by immunoblotting. The position of VP60 and GFP is indicated. 
 
6.3. Baculovirus-expressed RHDV-2-VP60 assembled to VLPs 
To elucidate whether the RHDV-2-VP60 molecules synthesized in transduced RK13 cells 
(using BacMam-A, -B) and infected SF9 cells (using BacBac-A, -B) assemble to VLPs, cell 
pellets from both cell lines were processed as described in the materials and methods section. 
The visible turbid virion band was collected after density gradient centrifugation, resuspended 
in PBS and analyzed by electron microscopy.  
In all four preparations VLPs, which resemble typical RHDV virions, were detected (only one 
picture for the BacMam- and BacBac recombinants, respectively, is shown) (Fig. 12). 
RHDV virions have the ability to agglutinate human erythrocytes by binding to histo-blood 
group antigens on the cell surface. To prove that the recombinant expressed VLPs had 
assembled to particles which had a comparable biological activity as RHDV-2 virions, the 
hemagglutination (HA) activity of these VLPs was compared to a native RHDV-2 
preparation. VLPs purified from RK13 cells transduced with both recombinant baculoviruses 
resulted in HA titers of 211 while VLPs generated in SF9 cells resulted in HA-titers of 213 for 
both CUs. 
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Fig. 12. Baculovirus-expressed RHDV-2-VP60 assembled to VLPs   
A) RHDV-2-VP60-VLPs derived from RK13 cells transduced with BacMam-A (CU AcMNPV) 
B) RHDV-2-VP60-VLPs derived from SF9 cells infected with BacBac-B (CU BHV-1) 
C) RHDV particles prepared from a liver of a RHDV infected rabbit for comparison (photograph taken by 
Dr. H. Granzow, FLI- Insel Riems) 
Cells were processed as described in the material and methods section and VLPs were visualized with electron 
microscopy (kindly provided by Dr. K. Franzke, FLI- Insel Riems). 
 
6.4. Animal experiments 
6.4.1. Immunogenicity of recombinant RHDV-2-VP60-VLPs - Proof of principle  
Since the in vitro analyses did not reveal significant differences of the RHDV-2-VP60-VLP 
expression levels between different codon usages used in the four generated recombinant 
baculoviruses (see 6.2.), only the recombinant RHDV-2-VP60-VLPs prepared from BacBac-
A and BacMam-A were chosen to test their immunogenicity as well as their protective 
capacity against lethal RHDV-2 infections (proof of principle). This was analyzed 
comparatively in a vaccination-challenge trial using crude extracts prepared from SF9 cells 
infected with BacBac-A at an MOI of 1 or RK13 cells transduced with BacMam-A at an MOI 
of 25 as described in the materials and methods section. The resulting recombinant RHDV-2-
VP60-VLP vaccines will be referred to as “recRHDV2-vacc; BacBac-A or BacMam-A”, 
respectively, in the following section.  
Non-vaccinated rabbits as well as rabbits vaccinated with the “convRHDV2-vacc” served as 
negative and positive controls. Rabbits immunized with the commercial anti-RHDV-1 vaccine 
“Cunivak RHD” were used as heterologous vaccine controls.  
Groups of 4 rabbits were vaccinated with 1ml crude extract of “recRHDV2-vacc; BacBac-A” 
or “recRHDV2-vacc; BacMam-A”; or 512 HU/dose of “convRHDV2-vacc” or “Cunivak 
RHD”, respectively. Two rabbits of each group received a booster immunization 14 days 
later. A fifth group served as non-vaccinated control group. After vaccinations as well as after 
challenge with RHDV-2 (at day 35 after first vaccination) all animals were observed for the 
development of any RHD related clinical signs. 
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None of the vaccinated or non-vaccinated rabbits displayed any sign of disease till challenge 
infection 35 days after the first vaccination. However, within 36h after challenge with  
RHDV-2 all non-vaccinated rabbits developed typical clinical symptoms and died. They 
displayed severe pathological alterations such as necrotizing hepatitis, lung edema and 
hemorrhages in different organs (Tab. 4) as detected by necropsy for RHD related 
pathological changes in inner organs.  
Two rabbits once vaccinated with the anti-RHDV-1 vaccine “Cunivak RHD” developed fever 
>40°C. One rabbit died after 36h with typical clinical symptoms and displayed similar 
pathological alterations as the non-vaccinated animals. The other animal survived and 
recovered 4 days later and only slight pathological alterations were found in inner organs at 
day 14 after challenge.  
All “convRHDV2-vacc” rabbits survived the challenge infection. Although not showing any 
clinical symptoms, focal necrotizing hepatitis or hemorrhages in kidneys were found in 3 of 4 
rabbits of the “convRHDV2-vacc” group but with less severity than in non-vaccinated rabbits. 
In contrast, all “recRHDV2-vacc; BacBac-A” and “recRHDV2-vacc; BacMam-A” vaccinated 
rabbits survived without any clinical symptoms or pathological alterations (Tab. 4).  
 
Tab. 4. Clinical and pathological findings in rabbits vaccinated with different RHDV-vaccines after 
challenge with RHDV-2 
vaccine 
Cunivak 
RHD 
BacBac-A 
recRHDV2-vacc 
MamBac-A 
recRHDV2-vacc 
convRHDV2-vacc non-vacc 
vaccination 2x 1x 1x 2x 1x 2x 1x 2x 1x - 
clinical outcome 
no. of animals 2 2 2 2 2 2 2 2 4 
survived 2 1 
 
2 2 2 2 2 2 
 
died 
  
1 
      
4 
mean survival time, h 336 336 36 336 336 336 336 336 336 36 
clinical symptoms/ pathological findings 
fever > 40°C 0 1 1 0 0 0 0 0 0 4 
necrotizing hepatitis 0 0 1 0 0 0 0 1 1 4 
lung edema 0 0 1 0 0 0 0 0 0 4 
hemorrhages 0 1 1 0 0 0 0 2 0 4 
 
In the liver samples of the deceased rabbits high viral RNA loads (q-RT-PCR), high amounts 
of RHDV-2 viral antigen (ELISA) and viral particles (HA titers) were detected. In the liver of 
the surviving „Cunivak RHD“ once vaccinated rabbit low amounts of virus genome but 
neither RHDV-2 antigen (ELISA) nor RHDV-2 viral particles (HA titers) were found. In the 
livers of all “recRHDV2-vacc; BacBac-A”, “recRHDV2-vacc; BacMam-A” and 
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“convRHDV2-vacc” rabbits as well as of the prime-boost anti-RHDV-1 vaccine “Cunivak 
RHD” rabbits no RHDV-2 RNA, antigen or particles were detected (Tab. 5). 
 
Tab. 5. Comparison between clinical outcome and viral load in liver of rabbits vaccinated with different 
RHDV-vaccines after challenge with RHDV-2 
Note the differences of viral load between vaccinated and non-vaccinated animals and also between the 
surviving “Cunivak RHD” one-time vaccinated rabbit and all the other surviving vaccinated rabbits.  
vaccine 
Cunivak 
RHD 
BacBac-A 
recRHDV2-vacc 
MamBac-A 
recRHDV2-vacc 
convRHDV2-vacc non-vacc 
vaccination 2x 1x 1x 2x 1x 2x 1x 2x 1x - 
clinical outcome 
no. of animals 2 2 2 2 2 2 2 2 4 
survived 2 1   2 2 2 2 2 2   
died     1 
 
          4 
mean survival time, h 336 336 36 336 336 336 336 336 336 36 
viral load 
RNA, q-RT-PCR;  2e 6,4 17,5 31,6 2,9 0 3,8 2 0 1,3 31,9 
viral particle, HA, 2e  0 0 12 0 0 0 0 0 0 12 
VP60, ELISA, OD 0,08 0,07 1,02 0,07 0,06 0,09 0,12 0,06 0,07 0,94 
 
In blood serum samples (taken weekly after first vaccination) all rabbits that received the 
recombinant or conventional RHDV-2 vaccines developed protective antibody titers against 
RHDV-2 which increased from day 0 until day 14 (Fig. 13). The anti-RHDV-2 antibody titers 
increased faster after the rabbits received a second immunization 3 weeks after the first one. 
But, after the challenge infection a-RHDV-2 antibody titers were always higher than 1:25600, 
independent whether the rabbits were vaccinated one or two times.  However, the antibody 
response after vaccination with “recRHDV2-vacc; BacBac-A” and “recRHDV2-vacc; 
BacMam-A” was less intense than after vaccination with the “convRHDV2-vacc”. After a 
single vaccination with the commercial anti-RHDV-1 vaccine “Cunivak RHD” the anti-
RHDV-2 antibody titers were not high enough to prevent disease in one animal which died 
after challenge infection. However, after a prime-boost immunization the RHDV-2 specific 
antibody titers reached protective levels also against a challenge infection with RHDV-2 (Fig. 
13B). 
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Fig. 13. Development of specific anti-RHDV-2 antibody titers in the sera of vaccinated and non-vaccinated 
rabbits (A) after a single or (B) after booster immunization with commercial anti-RHDV-1 vaccine 
“Cunivak RHD”, recombinant baculovirus-derived vaccines and “convRHDV2-vacc” 
d 0 = day of 1. vaccination; d 21 = day of 2. vaccination; d 35 = day of challenge; d 49 = end f trial  
†: One of the two “Cunivak RHD” once vaccinated-rabbits died shortly after challenge infection 
††: Death of the two non-vaccinated rabbits after challenge infection 
 
6.4.2. Naїve rabbits or rabbits vaccinated with “recbacGFP-vacc” displayed only very 
limited natural resistance 
The comparative analysis of all vaccination-challenge trials confirms, that almost all non-
vaccinated rabbits (21 of 24; 87,5%) died after infection (Tab. 6).  
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Tab. 6. Overview about clinical signs and pathological changes in non-vaccinated rabbits or rabbits 
vaccinated with “recbacGFP-vacc” after challenge with RHDV-2  
vaccine non-vaccinated recbacGFP-vacc 
challenge with RHDV-2 RHDV-2 
clinical outcome 
no. of animals 24 9 
survived 3 
 
0 
died 
 
21 9 
mean survival time, h 336 41 48 
clinical symptoms/ pathological findings 
fever > 40°C 2 13 7 
necrotizing hepatitis 0 21 9 
lung edema 0 21 9 
hemorrhages 0 21 9 
 
Before death all animals showed poor general condition and reduced food intake. 57,1% of 
those developed high fever over 40°C. In autopsy hepatitis, lung edema and hemorrhages 
were the main pathological alterations (Tab. 6; Fig. 14a, b). But also other findings that are 
often described in literature were seen such as bloody nasal discharge, congested conjunctivae 
or splenomegaly (Fig. 14a, b, c). Livers usually appeared swollen and fragile after RHDV-2 
infection and histopathological examination of livers confirmed hepatitis with signs of 
apoptosis of hepatocytes like pyknosis and karyorrhexis as is discussed in literature  
(Fig. 14b).  
All of the 3 surviving non-vaccinated animals displayed clinical symptoms like reduced food 
uptake and apathy, while only 2 of those 3 developed fever >40°C for 4 days and recovered. 
No pathological alterations were found (Tab. 6).  
 
 
 6. Results 
 
 
 
66 
  
F
ig
. 
1
4
a
. 
G
ro
ss
 l
es
io
n
s 
in
 n
o
n
-v
a
cc
in
a
te
d
 r
a
b
b
it
s 
th
a
t 
d
ie
d
 a
ft
er
 c
h
a
ll
en
g
e 
w
it
h
 R
H
D
V
-2
 s
tr
a
in
 “
W
er
n
e”
 
 
  
U
p
p
er
 r
o
w
: 
n
ar
es
, 
ep
is
ta
x
is
 (
le
ft
);
 c
o
n
ju
n
c
ti
v
a:
 c
o
n
g
es
te
d
 v
es
se
ls
 (
m
id
d
le
);
 k
id
n
e
y
: 
re
n
al
 p
et
ec
h
ia
e 
(r
ig
h
t)
 
L
o
w
er
 r
o
w
: 
h
ea
rt
: 
ep
ic
ar
d
ia
l 
ec
c
h
y
m
o
se
s 
(l
ef
t)
; 
lu
n
g
: 
tr
ac
h
ea
l 
a
n
d
 a
lv
e
o
la
r 
ed
em
a,
 p
et
ec
h
ia
e,
 e
cc
h
y
m
o
se
s 
(m
id
d
le
);
 t
h
y
m
u
s:
 p
et
e
ch
ia
e
 
an
d
 e
cc
h
y
m
o
se
s 
(r
ig
h
t)
 
 
  
(P
h
o
to
s 
k
in
d
ly
 p
ro
v
id
ed
 b
y
 D
r.
 R
. 
U
lr
ic
h
, 
F
L
I-
 I
n
se
l 
R
ie
m
s)
 
 6. Results 
 
 
 
67 
  
 
Fig. 14b. Pathological alterations in the liver from a non-vaccinated rabbit that died after challenge with 
RHDV-2 strain “Werne” in comparison to a liver from a healthy untreated control rabbit 
A) Comparison of normal liver (left) and cinnabar red, swollen, friable, diffusely necrotic liver (necrotizing 
hepatitis) after RHDV-2 infection (right) 
B) Histopathological image of normal liver from an uninfected rabbit (left) in comparison to necrotic liver 
from an RHDV-2 infected rabbit (right). Arrows indicate pyknotic and karyorrhectic hepatocellular 
nuclei (apoptosis and/or necrosis), H.E., bars = 20µm  
(Photos kindly provided by Dr. R. Ulrich, FLI- Insel Riems) 
 
 
 
Fig. 14c. Splenomegaly after infection with RHDV-2 strain “Werne” (left) in comparison to a normal sized 
spleen (right) 
(Photos kindly provided by Dr. R. Ulrich, FLI- Insel Riems) 
 6. Results 
 
 
 
68 
  
In post mortem liver samples of rabbits that succumbed to the RHDV-2 challenge infection, a 
high amount of viral RNA was detected between 36 and 96h post challenge by q-RT-PCR 
which was up to 220 times higher than in the three survivors. Viral antigen and particles were 
also measured in high amounts in deceased rabbits (Tab. 7; Fig. 17). 
 
Tab. 7. Overview about clinical outcome and viral load in non-vaccinated rabbits as well as rabbits 
vaccinated with “recbacGFP-vacc” after challenge with RHDV-2 
vaccination non-vaccinated recbacGFP-vacc 
challenge with RHDV-2 RHDV-2 
clinical outcome 
no. of animals 24 9 
survived 3 
 
0 
died 
 
21 9 
mean survival time, h 336 41 48 
viral load 
RNA, q-RT-PCR;  2e 5,1 29,9 31,5 
viral particle, HA; 2e 0,3 11,8 11,3 
VP60, ELISA; OD 0,04 1,01 0,98 
 
Interestingly, infection with RHDV-2 induced a strong decrease of the absolute numbers of 
CD4+ as well as CD8+ T-cells shortly after infection in non-vaccinated rabbits. In some 
rabbits, 36 hours post infection nearly no CD8+ T-cells were detectable in blood (Fig. 15).  
 
 
Fig. 15. Kinetics of CD4+ and CD8+ T-cells in blood of non-vaccinated rabbits after infection with  
RHDV-2 (Data kindly provided by Dr. B. Köllner, FLI- Insel Riems) 
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In surviving non-vaccinated rabbits an increase in CD4+ and CD8+ T-cells (Fig. 16) was 
observed as well as a significant increase of antibody titers after challenge infection. 
 
 
Fig. 16. Kinetics of CD4+ and CD8+ T-cells in blood of non-vaccinated rabbits which survived after 
infection with RHDV-2 (Data kindly provided by Dr. B. Köllner, FLI- Insel Riems) 
 
As a further negative control a group of 9 rabbits was vaccinated with recombinant 
baculovirus expressing GFP but not RHDV-2-VP60 (“recbacGFP-vacc”) for evaluation of the 
unspecific immune response after vaccination. Blood serum samples were taken at day 7 and 
14 after vaccination. At day 14 post vaccination this group was also challenged with  
RHDV-2. After challenge infection, animals were observed for the development of any RHD 
related clinical signs and evaluated by autopsy for RHD related pathological changes in inner 
organs after death. 
All 9 animals vaccinated with “recbacGFP-vacc” died between 30 and 125h after challenge 
infection. 7 out of 9 rabbits developed high fever over 40°C and, like the non-vaccinated 
control group, all of them showed poor general condition before death. In necropsy the same 
pathological alterations as in the non-vaccinated control group occurred (Tab. 6; Fig. 14a, b, 
c). In post mortem liver samples of these rabbits a similar high viral load was detected 
between 36 and 125h post challenge (Tab. 7; Fig. 17) as in non-vaccinated rabbits. No 
specific anti-RHDV-2 antibody titers were measured in serum before challenge infection. 
The kinetics of mortality in comparison to viral load of RHDV-2 in liver samples from both 
groups is shown in Fig. 17. 
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Fig. 17. Cumulative mortality (lines) of differentially treated rabbits after infection with RHDV-2 and 
corresponding viral load (columns) in liver samples taken from these rabbits 
Rabbits were vaccinated with “recbacGFP-vacc” and compared to non-vaccinated rabbits.  
Note the high viral load in rabbits that died after infection before end of trial in comparison to survivors at 336 
hours post challenge. 
 
6.4.3. An immunization with RHDV-2 vaccine formulation provided protection against 
RHDV-2 induced disease 
After the proof of principle trial, the induction of protective immunity by vaccination with the 
newly established recombinant “recRHDV2-vacc” was further evaluated in comparison to a 
vaccination with the conventional “convRHDV2-vacc” by intramuscular challenge infection 
of immunized rabbits with RHDV-2. In the following trials only the newly established 
recombinant vaccine prototype “BacBac-A” prepared in SF9 cells infected with MOI 1 was 
further used.  It will be referred to as “recRHDV2-vacc” in the following sections.  
In total, 97,6% (40 of 41) of rabbits vaccinated with the newly developed “recRHDV2-vacc” 
survived after RHDV-2 challenge infection. 37 did not show any RHD specific clinical 
symptoms or pathological alterations in inner organs (Tab. 8). 4 animals displayed rectal body 
temperatures over 40°C after challenge infection but only at single time points in the 2 weeks 
after challenge. In the challenge experiment performed 14 months after vaccination 3 rabbits 
displayed mild clinical symptoms (low food intake and apathy) for 2 days but finally 
survived. One rabbit developed the typical severe RHD symptoms (apathy, no food intake) 
but no fever and died 34h after challenge infection with RHDV-2. This is in detail described 
in 6.4.6. 
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The control rabbits vaccinated with the “convRHDV2-vacc” survived to 100% (23 of 23) 
after RHDV-2 challenge infection without RHD specific clinical symptoms (Tab. 8).  
 
Tab. 8. Overview about clinical signs and pathological changes in rabbits vaccinated with the newly 
established “recRHDV2-vacc” in comparison to “convRHDV2-vacc” after challenge with RHDV-2 
vaccine recRHDV2-vacc convRHDV2-vacc 
challenge with RHDV-2 RHDV-2 
clinical outcome 
no. of animals 41 23 
survived 40 
 
23 
died 
 
1 0 
mean survival time, h 336 34 336 
clinical symptoms/ pathological findings 
fever > 40°C 4 0 2 
necrotizing hepatitis 0 1 2 
lung edema 0 1 0 
hemorrhages 0 1 2 
 
2 animals displayed rectal body temperatures over 40°C after challenge infection but only at 
single time points in the 2 weeks after challenge. Slight pathological alterations were found in 
3 animals like focal necrotizing hepatitis and renal hemorrhages (Tab. 8; Suppl. 1).  
 
Tab. 9. Summarized overview about clinical outcome and viral load in RHDV-2 vaccination/challenge 
trials of rabbits vaccinated with the newly established “recRHDV2-vacc” in comparison to “convRHDV2-
vacc”  
vaccine recRHDV2-vacc convRHDV2-vacc 
challenge with RHDV-2 RHDV-2 
clinical outcome 
no. of animals 41 23 
survived 40 
 
23 
died 
 
1 
 
mean survival time, h 336 34 336 
viral load 
RNA, q-RT-PCR;  2e 0,3 27,8 0,11 
viral particle, HA; 2e 0 12 0 
VP60, ELISA; OD 0,05 0,72 0,06 
 
In liver samples of all surviving animals vaccinated with the recombinant or the conventional 
vaccine candidate no RHDV-2 was detected. In the single “recRHDV2-vacc” immunized 
animal, which died 34h post challenge, a high amount of RHDV-2 was detected (RNA, viral 
antigen and viral particles) (Tab. 9). 
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The induction of a protective humoral immunity after vaccination was combined with a 
stimulation of both CD4+ and CD8+ T-cells in the blood but with a different pattern: whereas 
“recRHDV2-vacc” induced a strong increase of both T-cell populations, “convRHDV2-vacc” 
induced only a CD4+ increase (Fig. 18).  
 
 
Fig. 18. Kinetics of CD4+ and CD8+ T-cells in blood of rabbits vaccinated with “recRHDV2-vacc” or 
“convRHDV2-vacc”  
(Data kindly provided by Dr. B. Köllner, FLI- Insel Riems) 
 
The vaccination of rabbits with the newly established “recRHDV2-vacc” or with the 
“convRHDV2-vacc” induced high titers of RHDV-2-VP60 specific antibodies in serum 
within 14 days post vaccination (for details see 6.4.4.; 6.4.7). In contrast, no RHDV-2 specific 
antibodies were measured in non-vaccinated or rabbits vaccinated with the “recombinant 
baculovirus-GFP” preparation. 
 
6.4.4. A low dose of “recRHDV2-vacc” induced protection against RHDV-2 and 
protective anti-RHDV-2 antibody titers  
To determine whether a protective immunity could be induced by vaccination with low doses 
of the recombinant vaccine, three different doses of “recRHDV2-vacc” with 256, 512 and 
1024 HU, respectively, were used to immunize rabbits in comparison to rabbits that received 
512 HU of “convRHDV2-vacc” and non-vaccinated rabbits as control. The animals were 
challenged 14 days post vaccination with RHDV-2. After vaccination blood serum samples 
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were taken weekly for 4 weeks. All surviving rabbits were euthanized two weeks after 
challenge infection for pathological observation and organ sampling as described.  
A protective immune response could be induced already with the lowest dose of “recRHDV2-
vacc” of 256 HU 2 weeks after a single immunization. All rabbits vaccinated either with 
“recRHDV2-vacc” or the “convRHDV2-vacc” survived the homologous challenge with 
virulent RHDV-2 without any clinical signs of RHD and pathological alterations in inner 
organs. Neither viral RNA nor viral VP60 or viral particles were detected in livers of 
vaccinated rabbits at the end of the trial. In contrast, 3 of 4 non-vaccinated rabbits died within 
50h after challenge with severe clinical signs, pathological alterations in inner organs and 
high viral load in the liver (Tab. 6 + 10). The surviving non-vaccinated rabbit developed 
clinical signs with fever over 40°C but recovered after 4 days. No pathological alterations 
were found in the liver of that rabbit but viral RNA and even a very low amount of viral 
capsid (HA titer 1) was still detected 14 days after challenge infection.  
 
Tab. 10. Clinical outcome and viral load in rabbits vaccinated with different doses of “recRHDV2-vacc” in 
comparison to rabbits vaccinated with “convRHDV2-vacc” and non-vaccinated rabbits after challenge 
with RHDV-2 
 
 
 
 
 
 
 
  
 
The vaccination with different dosages of “recRHDV2-vacc” induced low titers of RHDV-2 
specific antibodies which did not correlate to the dose used for vaccination and which are 
lower than after vaccination with “convRHDV2-vacc”. These RHDV-2 specific titers 
increased significantly after challenge with RHDV-2 in all vaccinated rabbits. 
In contrast, in sera of non-vaccinated rabbits no RHDV-2 specific antibodies could be 
detected prior challenge. After challenge, the surviving, non-vaccinated rabbit developed also 
a high RHDV-2 specific antibody titer comparable to the vaccinated rabbits (Fig. 19). 
 
vaccine recRHDV2-vacc convRHDV2-vacc non-vacc 
HU per dose 1024 512 256 512  - 
clinical outcome 
no. of animals 4 4 4 4 4 
survived 4 4 4 4 1   
died 0 0 0 0   3 
mean survival time, h 336 336 336 336 336 41 
viral load 
RNA, q-RT-PCR;  2e 0 0 0 0 18,3 32,2 
viral particle, HA; 2e  0 0 0 0 1 12,7 
VP60, ELISA; OD 0,06 0,06 0,06 0,07 0,08 1,01 
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Fig. 19. Anti-RHDV-2 antibody titers in sera of rabbits vaccinated with different dosages of “recRHDV2-
vacc” in comparison to rabbits vaccinated with “convRHDV2-vacc” and non-vaccinated rabbits 
d 0 = day of vaccination; d 14 = day of challenge; d 28 = end of trial 
 
6.4.5. The protective immune response against RHDV-2 infection was induced already 
7 days post vaccination 
To elucidate the onset of protective immunity, rabbits were immunized with 1024 HU of 
“recRHDV2-vacc” or 512 HU of “convRHDV2-vacc” and challenged with RHDV-2 seven 
days post vaccination. No viral load in liver samples from surviving rabbits was examined 
after challenge infection as these rabbits were kept for long-term antibody titer observations to 
determine if an early infection with RHDV-2 shortly after vaccination has an impact on 
duration of immunity (see 6.4.6.). Blood serum samples were taken weekly for 4 weeks, then 
monthly. 
All rabbits immunized one times either with “recRHDV2-vacc” or with “convRHDV2-vacc” 
survived the challenge infection with RHDV-2 and developed no clinical signs of RHD. 
The 4 non-vaccinated rabbits died between 40 and 64h with severe clinical signs of RHD, 
pathological alterations in inner organs and comparable high viral load as in the other trials 
before (Tab. 6 + 11). 
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Tab. 11. Clinical outcome and viral load in rabbits challenged with RHDV-2 already 7 days post 
vaccination with “recRHDV2-vacc” in comparison to “convRHDV2-vacc” and non-vaccinated rabbits 
n.d. = not determined after the first challenge infection 
vaccine recRHDV2-vacc convRHDV2-vacc non-vacc 
clinical outcome 
no. of animals 4 4 4 
survived 4 4 1 
 
died 0 0 
 
3 
mean survival time, h    51 
Mean survival time, mths 14 14 14  
viral load 
RNA, q-RT-PCR;  2e n.d. n.d. n.d. 32,5 
viral particle, HA; 2e  n.d. n.d. n.d. 11 
VP60, ELISA; OD n.d. n.d. n.d. 1,12 
 
However, this protection was not correlated in all rabbits with high anti-RHDV-2 antibody 
titers in sera sampled before challenge. After challenge the titers of RHDV-2 specific 
antibodies increased significantly (Fig. 20). 
 
 
Fig. 20. Anti-RHDV-2 antibody titers in sera of rabbits challenged 7 days after vaccination with 
“recRHDV2-vacc” in comparison to rabbits vaccinated with “convRHDV2-vacc” and non-vaccinated 
rabbits   
d 0 = day of vaccination; d 7 = day of challenge 
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6.4.6. A single immunization with the “recRHDV2-vacc” induced a long-lasting 
immunity against RHDV-2 infection 
To evaluate the duration of immunity induced by vaccination with “recRHDV2-vacc”, rabbits 
were immunized and challenged with RHDV-2 either 6 months or 14 months post 
vaccination. A group of 18 rabbits was vaccinated with 1024 HU of “recRHDV2-vacc”, 21 
days post vaccination 8 rabbits received a second vaccination with the same vaccine. A group 
of 10 rabbits vaccinated once with 512 HU of “convRHDV2-vacc” served as positive control 
and 8 non-vaccinated rabbits served as negative controls. From all rabbits blood serum was 
sampled weekly over 4 weeks and then monthly for measuring of antibody titers. 6 months 
post vaccination 4 rabbits of each group were challenged with RHDV-2. The remaining 
rabbits were challenged 14 months after vaccination. Blood serum samples were collected 
weekly after challenge infection. Two weeks after challenge infection the rabbits were 
euthanized for pathological observation and organ sampling as described. 
6 months after vaccination all rabbits immunized either once or twice with “recRHDV2-vacc” 
as well as all rabbits immunized once with “convRHDV2-vacc” survived after challenge 
infection with RHDV-2 without any clinical signs or pathological alterations in inner organs. 
In liver samples from all vaccinated rabbits neither viral RNA nor viral proteins or viral 
particles were detected at the end of the trial (Tab. 12).  
 
Tab. 12. Clinical outcome and viral load in rabbits challenged with RHDV-2 6 months after vaccination 
once or twice with “recRHDV2-vacc” in comparison to “convRHDV2-vacc” and non-vaccinated rabbits 
vaccine recRHDV2-vacc convRHDV2-vacc non-vacc 
vaccination 1x 2x 1x - 
clinical outcome 
no. of animals 4 4 4 4 
survived 4 4 4 1 
 
died 0 0 0 
 
3 
mean survival time, h 336 336 336 336 32 
viral load 
RNA, q-RT-PCR;  2e 0 0,5 0 2,2 32,8 
viral particle, HA; 2e  0 0 0 0 13 
VP60, ELISA; OD 0,05 0,05 0,05 0,05 0,96 
 
In contrast, 3 of 4 non-immunized rabbits died within 32h post challenge with displaying 
typical clinical symptoms before death. Pathological alterations in inner organs (Tab. 6) and a 
similar high viral load were found as in other non-vaccinated rabbits after challenge infection. 
The surviving non-vaccinated rabbit displayed typical clinical symptoms but without fever. In 
the liver of this rabbit no viral load was detected (Tab. 12).  
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14 months after vaccination all rabbits immunized once with “recRHDV2-vacc” or with 
“convRHDV2-vacc” survived the homologous challenge infection with RHDV-2 with no 
clinical signs and pathological alterations in inner organs.  
However, all 4 rabbits immunized a second time 21 days after the first vaccination developed 
clinical signs like apathy and low food uptake and one of them died 34h after challenge 
infection with RHDV-2 without fever. Typical pathological alterations in inner organs were 
detectable (Tab. 8). In the surviving twice-vaccinated rabbits, no typical pathological 
alterations were found and there was no indication for replication of RHDV-2 challenge virus 
as neither viral RNA nor viral VP60 or viral particles were detected in livers (Tab. 13). 
However, in liver samples of the vaccinated, deceased rabbit a high viral load (viral RNA, 
viral protein and particles) was measured (Tab. 13). 
All 4 non-vaccinated rabbits died within 30-34h after challenge with severe clinical signs, 
pathological alterations and high viral load in the liver (Tab. 6 + 13). 
 
Tab. 13. Clinical outcome and viral load in rabbits challenged with RHDV-2 14 months after vaccination 
once or twice with “recRHDV2-vacc” in comparison to “convRHDV2-vacc” and non-vaccinated rabbits 
Note: Due to losses of rabbits during the year, at time of challenge only 4 two-time “recRHDV2-vacc” 
vaccinated rabbits and 3 “convRHDV2-vacc” immunized rabbits were left at time of challenge 
 
 
 
 
 
The kinetics of RHDV-2 specific antibody titers was measured in ELISA using the sera of 
these rabbits sampled over 6 or 14 months, respectively. In both “recRHDV2-vacc” groups 
and the “convRHDV2-vacc” group titers rose steadily over a time of approximately 2 months 
after the first vaccination. Between month 2 and 5 a slight decline of titers began which 
continued for the next 14 months (Fig. 21 + 22). Nonetheless, almost all rabbits of all three 
vaccinated groups still had protective antibody levels 6 months after the first vaccination and 
survived a challenge infection with RHDV-2. One exception was a rabbit that received a 
prime-boost vaccination and did not show antibody titers anymore at the time of challenge 
infection 6 months later (data not shown) but still survived without signs of RHD.  
vaccine recRHDV2-vacc convRHDV2-vacc non-vacc 
vaccination 1x 2x 2x 1x - 
clinical outcome 
survived 5 3 
 
3 0 
died 0 
 
1 0 4 
mean survival time, h 336 336 36 336 34 
viral load 
RNA, q-RT-PCR;  2e 0,8 0 27,8 0 27,3 
viral particle, HA, 2e  0 0 12 0 12 
VP60, ELISA, OD 0,05 0,05 0,72 0,04 0,74 
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Fig. 21. Long-term observation over 6 months of anti-RHDV-2 antibody titers in sera of rabbits after 
vaccination once or twice with “recRHDV2-vacc” in comparison to rabbits vaccinated with “convRHDV2-
vacc” once 
d 0 + d 21 = vaccination; d 203 = challenge after 6 month observation; d 217  = end of trial 
 
 
 
 
Fig. 22. Long-term observation over 14 months of anti-RHDV-2 antibody titers in sera of rabbits after 
vaccination once or twice with “recRHDV2-vacc” in comparison to rabbits vaccinated with “convRHDV2-
vacc” once 
d 0 + d 21 = vaccination; d 427 = challenge after 14 month observation; d 441 = end of trial 
Note: One rabbit which received a prime-boost vaccination did not have any RHDV-2 specific antibody titers at 
day 427 before challenge and died after challenge with RHDV-2 
†: death of one 2x “recRHDV2-vacc” vaccinated rabbit 
 
 6. Results 
 
 
 
79 
  
Generally, in sera of twice “recRHDV2-vacc” immunized rabbits a stronger decline of 
RHDV-2 specific antibody titers was measured in comparison to once “recRHDV2-vacc” and 
“convRHDV2-vacc” immunized rabbits (Fig. 22). The “recRHDV2-vacc” vaccinated rabbit 
which did not survive the challenge infection after 14 months had no RHDV-2 specific serum 
antibodies at the time of challenge infection (data not shown). 
These rabbits were compared with once “recRHDV2-vacc” or “convRHDV2-vacc” 
vaccinated animals that received an early infection with RHDV-2 seven days after vaccination 
(see 6.4.5). After a second RHDV-2 infection 14 months after the first, all rabbits survived 
without clinical symptoms and pathological alterations. No viral load was detected in the 
livers of those rabbits (Tab. 14).  
 
Tab. 14. Clinical outcome and viral load in rabbits challenged with RHDV-2 14 months after a single 
vaccination with “recRHDV2-vacc” with first challenge infection 7 days after vaccination and a second 
challenge infection 14 months later in comparison to “convRHDV2-vacc” and non-vaccinated rabbits 
vaccine recRHDV2-vacc convRHDV2-vacc non-vacc surv. non-vacc 
clinical outcome 
no. of animals 4 4 
 
4 
survived 4 4 1 0 
died 0 0 
 
4 
mean survival time, h 336 336 336 34 
viral load         
RNA, q-RT-PCR;  2e 0 0 0 27,3 
viral particle, HA; 2e  0 0 0 12 
VP60, ELISA; OD 0,05 0,04 0,05 0,74 
 
Rabbits of both vaccine groups developed high antibody titers. These titers did not decline 
from month 2. At the time of the second challenge infection all rabbits still had protective 
antibody titers (Fig. 23).  
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Fig. 23. Long-term observation over 14 months of anti-RHDV-2 antibody titers in sera of rabbits after a 
single vaccination with “recRHDV2-vacc” with first challenge infection 7 days after vaccination and 
second challenge infection 14 months later in comparison to rabbits vaccinated with “convRHDV2-vacc” 
d 0 = vaccination; d 28 = 21 days after challenge infection with RHDV-2; d 427 = 2. challenge infection with 
RHDV-2 after 14 month observation; d 441 = end of trial 
 
6.4.7. A limited cross-protection against heterologous RHDV-1 challenge was induced 
by a single vaccination with “recRHDV2-vacc” 
To determine whether the “recRHDV2-vacc” provides a cross-protective immunity, two 
groups of 4 rabbits each were vaccinated with 1024 HU “recRHDV2-vacc” or 512 HU of 
“convRHDV2-vacc”, respectively. Two groups of 4 non-vaccinated rabbits served as controls. 
After vaccination, blood serum samples were taken weekly over 4 weeks. Each vaccinated 
group and control group was challenged with either homologous RHDV-2 or heterologous 
RHDV-1, respectively, and the course of the disease was monitored over 14 days after 
challenge infection.  
All 4 rabbits vaccinated either with the “recRHDV2-vacc” or with the “convRHDV2-vacc”, 
survived the homologous challenge infection with RHDV-2 and developed no clinical signs 
or pathological alterations in inner organs. In contrast, only 2 rabbits of the “recRHDV2-
vacc” group and 3 rabbits of the “convRHDV2-vacc” group survived the heterologous 
challenge infection with RHDV-1. Of the non-vaccinated rabbits all animals died after 
RHDV-2 infection within 90h and 3 of 4 rabbits died after RHDV-1 challenge infection 
within 52h.  
 6. Results 
 
 
 
81 
  
All of the rabbits which did not survive the challenge infections developed severe clinical 
signs of RHD (fever, reduced food uptake, apathy) and displayed typical pathological 
alterations in inner organs whether they were vaccinated or not. In vaccinated rabbits that 
survived the heterologous challenge, clinical signs and pathological alterations in inner organs 
were recorded also, but with reduced severity. Whereas no viral load was measured after 
challenge infection with RHDV-2 in livers of all vaccinated rabbits, RHDV-1 RNA was 
detected in livers of vaccinated rabbits after heterologous challenge. However, viral particles 
or viral VP60 were only detected in rabbits which died after infection. In livers of the non-
immunized rabbits high viral loads of RHDV-2 or RHDV-1, respectively, were found after 
the challenge infections (Tab. 15). 
 
Tab. 15. Clinical outcome and viral load in rabbits after heterologous challenge with RHDV-1 or 
homologous challenge with RHDV-2 after vaccination with “recRHDV2-vacc” in comparison to 
“convRHDV2-vacc” and non-vaccinated rabbits 
vaccine recRHDV2-vacc convRHDV2-vacc non-vacc 
challenge with RHDV-2 RHDV-1 RHDV-2 RHDV-1 RHDV-2 RHDV-1 
clinical outcome 
no. of animals 4 4 
 
4 4 
 
4 4 
 survived 4 2  
4 3 
 
0 1 
 
died 0 
 
2 0 
 
1 4 
 
3 
mean survival time, h 336 336 48 336 336 42 52 336 45 
viral load 
RNA, q-RT-PCR;  2e 0 9,5 32,3 0 8,1 33,1 31,9 8,8 32,5 
viral particle, HA; 2e  0 0 12,5 0 0 13 10,8 0 12 
VP60, ELISA; OD 0,05 0,07 1,72 0,06 0,07 1,61 1,33 0,06 1,4 
 
As in the earlier experiments, in all sera of the vaccinated rabbits, high titers of specific anti-
RHDV-2 antibodies were measured after vaccination (Tab. 24) and challenge infection with 
RHDV-2 (data not shown). However, after vaccination with “recRHDV2-vacc” as well as 
“convRHDV2-vacc”, only low titers of RHDV-1 cross-reactive antibodies were measured. 
“ConvRHDV2-vacc” was able to induce slightly higher amounts of cross-reactive antibodies 
than “recRHDV2-vacc” (Fig. 24). 
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Fig. 24. Anti-RHDV-2 and anti-RHDV-1 antibody titers in sera of rabbits challenged with RHDV-2 14 
days after vaccination with “recRHDV2-vacc” in comparison to rabbits vaccinated with “convRHDV2-
vacc” or non-vaccinated rabbits 
d 0: day of vaccination; d 14: day of challenge 
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7. Discussion: 
Since in 1984 a newly emerging virus infection killed several millions of rabbits in 
commercial husbandries in China (Liu et al., 1984; Xu and Chen, 1989; Xu, 1991), it was 
clear that there is a strong need for effective vaccines to protect rabbits against this severe 
virus induced hepatitis with up to 100% mortality. However, all approaches to develop a cell 
culture based vaccine failed because the new Calicivirus could not be cultivated in cell culture 
(Granzow et al., 1989; Ohlinger et al., 1989; Ohlinger et al., 1990; Parra and Prieto, 1990; 
Meyers et al., 1991; Moussa et al., 1992). Therefore, vaccines were developed based on an 
inactivated virus suspension prepared from liver material of rabbits infected with RHDV-1. 
These vaccines were very effective and even the variability of RHDV-1 did not affect the 
success of these vaccines (Argüello-Villares, 1991; Smíd et al., 1991; Schirrmeier et al., 
1999). However, this approach to infect and kill rabbits after induction of a severe hepatitis to 
produce a vaccine to protect other rabbits is not only a critical ethical issue but has also the 
disadvantage of the transfer of allogeneic material and of potentially remaining infectivity in 
the inactivated vaccine. 
Since 1994 experimental vaccines based on recombinant VP60, the capsid protein of RHDV, 
have been developed and tested (Laurent et al., 1994). However, so far, only one recombinant 
anti-RHDV-1 vaccine based on a myxoma virus vector that expresses RHDV-1-VP60 is 
available on the market (“Nobivac Myxo-RHD”; Intervet International BV, Netherlands). The 
appearance of new strains of RHDV-1 with a different virulence and the emergence of the 
new variant RHDV-2 in 2010 in France (Le Gall-Reculé et al., 2013), which causes 
significant losses even in RHDV-1-vaccinated rabbits, underlines the requirement of further 
developments for improved vaccines. Therefore, the task of the presented thesis was (a) the 
development of an effective recombinant vaccine to protect rabbits against the new RHDV-2, 
(b) to characterize the onset, duration and possible cross-protection of the newly developed 
vaccine and (c) to evaluate some correlates of protection (RHDV-2 specific antibodies and 
cellular effectors) after vaccination with the newly developed vaccine. 
 
7.1. Construction of recombinant RHDV-2-VP60 
In all available RHDV vaccines the viral capsid protein VP60 is the main immunogenic 
component to induce a protective immune memory. This is proven by the kinetics of VP60 
specific antibodies in sera of vaccinated rabbits which correlates with protection following 
challenge infection (Parra and Prieto, 1990; Laurent et al., 1994; Marín et al., 1995). 
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Since VP60 of classical RHDV-1 and its variants expressed by different vector systems like 
baculovirus (Laurent et al., 1994; Marín et al., 1995; Nagesha et al., 1995; Plana-Duran et al., 
1996; Gromadzka et al., 2006; López-Vidal et al., 2015), E.coli (Boga et al., 1994; Guo et al., 
2016), adenovirus (Fernández et al., 2011), vaccinia virus (Bertagnoli et al., 1996b), myxoma 
virus (Bertagnoli et al., 1996a; Bárcena et al., 2000), ORF virus (Rohde et al., 2011), yeast 
(Farnós et al., 2005), or Canarypox virus (Fischer et al., 1997) induced protective antibodies 
in vaccinated rabbits, in the present thesis a comparable cloning and expression strategy was 
used. Moreover, the advantage of the chosen baculovirus expression system is the disability of 
baculoviruses to replicate in mammalian cells (Hu, 2005) which increases the safety of 
recombinant vaccines in mammals. As shown for other capsid proteins of viruses that could 
not be cultivated in cell culture, like human papilloma virus or hepatitis C virus (Kost et al., 
2005), the expression by recombinant baculoviruses can lead to self-assembly into highly 
immunogenic virus like particles (VLPs). 
Another point for the decision to establish a baculovirus based expression system for the 
production of recombinant RHDV-2-VP60-VLPs was the need of a cost-effective vaccine to 
replace the ethically critical production of RHDV by infected rabbits. Such a vaccine 
approach was also used for recently established recombinant RHDV-1 vaccines (Gao et al., 
2013; López-Vidal et al., 2015). Finally, recombinant baculovirus-expressed VLPs can be 
produced in high yields also for the use in diagnostic tests (Kost et al., 2005). 
For the cloning and construction of the recombinant VP60, the sequence of the RHDV-2 
strain 10-05 (GenBank FR819781) from the first outbreak in France in 2010 (Le Gall-Reculé 
et al., 2013), defined as reference strain, was used. Several other RHDV-2 isolates were 
shown to be very closely related with minimal sequence variation in the VP60 protein but 
quite different from RHDV-1 isolates (Le Gall-Reculé et al., 2013). These antigenic 
differences stress the need for a RHDV-2 vaccine.  
To provide an optimal regulation of the RHDV-2-VP60 expression in different cell cultures, 
two promoter systems, the promotor P10 for VP60 expression in insect cells (SF9) and the 
CAG(GS) enhancer/promotor element for VP60 expression in rabbit kidney (RK13) cells 
were chosen with regard to a later possible commercial use of the vaccine, and also to ensure 
higher expression rates and to gain higher yields of VP60. The very late promotor P10 of 
baculoviruses is a commonly used promotor in baculovirus expression systems (van Oers et 
al., 2015) for protein expression in insect cells, and was proven to be very effective. The 
CAG(GS) enhancer/promotor element was developed for high yield protein expression in 
mammalian cells using recombinant baculoviruses (Shoji et al., 1997; Hu, 2005; Keil et al., 
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2009, 2016). The strategy used in this thesis resulted in the construction of four recombinant 
baculoviruses expressing RHDV-2-VP60 with no significant differences in baculovirus titers. 
Therefore, all four were tested in comparison for the quantitative and qualitative expression of 
RHDV-2-VP60 in the chosen cell systems. 
 
7.2. Influence of the baculovirus construction on RHDV-2-VP60 expression 
7.2.1. Influence of chosen promotors 
Both promotors induced the expression of RHDV-2-VP60 in SF9 or RK13 cells, respectively. 
The expression of viral proteins as early as 24h after transduction was also shown for other 
viruses in different mammalian cells (Kost et al., 2007; Keil et al., 2009).  
The comparative quantitative analysis of the two different promotors used for RHDV-2-VP60 
expression in the respective cell system confirmed that expression under the promotor P10 in 
SF9 cells is more efficient than expression under the enhancer/promotor element CAG(GS) in 
RK13 cells. Additionally, the higher MOI necessary for the transfection of RK13 cells 
indicated a limited efficacy of VP60 expression. This is in accordance with the lower protein 
expression for capsid protein VP6 of rotaviruses after transfection of human embryonic 
kidney cells in comparison to infection of SF9 cells (Da Silva Junior et al., 2012).  
 
7.2.2. Influence of the codon usage 
To optimize protein expression rates, two different codon usages were tested. The classical 
baculovirus codon usage “AcMNPV” was chosen because native baculoviruses replicate with 
high efficiency in SF9 cells and it has been proven to be efficient regarding protein expression 
with recombinant baculoviruses in insect cells (Hu, 2005). The “BHV-1” codon usage was 
chosen because BHV-1 replicates efficiently in RK13 cells, the envisaged target cell line for 
transduction with RHDV-2-VP60 baculoviruses. Moreover, previous experience had shown 
that this CU adaptation leads to increased expression levels of proteins encoded by RNA 
viruses (Kühnle et al., 1998; Schmitt et al., 1999).  
The comparative analysis of both codon usages for the ORFs of the RHDV-2-VP60 revealed 
no general influence on the expression of RHDV-2-VP60 in both cell systems (SF9, RK13) as 
increasing amounts of complete VP60 were detected. Therefore, both codon usages proved to 
be sufficient to gain high amounts of RHDV-2-VP60 in both cell systems. Similar 
observations were made in studies for the expression of BHV-1 glycoprotein D (Keil et al., 
2009) and indicate that translation efficiency may not be solely dependent on the codon usage 
(Menzella, 2011).  
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The nature of minor bands of about 36kDa appearing 72h after infection irrespective of the 
codon usage in SF9 cells (see 6.2; Fig. 10) is not clear, although the polyclonal rabbit  
anti-RHDV-2-VP60 serum used for detection of VP60 in Western Blot analysis indicated that 
these fragments likely are VP60 related. The phenomenon of degraded VP60 in SF9 cells has 
been discussed earlier (Marín et al., 1995), but a negative effect in immunogenicity was 
excluded. Protein degradation using baculovirus expression systems was correlated with the 
lytic replication of baculoviruses in SF9 cells which negatively influences the correct 
expression and folding of recombinant proteins (Ho et al., 2004). The baculoviruses used in 
this thesis displayed a lysis of SF9 cells especially after longer incubation. This was not seen 
after transduction of RK13 cells most likely because baculoviruses are unable to lyse RK13 
cells.  
As all of these proteins were detected by a polyclonal RHDV-2-VP60 specific rabbit 
antiserum in Western Blot analysis one can assume that they still contain epitopes which also 
induce an anti-VP60 specific immune response. Hypervariable motifs in RHDV-VP60 are 
distributed over the whole protein and 7 regions (V1-V7) were identified as being important 
for immunogenicity (Wang et al., 2013b). Using RHDV type specific monoclonal antibodies 
antigenic differences between RHDV-1 and RHDV-2 but also possible overlapping epitopes 
could be defined (Le Gall-Reculé et al., 2013). This indicates that not just one part of VP60 is 
responsible for the induction of VP60 specific antibodies. Whether degraded VP60 proteins 
might interfere with the induction of a protective humoral immunity in rabbits after 
vaccination is unclear.  
Since the expression level of RHDV-2-VP60 “AcMNPV” was slightly higher in SF9 
(BacBac-A) as well as in RK13 (BacMam-A) cells, both preparations were selected for a 
“proof of principle” vaccination/challenge experiment to investigate the induction of a 
protective immune response against RHDV-2 infection. 
 
7.2.3. Generation of RHDV-2-VP60-VLPs 
For many capsid proteins e.g. from Norwalk-virus, Feline Calicivirus or Canine Parvovirus 
self-assembly to empty virus like particles (VLP), which do not contain viral genetic material, 
occurs spontaneously (Green et al., 1993; Di Martino et al., 2006; Jin et al., 2016). Moreover, 
in immunization experiments a higher immunogenicity of assembled compared to non-
assembled capsid proteins was demonstrated (Grgagic and Anderson, 2006; Chen and Lai, 
2013). Self-assembly to VLPs was also found for VP60 of RHDV-1 (Laurent et al., 1994; 
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Nagesha et al., 1995; Gromadzka et al., 2006) and RHDV-2 (Bárcena et al., 2015), which, 
however was not observed in all studies using recombinant baculoviruses (Marín et al., 1995).  
As demonstrated by electron microscopy and analyzed quantitatively by HA tests, all four 
recombinant RHDV-2-VP60 assembled to VLPs. This indicates that the two different codon 
usages to generate the synthetic RHDV-2-VP60 ORF in combination with two different 
promotors for the expression in two different cell culture systems had no detectable influence 
on the self-assembly to VLPs. This revealed that the VP60 gene cassette within the different 
vectors was translated completely to the correct VP60, independent from the cell system. 
VLPs of RHDV-1 were shown to induce a protective immunity in rabbits after vaccination 
(Nagesha et al., 1995; Gao et al., 2013; Guo et al., 2016). Therefore, it was expected to find a 
similar induction of protective immunity after vaccination with the two recombinant 
baculoviruses expressing RHDV-2-VP60 (BacBac-A and BacMam-A). 
 
7.3. Induction of protective immunity after vaccination with the newly established 
RHDV-2-VP60 vaccine 
7.3.1. General findings after vaccination – proof of principle trial 
As RHDV-2 is a highly virulent virus, beside strict hygiene management, vaccination of 
rabbits is the only tool to protect rabbits against the Rabbit hemorrhagic disease. Therefore, 
vaccines that induce a long-lasting immunity against RHDV-2 are desired (Le Gall-Reculé et 
al., 2013; Bárcena et al., 2015).  
The protective capacity against RHDV-2 infection of the newly established recombinant 
vaccines was analyzed in rabbits immunized once or twice with the two recombinant vaccine 
candidates. Obviously, the vaccination with “recRHDV2-vacc” provides a protection against 
challenge infection with RHDV-2 proved by survival and absence of RHD specific clinical 
symptoms. This clinical outcome after vaccination with both recombinant RHDV-2 vaccines 
was comparable to the protection induced by a conventional liver-derived vaccine 
“convRHDV2-vacc”. The protective potential of recombinant VP60 was known from other 
recombinant vaccines generated with baculoviruses against classical RHDV-1 after prime or 
prime-boost vaccinations (Plana-Duran et al., 1996; Fernández-Fernández et al., 2001; Guo et 
al., 2016).  
The increased body temperature measured in 4 of 41 rabbits vaccinated with “recRHDV2-
vacc” and in 2 of 23 rabbits vaccinated with “convRHDV2-vacc” at single time points could 
not be correlated to other RHDV infection related clinical signs and was most presumably 
related e.g. to individual handling stress responses. Also mild histopathological alterations 
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detected in some vaccinated rabbits could not be associated with RHDV infection. In livers of 
3 rabbits immunized with “convRHDV2-vacc”, sampled 14 days post challenge, more RHD 
typical pathological alterations were found, although these rabbits survived without visible 
clinical signs after challenge infection. Whether these pathological alterations in the liver 
were vaccination-induced, due to the RHDV challenge infection or even induced by unknown 
pathological processes, could not be verified. The fact that at the time of sampling two weeks 
after RHDV-2 challenge infection no viral loads (RHDV-2 RNA, viral protein or capsids) 
were detected in all of these animals might indicate that RHDV induced pathological changes 
in liver need a longer time to be completely healed. Furthermore, the absence of clinical signs 
(fever, apathy etc.) not necessarily excludes, that a viral infection of liver cells followed by 
pathological alterations happened before the RHDV is eliminated by the vaccine induced 
immunity. Continuing viral replication in RHDV-vaccinated or in RHDV-infected, but 
surviving rabbits have been reported. Severe clinical courses of the disease or even a RHDV 
infection induced mortality in vaccinated rabbits was rarely observed (Plana Duran et al., 
1996; Guo et al., 2016). 
The immunogenicity measured by the induced VP60 specific serum antibody titers showed no 
significant differences between both recombinant vaccines (BacBac-A or BacMam-A). The 
differences in the induction of specific anti-RHDV-2 serum antibodies by “convRHDV2-
vacc” indicated a higher amount of either VP60 or of additional viral components. The 
comparable antigen titers in all vaccines determined by the HA test only quantifies the 
amount of VLP or viral particles in the vaccine. Further, VP60-derived antigenic structures 
could also induce VP60 specific antibodies after vaccination. Whether such antibodies 
provide an antiviral activity after infection is not clear. This was also measured in several 
other studies were a strong induction of RHDV specific serum antibodies was especially 
measured after vaccination with comparable conventionally prepared vaccines (Laurent et al., 
1994; Plana-Duran et al., 1996; Fernández-Fernández et al., 2001).  
The overall strong CD8+ T-cell activation by the recombinant RHDV-2 vaccines could be an 
advantage for an early effective protection against RHDV-2, because surviving non-
vaccinated rabbits display also a very strong CD4+ and CD8+ T-cell activation. T-cell 
activation was confirmed before for the recombinant RHDV-1-VP60 vaccine candidates as 
well as for liver-derived vaccines. However, no differentiation between CD4+ and CD8+ T-
cells was made, whereas a general advantage of recombinant vaccine candidates over 
conventional vaccines in the stimulation of T-cell effector mechanisms also has to be further 
investigated (Guo et al., 2016). 
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As expected, the anti-RHDV-1 vaccine “Cunivak RHD” was not able to induce a sufficient 
protective immune response against RHDV-2 challenge in once immunized rabbits. The 
severe clinical symptoms and the induced mortality clearly showed that the induced  
anti-RHDV-1 antibodies were not able to efficiently neutralize RHDV-2. Furthermore, that 
vaccination did not appear to strengthen innate immune mechanisms. However, twice 
vaccinated rabbits survived without detectable clinical symptoms but with still measureable 
viral load (RHDV-2 RNA) in livers sampled 14 days post infection. This indicates that an 
only partial cross-protection was induced by prime-boost vaccination with the anti-RHDV-1 
“Cunivak RHD” vaccine. The molecular basis of a possible cross-protection was analyzed 
after the emergence of the new RHDV-2 virus by comparative analysis of the VP60 of 
different RHDV strains. In 7 hypervariable regions distributed over the VP60 protein 
remarkable differences were detected. Using specific monoclonal antibodies against different 
RHDV variants, possible cross-reactive epitopes were also defined (Le-Gall Reculé et al., 
2013). Very recently, it was found that the RHDV-1 strain K5 was able to break the immunity 
induced in wild rabbits that survived an infection with the Czech RHDV-1 strain V351 in 
Australia (www.pestsmart.org.au). This is a first hint of a necessary continued adaptation of 
anti-RHDV vaccines to recent circulating virus variants. 
In summary, both newly developed recombinant RHDV-2 vaccine candidates (BacBac-A; 
BacMam-A) were able to induce an efficient protection against RHDV-2 infection. This 
reflects the high immunogenicity of these recombinant RHDV-2 vaccines due to the high 
content of self-assembled VLPs. Furthermore, it reassures the expectation from former studies 
that an immunization using recombinant RHDV-1-VP60 vaccines induced a protection, 
especially when a self-assembly of the expressed VP60 to VLPs was detected (Laurent et al., 
1994; Plana-Duran et al., 1996; Gao et al., 2013). 
 
7.3.2. General findings in “non-vaccinated” or in “recbacGFP” vaccinated rabbits   
To assess the protective potential of the newly established vaccine in more detail a 
comparative analysis with non-vaccinated animals was necessary. For the recombinant 
RHDV-2-VP60 vaccines a further control was used, especially to determine the possible 
influence of recombinant baculovirus particles itself. 
After analyzing the clinical course of the disease in non-vaccinated control animals (24 
rabbits), the fast acting character of the disease was confirmed. The total mortality in this 
study with 21 of 24 (=88%) non-vaccinated, i.m. infected rabbits was even higher than 
described in a comparatively study earlier (Le Gall-Reculé et al, 2013). There in 3 
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experiments 5 of 12 (=42%) i.m. infected rabbits died. The high mortality in the present study 
might be induced by a higher challenge dose but also indicates the differences in virulence of 
different RHDV-2 strains.  
The severe character of the induced RHD after infection with RHDV-2 is also proofen by the 
very short mean survival time of just 41 hours after infection, with displaying typical 
symptoms of RHD, prominent severe pathological alterations in inner organs, high viral loads 
in the liver and depletion of leukocytes in these 21 rabbits that died after infection. Similar 
findings are described for RHDV-1 or RHDV-2 in non-vaccinated rabbits (Prieto et al., 2000; 
Ferreira et al., 2006; Abrantes et al., 2012; Le Gall-Reculé et al., 2013). The survival time is 
too short to expect a humoral antibody response in sera of rabbits which died after infection 
very quickly. However, the cellular immune response or better the influence of the infection 
on the leukocytes was measured in different studies (Ferreira et al., 2005, 2006). Similar to 
the reported results a quick and severe depletion after an initial increase of both CD4+ and 
CD8+ T-cell populations were measured in this study in non-vaccinated rabbits which died 
after infection. Especially the CD8+ T-cells were not measurable in about 50% of all 
investigated rabbits shortly before death, indicating (a) the impact of RHDV induced 
pathological processes of this cell population and (b) a possible involvement in protective 
immune responses in naïve rabbits which survive. The depletion of both T-cell populations 
was shown to be related to apoptosis and one reason of the very rapid fatal progress with high 
mortality after RHDV infection in naïve rabbits (Ferreira et al., 2006). 
A completely different picture was seen in the three surviving, non-vaccinated rabbits. 
Although 2 of 3 reacted with high fever, all three finally survived after displaying mild 
clinical signs but with no pathological alterations in organs sampled 14 days post infection.  
These rabbits displayed a more effective cellular immunity after challenge infection. The 
complete depletion of CD8+ T-cells as found in moribund rabbits was not observed and 
especially CD4+, CD8+ T-cells, which display the regulatory phenotype, were increased in all 
three surviving animals. A similar response was reported in rabbits surviving a RHDV-1 
infection which had significantly increased interferon (IFN) γ levels in the liver. Finally, an 
early activation of B- and T-cell and macrophages as well as pro-inflammatory cytokines like 
IFNα and IFNγ, as is seen in young RHDV-1 resistant rabbits (Ferreira et al., 2005; Marques 
et al., 2012) could have been induced also in naïve rabbits surviving the RHDV-2 challenge 
infection in this study. This would explain the significantly decreased viral load, especially 
the very low HA titers, indicating that the replication of RHDV-2 is blocked. 
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A further difference, which is discussed for resistant rabbits, is a different HBGA pattern 
resulting in a lower susceptibility of host cell populations in the liver. Therefore, the infection 
of such cells is less effective or impossible which would result in a much lower replication 
level in the whole organ (Nyström et al., 2011; Le Pendu et al., 2014). The lower infection 
pressure would allow activating necessary immune mechanisms and would result in decreased 
damage of liver tissue. This was exactly found in naïve rabbits surviving the infection. 
Because of the similar induction of a protective humoral anti-RHDV-2 immune response, the 
“BacBac-A” SF9 cell-derived vaccine (further referred to as “recRHDV2-vacc”) was used in 
all following experiments to characterize the onset, duration or cross-protection. 
 
7.3.3. Determination of minimal protective vaccine dose 
To determine the minimal protective dose three different doses of “recRHDV2-vacc” were 
used for single vaccinations of rabbits followed by a challenge infection 14 days later. The 
high potency of “recRHDV2-vacc” was demonstrated by the fact that even the rabbits 
vaccinated with the lowest dose of 256 HU developed high titers of RHDV-2-VP60 specific 
antibodies and survived the challenge infection without any clinical signs and without 
detectable viral replication in liver. This correlates with previous studies where rabbits 
vaccinated with comparable low doses of either inactivated RHDV virus or recombinant 
VP60 expressed by recombinant baculoviruses (Argüello-Villares, 1991; Smíd et al., 1991; 
Laurent et al, 1994; Nagesha et al., 1995) survived following challenge infections.  
Whether even a lower dose would have induced similar protection was not tested. 
Interestingly, the induced titers of RHDV-2-VP60 specific antibodies did not correlate 
directly with the used vaccine dose as reported for RHDV-1-VP60 (Marín et al., 1995; Plana-
Duran et al., 1996). As mentioned above, the increased number of CD4+ as well as CD8+ T-
cells in the blood of immunized rabbits shortly after immunization indicated that also the 
cellular immune response was stimulated possibly explaining why also low vaccine doses are 
able to protect rabbits. The involvement of T-cells in the protective immunity against RHDV 
was recently confirmed in studies with mice after intranasal or intramuscular vaccination 
(Farnós et al., 2006), and in infection trials with rabbits (Guo et al., 2016) where an induction 
of IFNγ and IL-4 production has been shown as soon as 7 days post vaccination. 
A dose of 256 HU of the “recRHDV2-vacc” was able to induce full protection against the 
RHDV-2 challenge infection, although the antibody response was comparably low. Therefore, 
to ensure that the antibody titer is high enough for the investigation of onset, duration and 
possible cross-protection a dose of 1024 HU “recRHDV2-vacc” was chosen. The dose of 512 
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HU of the “convRHDV2-vacc” was selected because this is also the dose used in the 
commercial anti-RHDV-1 vaccine “Cunivak RHD”. 
 
7.3.4. Onset of protection after vaccination 
Vaccination against pathogens with a rapid progress of the disease requires an early onset of 
protective immunity. This is especially necessary in case of epidemic spread of a virus in 
susceptible host populations (Elnekave et al., 2015; Piontkowski et al., 2016). To test the 
onset of protective immunity after a single vaccination, rabbits were infected with RHDV-2 
seven days after vaccination. The survival of all vaccinated rabbits indicated that early 
protective immunity had been induced by “recRHDV2-vacc”. Furthermore, because no 
clinical signs were found in vaccinated rabbits after challenge infection in contrast to non-
vaccinated rabbits, which died, this induced immunity seems to inhibit the productive 
infection of RHDV at this early time point. This was also seen after vaccination with 
“convRHDV2-vacc”. Such early protection after vaccination with recombinant VP60 was 
reported before after vaccination with a recombinant baculovirus-derived RHDV-1-VP60 
vaccine as already 5 days after a single vaccination most rabbits were protected against 
RHDV-1 infection (Laurent et al., 1994).  
Conventional RHDV-1 vaccines induce a humoral protective immune response from day 4-5 
after vaccination which is claimed to be effective enough to protect rabbits from illness and 
death (Argüello-Villares, 1991; Smíd et al., 1991). Whether innate resistance related immune 
mechanisms like type I IFN-mediated antiviral activity are also induced by recombinant 
RHDV vaccines is unknown.  
Interestingly, at the timepoint of challenge only low antibody titers were measured in 
vaccinated rabbits which indicates an involvement of other early immune mechanisms (like 
type I interferon or IFNγ induced resistance or early activation of T-cells) which was not 
measured in the present study. An induction of IFNγ and IL-4 has been shown as soon as 7 
days post vaccination in rabbits immunized with RHDV-1-VP60-VLPs and liver-derived 
RHDV-1 vaccines (Guo et al., 2016). The resistance of young rabbits against RHDV seems to 
be correlated with elevation of pro-inflammatory cytokines (TNF-α, IL-1, IFN-α, IFN-γ, IL-6, 
IL-8) (Marques et al., 2012).  
An induction of interferons after vaccination with baculovirus alone (as negative control for 
recombinant baculovirus-derived RHDV vaccines) has been discussed (Gronowski et al., 
1999). However, the fatal outcome of RHDV challenge infection of rabbits vaccinated with 
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“recbacGFP-vacc” alone in this study does not indicate any influence of an innate, IFN-based 
unspecific resistance against RHDV in the liver as main target organ. 
It is not yet clear whether early, so called natural antibodies of IgM isotype (Holodick et al., 
2017) might be stimulated and involved in early protection against RHDV infection, but IgM 
was detected in young rabbits after infection with apathogenic RCV (Capucci et al., 1997).  
 
7.3.5. Duration of anti-RHDV-2 immunity after vaccination 
One very important parameter of a good vaccine is the induction of a long-lasting immunity 
without the need of repeated booster vaccination (Castellino et al., 2009).  
In this study, all vaccinated rabbits were completely protected 6 months after vaccination, 
independent of a prime or prime-boost vaccination scheme, and neither clinical signs of RHD 
nor indications for viral replication were found. Interestingly, although about 5 weeks after 
the second vaccination the titers were much higher in prime-boost vaccinated than in just 
single-shot vaccinated rabbits. These higher RHDV-2 specific antibody titers did not last over 
6 months. The influence of the time schedule for prime-boost vaccinations was investigated in 
detail in studies where rabbits served as models for human diseases. It was demonstrated that 
a too early second vaccination could end up in an unwanted reduction of serum antibody titers 
late after vaccination (Radaelli et al., 2003; Vaine et al., 2008). 
A completely different outcome after challenge was seen 14 months after vaccination, where 
all prime vaccinated rabbits completely survived, but the prime-boost vaccinated rabbits 
displayed mild to severe clinical signs and one rabbit died after 36h. The boost vaccination 21 
days after the prime vaccination seemed to interfere with the developing antibody response 
most presumably due to a “catching” of VP60 specific antibodies induced by the first 
vaccination. A premature second vaccination might influence the development of higher 
antibody titers or the formation of long-lasting B-cell memory (Radaelli et al., 2003; Vaine et 
al., 2008). A comparable effect was reported in rabbits vaccinated with a conventional 
vaccine where the induced anti-RHDV-antibody titers decrease already 3 months after 
vaccination (Argüello-Villares, 1991). Similar findings were reported for recombinant 
RHDV-1 vaccines where a booster vaccination three weeks after the first immunization did 
not induce an increase of RHDV specific antibodies (Farnós et al., 2009; Fernández et al., 
2011).    
Whereas the protection against RHDV-2 14 months after vaccination seems to be dependent 
on the presence of specific anti-RHDV-2 antibodies, the situation 6 months after vaccination 
seems to be different. One rabbit did not have detectable RHDV-2 specific antibody titers  
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6 months after prime-boost vaccination but survived a RHDV-2 infection without clinical 
symptoms. This survival could be a result of a quick activation of memory B-cells and by 
activation of CD8+ T-cells followed by strongly elevated IFNγ levels resulting in resistance 
against the challenge infection (West and Calandra, 1996).  
As expected, after challenge infection the antibody titers increased even further. The very 
effective biological activity of a humoral immune response induced by a RHDV infection was 
also seen in the group of rabbits which were challenged already after 7 days post prime 
vaccination. These rabbits were kept for 14 months after the vaccination/challenge infection 
to evaluate the impact of a RHDV-2 infection shortly after vaccination on long-term 
protection. After the second challenge infection they were also completely protected from 
disease and showed no sign of viral replication. In contrast to only vaccinated rabbits, these 
animals displayed a stronger increase of antibody titers after the first challenge. The sharp 
increase of RHDV specific antibodies after infection confirmed earlier studies with 
recombinant vaccines (Plana-Duran et al., 1996). However, for some conventional vaccines 
this was not the case (Argüello-Villares, 1991).  
As seen in surviving, non-vaccinated rabbits, a RHDV-2 infection led to a strong stimulation 
of the cellular immune system, which should be also stimulated in vaccinated rabbits after 
challenge. Hence those rabbits were still protected after 14 months although the circulating 
antibodies induced by vaccination were apparently partly consumed already after the first 
challenge infection shortly after vaccination. A strong and reliable cellular immunity in 
combination with the formation of long-living B-memory cells that convey lifelong protection 
against RHD is also seen in rabbits that survived a RHDV infection (Patton, 1989; Ferreira et 
al., 2005; Marques et al., 2012).  
In summary, the long-lasting immunity is mainly based on circulating RHDV specific 
antibodies. Whether the booster vaccination 3 weeks after the first one interferes negatively 
with the induced humoral immune response might also depend on the used adjuvants and on 
the vaccination route which was different in most cited studies. 
Generally, the protective immunity after RHDV vaccination lasts at least 12 months. This was 
comparable after vaccination with “convRHDV2-vacc” and also seen in RHDV-1 vaccines 
(either for recombinant vaccine candidates or conventional liver-derived vaccines) after 
subcutaneous or intramuscular administration (Argüello-Villares, 1991; Farnós et al., 2009; 
Fernández et al., 2011).  
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7.3.6. Cross-protection against RHDV-1 after vaccination against RHDV-2 
Since a vaccination with “recRHDV2-vacc” proved to be protective against RHDV-2, cross-
protection against RHDV-1 was also tested. Rabbits infected with RHDV-1 two weeks after 
RHDV-2 vaccination were only partially protected as about 50% of the rabbits died. In liver 
samples of surviving rabbits the viral load (viral RNA, viral proteins and particles) was 
measured 14 days after challenge infection. Comparable results were seen in rabbits after 
vaccination with “convRHDV2-vacc”. Similar results were found after vaccination with 
conventional anti-RHDV-1 vaccine “Cunivak RHD”, where only a partial cross-protection 
against RHDV-2 was induced after a single vaccination. However, a prime-boost vaccination 
with “Cunivak RHD” conveyed full cross-protection against RHDV-2 (this thesis and Dr. M. 
Müller, IDT, personal communication).  
Development of cross-protective anti-RHDV-1 antibodies against RHDVa after a single or 
double vaccination with baculovirus-derived RHDV-1-VP60 has been shown whereas 
vaccination with a conventional liver-derived vaccine could not always induce high anti-
RHDVa titers (Farnós et al., 2009; Fernández et al., 2011). However, cross-protection of 
conventional RHDV-1 vaccines against RHDVa has been confirmed (Schirrmeier et al., 
1999). This could be explained by the low genetic divergence between RHDV-1 and RHDVa 
whereas there is a greater genetic distance between RHDV-1 and RHDV-2 (Capucci et al., 
1998; LeGall-Reculé et al., 2013). As is described, cross-protectivity occurs also under 
natural conditions between different RHDV variants. Non-virulent virus strains are able to 
convey cross-protection in rabbits, e.g. in Australia where the non-pathogenic Australian 
strain RCV-A1 induced partial cross-protection in rabbits against the virulent RHDV-1 which 
was released into the wild to decimate rabbit populations, and therefore RCV-A1 interfered 
with the reduction of rabbits (Strive et al., 2009). Because there is constant adaptation of 
RHDV strains it is likely that new RHDV variants will appear in the future. Thus, it may be 
necessary to constantly adapt RHDV vaccines.  
In conclusion, the data shown in this present study confirm that the newly established 
recombinant vaccine based on RHDV-2-VP60 not only protects rabbits after a single 
vaccination against clinical signs and death caused by RHDV-2 but also reduces viral 
replication to a minimum level and therefore seems to restrict viral shedding. During these 
studies two phenomena occurred that still need clarification though. Rabbits that received a 
second immunization 3 weeks after the first were less protected against RHDV-2 14 months 
after vaccination than rabbits that received a single immunization. So, further characterization 
of the differences in the immune responses of those two groups needs to be done. Another 
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question that needs to be addressed is the ability of the vaccine to protect rabbits younger than  
12 weeks. As RHDV-2 affects rabbits from 4 weeks of age, it needs to be examined further if 
the vaccine is able to induce protection also in such young animals or if reactions of the innate 
immune system or maternal anti-RHDV-1 or anti-RHDV-2 antibodies transmitted by 
vaccinated mothers would interfere with the vaccine. 
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8. Summary 
The calicivirus Rabbit hemorrhagic disease virus (RHDV) causes the Rabbit hemorrhagic 
disease in rabbits. RHDV emerged 1984 in angora rabbits in China. In the following years it 
spread to many parts of the world resulting in huge losses among wild rabbit populations and 
rabbits used in fur and meat industry. It is a fatal disease to which rabbits from age of 9 weeks 
are fully susceptible. After an incubation period of 1-3 days, animals often develop high fever 
(>40°C) and die by acute liver failure and internal bleeding due to blood coagulation disorders 
(Abrantes et al., 2012). 2010 a new virus variant, called RHDV-2, emerged in France and is 
spreading through Europe at the moment. It causes the same clinical symptoms and 
pathological alterations as classical RHDV but also more prolonged clinical courses are 
described. The most important difference is, however, the susceptibility of rabbits from  
4 weeks of age, sometimes even younger, and susceptibility of different hare species. There is 
no cure and the only prevention of disease is vaccination of rabbits (Le Gall-Reculé et al., 
2013; Puggioni et al., 2013). An ethical problem is that most currently available conventional 
RHDV vaccines contain inactivated liver material-derived from RHDV infected rabbits and 
many rabbits have to die for vaccine development and production (Argüello-Villares, 1991). 
Conventional vaccines developed against classical RHDV only induce a partial protection 
against RHDV-2, which leads to significant economic problems in the fur and meat industry. 
Therefore, development of new vaccines against RHDV-2 is urgently necessary. Recently, 
vaccines against RHDV-2 came to economical use. However, these vaccines are also derived 
from livers of RHDV-2 infected rabbits.  
Thus, the goal of this study was to develop a vaccine candidate that protects rabbits against 
illness and death by RHDV-2 and to bypass the questionable use of liver material of infected 
rabbits for vaccine production at the same time. Therefore, the virus capsid protein VP60 of 
RHDV-2 was expressed in cell culture by recombinant baculoviruses which self-assembled to 
VLPs. A vaccine candidate against RHDV-2, containing VLPs consisting of RHDV-2-VP60, 
was generated, that after a single dose vaccination protects rabbits against RHDV-2. In 
detailed vaccination/challenge experiments the induction of a protective long-lasting humoral 
and cellular immune response with an early onset already 7 days after a single immunization 
and partial cross-protection against classical RHDV was confirmed.  
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9. Zusammenfassung 
Das Calicivirus Rabbit hemorrhagic disease virus (RHDV) ruft die „Rabbit hemorrhagic 
disease” in Kaninchen hervor. RHDV ist das erste Mal 1984 bei Angorakaninchen in China 
aufgetreten. In den darauffolgenden Jahren verbreitete es sich weltweit und verursachte hohe 
Verluste in wilden Kaninchenpopulationen und bei Kaninchen in der Pelz- und 
Fleischindustrie. Es ist eine tödlich verlaufende Krankheit, für die Kaninchen ab der  
9. Lebenswoche voll empfänglich sind. Nach einer Inkubationszeit von 1-3 Tagen entwickeln 
die Tiere oft hohes Fieber (>40°C) und sterben an akutem Leberversagen und inneren 
Blutungen aufgrund von Blutgerinnungsstörungen (Abrantes et al., 2012). 2010 tauchte eine 
neue Virusvariante, genannt RHDV-2, in Frankreich auf und verbreitet sich momentan in 
Europa. Es verursacht die gleichen klinischen Symptome und pathologischen Veränderungen 
wie die klassische RHDV Variante, allerdings sind auch langwierigere Verläufe beschrieben. 
Der größte Unterschied ist jedoch die Empfänglichkeit von Kaninchen ab der vierten 
Lebenswoche, manchmal sogar jünger, und von verschiedenen Hasenarten. Die Krankheit ist 
nicht heilbar und der einzige Schutz besteht darin, Kaninchen zu impfen  
(Le Gall-Reculé et al., 2013; Puggioni et al., 2013). Ein ethisches Problem ergibt sich aus der 
Verwendung von inaktiviertem Lebermaterial von mit RHDV infizierten Kaninchen für die 
Herstellung der meisten konventionell erhältlichen RHDV Vakzinen und dem Umstand, dass 
viele Kaninchen für die Impfstoffentwicklung und -herstellung sterben müssen  
(Argüello-Villares, 1991). Konventionelle Impfstoffe, entwickelt gegen klassisches RHDV, 
induzieren nur einen Teilschutz gegen RHDV-2, was zu erheblichen wirtschaftlichen 
Verlusten in der Pelz- und Fleischindustrie führt. Somit ist die Entwicklung von Impfstoffen 
gegen RHDV-2 dringend notwendig. Seit kurzem sind RHDV-2 Vakzinen auf dem Markt, 
welche jedoch ebenfalls mit Lebermaterial von infizierten Kaninchen hergestellt werden. Das 
Ziel der vorliegenden Arbeit war daher die Entwicklung eines Impfstoffkandidaten, der in der 
Lage ist, Kaninchen vor Erkrankung und Tod durch RHDV-2 zu schützen und gleichzeitig 
den fragwürdigen Einsatz von Lebermaterial infizierter Kaninchen in der Impfstoffherstellung 
zu umgehen. Daher wurde das Viruskapsidprotein VP60 von RHDV-2 in Zellkultur mithilfe 
rekombinanter Baculoviren exprimiert, welches sich dann selbstständig zu VLPs 
zusammenlagerte. Dieser rekombinante Impfstoff gegen RHDV-2, der VLPs aus RHDV-2-
VP60 enthält, schützt Kaninchen gegen RHDV-2. In verschiedenen Immunisierungs- und 
Challenge-Versuchen wurde die induzierte langanhaltende humorale und zelluläre 
Immunantwort, die bereits 7 Tage nach einmaliger Impfung eintritt und auch eine partielle 
Kreuzprotektivität gegen die klassische RHDV Variante erzeugt, bestätigt. 
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Suppl. 7. Gene sequences of the artificial genes of RHDV-2-VP60 with the different codon usage of “BHV-
1” or “AcMNPV” 
Name of the gene: RHDV-2_VP60_BHV1_Cod 
 
  BglII    EcoRI   NcoI 
CACTATAGGGCGAATTGAAGGAAGGCCGTCAAGGCCGCATAGATCTGAATTCCACCATGG 
1  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GTGATATCCCGCTTAACTTCCTTCCGGCAGTTCCGGCGTATCTAGACTTAAGGTGGTACC 
 
 
     BsmBI 
AGGGGAAGGCCCGCGCCGCGCCGCAGGGGGAGACGGCGGGCACGGCCACCACAGCCTCCG 
61  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TCCCCTTCCGGGCGCGGCGCGGCGTCCCCCTCTGCCGCCCGTGCCGGTGGTGTCGGAGGC 
 
   
 SmaI                                          AatII 
TCCCGGGCACGACCACGGACGGGATGGACCCCGGCGTGGTCGCGACGACGTCGGTGGTGA 
121  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AGGGCCCGTGCTGGTGCCTGCCCTACCTGGGGCCGCACCAGCGCTGCTGCAGCCACCACT 
 
 
PflMI    
          BspMI 
            BtgZI                                   AarI  
CGACCGAAAATGCTTCCACCAGCATCGCGACCGCCGGTATCGGCGGCCCTCCCCAGCAGG 
181  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCTGGCTTTTACGAAGGTGGTCGTAGCGCTGGCGGCCATAGCCGCCGGGAGGGGTCGTCC 
 
 
BsmBI 
TGGACCAGCAGGAGACGTGGCGGACGAACTTCTACTACAACGACGTGTTCACTTGGAGCG 
241  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACCTGGTCGTCCTCTGCACCGCCTGCTTGAAGATGATGTTGCTGCACAAGTGAACCTCGC 
 
 
TGGCAGACGCGCCAGGGAACATTCTGTACACTGTGCAGCACAGCCCTCAGAACAACCCGT 
301  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACCGTCTGCGCGGTCCCTTGTAAGACATGTGACACGTCGTGTCGGGAGTCTTGTTGGGCA 
 
 
TTACGGCGGTCCTGTCGCAGATGTACGCTGGATGGGCCGGCGGGATGCAGTTCCGGTTTA 
361  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AATGCCGCCAGGACAGCGTCTACATGCGACCTACCCGGCCGCCCTACGTCAAGGCCAAAT 
 
 
             EagI              SmaI 
TCGTCGCGGGATCTGGCGTGTTTGGCGGACGCCTGGTGGCGGCCGTGATCCCGCCCGGGA 
421  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AGCAGCGCCCTAGACCGCACAAACCGCCTGCGGACCACCGCCGGCACTAGGGCGGGCCCT 
 
 
TTGAGATCGGCCCCGGCCTAGAGGTTCGGCAGTTCCCGCACGTGGTAATTGACGCCCGCA 
481 ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AACTCTAGCCGGGGCCGGATCTCCAAGCCGTCAAGGGCGTGCACCATTAACTGCGGGCGT 
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    BspMI 
GTCTGGAGCCGGTGACGATTACGATGCCGGACCTGCGACCGAACATGTACCATCCGACGG 
541  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CAGACCTCGGCCACTGCTAATGCTACGGCCTGGACGCTGGCTTGTACATGGTAGGCTGCC 
 
 
GCAACCCTGGGCTGGTGCCCACCCTGGTGCTGTCCGTGTATAACAACCTGATTAACCCCT 
601  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CGTTGGGACCCGACCACGGGTGGGACCACGACAGGCACATATTGTTGGACTAATTGGGGA 
 
 
  BsmBI 
TCGGAGGCAGTACCAGCGCCATCCAGGTGACGGTGGAGACGCGGCCCAGCGAGGACTTCG 
661 ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AGCCTCCGTCATGGTCGCGGTAGGTCCACTGCCACCTCTGCGCCGGGTCGCTCCTGAAGC 
 
 
  SalI   
  HincII 
         ApaI                 AccI   
AGTTTGTGATGATCCGGGCCCCGTCGAGCAAGACCGTCGACAGCATCAGCCCGGCGGACC 
721  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TCAAACACTACTAGGCCCGGGGCAGCTCGTTCTGGCAGCTGTCGTAGTCGGGCCGCCTGG 
 
 
TCCTGACGACGCCCGTGCTTACTGGGGTGGGGACGGACAACCGCTGGAACGGGGAGATTG 
781  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AGGACTGCTGCGGGCACGAATGACCCCACCCCTGCCTGTTGGCGACCTTGCCCCTCTAAC 
 
 
TGGGCTTGCAGCCCGTCCCTGGCGGTTTCTCGACATGCAACCGGCACTGGAACCTTAACG 
841  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACCCGAACGTCGGGCAGGGACCGCCAAAGAGCTGTACGTTGGCCGTGACCTTGGAATTGC 
 
 
   SalI                                    
   HincII                                  
   AccI                       SacI                 PvuI 
GGTCGACGTTTGGCTGGAGCTCCCCGCGCTTCGCTGCGATCGACCACGATAGGGGCAACG 
901  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CCAGCTGCAAACCGACCTCGAGGGGCGCGAAGCGACGCTAGCTGGTGCTATCCCCGTTGC 
 
 
    XhoI                        XhoI 
CCTCGTACCCTGGCTCGAGCAGCAGCAACGTCCTCGAGTTGTGGTACGCGAGCGCGGGGT 
961  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GGAGCATGGGACCGAGCTCGTCGTCGTTGCAGGAGCTCAACACCATGCGCTCGCGCCCCA 
 
 
EagI 
CGGCCGCCGACAACCCCATCTCTCAGATCGCCCCGGACGGCTTCCCGGATATGAGCTTTG 
1021  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCCGGCGGCTGTTGGGGTAGAGAGTCTAGCGGGGCCTGCCGAAGGGCCTATACTCGAAAC 
 
 
TGCCGTTCTCGGGGACAACGGTCCCGACGGCGGGCTGGGTTGGCTTCGGGGGCATCTGGA 
1081  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACGGCAAGAGCCCCTGTTGCCAGGGCTGCCGCCCGACCCAACCGAAGCCCCCGTAGACCT 
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  BssHII                           
AscI                                       BsiWI 
ACAGCAACAACGGCGCGCCGTTCGTCACCACGATGCAGGCGTACGAGCTGGGCTTTGCCA 
1141  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TGTCGTTGTTGCCGCGCGGCAAGCAGTGGTGCTACGTCCGCATGCTCGACCCGAAACGGT 
 
 
      BssHII 
CTGGCGCACCTAGCAATCCCCAGCCCACGACCACCACGAGCGGCGCGCAGATCGTGGCCA 
1201  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GACCGCGTGGATCGTTAGGGGTCGGGTGCTGGTGGTGCTCGCCGCGCGTCTAGCACCGGT 
 
 
              EagI 
AGAGTATCTACGGTGTGGCCACGGGGATCAACCAGGCGGCGGCCGGCTTATTCGTGATGG 
1261 ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TCTCATAGATGCCACACCGGTGCCCCTAGTTGGTCCGCCGCCGGCCGAATAAGCACTACC 
 
 
CGTCCGGCGTCATCTCTACGCCGAACTCGTCGGCCATCACGTACACGCCCCAACCGAACC 
1321  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCAGGCCGCAGTAGAGATGCGGCTTGAGCAGCCGGTAGTGCATGTGCGGGGTTGGCTTGG 
 
 
    SmaI          EagI 
GTATTGTGAACGCCCCGGGCACCCCGGCCGCCGCGCCCGTGGGCAAGAACACCCCAATCA 
1381  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CATAACACTTGCGGGGCCCGTGGGGCCGGCGGCGCGGGCACCCGTTCTTGTGGGGTTAGT 
 
 
TGTTCGCGTCGGTCGTGCGGCGCACCGGGGACATCAACGCGGAGGCAGGCAGTGCCAACG 
1441  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACAAGCGCAGCCAGCACGCCGCGTGGCCCCTGTAGTTGCGCCTCCGTCCGTCACGGTTGC 
 
 
GTACGCAGTACGGCGCGGGCAGCCAGCCGTTGCCCGTGACCGTCGGGCTCTCGCTGAACA 
1501  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CATGCGTCATGCCGCGCCCGTCGGTCGGCAACGGGCACTGGCAGCCCGAGAGCGACTTGT 
 
 
     SrfI                        
       SmaI                PvuII 
ATTACAGCTCCGCGCTCATGCCCGGGCAATTTTTCGTCTGGCAGCTGAACTTTGCCTCCG 
1561  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TAATGTCGAGGCGCGAGTACGGGCCCGTTAAAAAGCAGACCGTCGACTTGAAACGGAGGC 
 
 
          NarI 
          KasI 
GGTTCATGGAATTGGGTCTATCGGTGGACGGGTACTTTTACGCAGGGACGGGCGCCAGCG 
1621  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CCAAGTACCTTAACCCAGATAGCCACCTGCCCATGAAAATGCGTCCCTGCCCGCGGTCGC 
 
 
        SalI                  
        HincII                
        AccI                       ApaI 
CAACGCTGATCGACCTCAGCGAGCTGGTCGACATCCGCCCCGTGGGCCCTCGCCCGAGCA 
1681 ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GTTGCGACTAGCTGGAGTCGCTCGACCAGCTGTAGGCGGGGCACCCGGGAGCGGGCTCGT 
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        KpnI                              EcoRI 
CGTCCACGCTGGTGTACAATCTGGGCGGTACCACGAACGGGTTTAGCTACGTATAGAATT 
1741  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCAGGTGCGACCACATGTTAGACCCGCCATGGTGCTTGCCCAAATCGATGCATATCTTAA 
 
 
  HindIII 
CAAGCTTCTGGGCCTCATGGGCCTTCCTTTCACTGCCCGCTTTCCAG 
1801  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GTTCGAAGACCCGGAGTACCCGGAAGGAAAGTGACGGGCGAAAGGTC 
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Name of the gene: RHDV-2_VP60_AcMNPV 
 
 BglII    EcoRI           NcoI 
CACTATAGGGCGAATTGAAGGAAGGCCGTCAAGGCCGCATAGATCTGAATTCCACCATGG 
1 ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GTGATATCCCGCTTAACTTCCTTCCGGCAGTTCCGGCGTATCTAGACTTAAGGTGGTACC 
 
 
AGGGCAAAGCCCGCGCGGCACCGCAAGGAGAAACGGCGGGTACGGCCACAACAGCGAGTG 
61 ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TCCCGTTTCGGGCGCGCCGTGGCGTTCCTCTTTGCCGCCCATGCCGGTGTTGTCGCTCAC 
 
 
              SmaI 
TGCCTGGCACCACCACCGACGGTATGGACCCGGGAGTGGTGGCTACCACCTCGGTTGTAA 
121  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACGGACCGTGGTGGTGGCTGCCATACCTGGGCCCTCACCACCGATGGTGGAGCCAACATT 
 
 
  PflMI    
          BspMI 
                  NheI                PvuII                                AarI  
CGACGGAAAACGCTAGCACTTCGATTGCCACAGCTGGTATTGGAGGACCGCCCCAGCAGG 
181 ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCTGCCTTTTGCGATCGTGAAGCTAACGGTGTCGACCATAACCTCCTGGCGGGGTCGTCC 
 
 
TGGACCAGCAAGAAACTTGGCGAACGAATTTCTACTACAACGACGTATTTACTTGGTCAG 
241  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACCTGGTCGTTCTTTGAACCGCTTGCTTAAAGATGATGTTGCTGCATAAATGAACCAGTC 
 
 
      AccI 
TCGCGGATGCACCCGGCAACATATTGTATACAGTACAACACAGCCCTCAAAACAACCCCT 
301  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AGCGCCTACGTGGGCCGTTGTATAACATATGTCATGTTGTGTCGGGAGTTTTGTTGGGGA 
 
 
                    SphI 
TCACGGCAGTTTTATCGCAAATGTACGCTGGCTGGGCCGGTGGCATGCAATTTCGCTTTA 
361  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AGTGCCGTCAAAATAGCGTTTACATGCGACCGACCCGGCCACCGTACGTTAAAGCGAAAT 
 
 
                             BspMI                 BsmBI 
TTGTCGCAGGTAGCGGCGTTTTTGGTGGTCGTCTCGTTGCAGCCGTCATTCCCCCAGGCA 
421  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AACAGCGTCCATCGCCGCAAAAACCACCAGCAGAGCAACGTCGGCAGTAAGGGGGTCCGT 
 
 
            SrfI  
                  SmaI 
      ApaI    
TTGAAATAGGGCCCGGGCTGGAAGTGCGACAATTTCCGCATGTGGTGATTGATGCACGAA 
481  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AACTTTATCCCGGGCCCGACCTTCACGCTGTTAAAGGCGTACACCACTAACTACGTGCTT 
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GTTTGGAACCTGTAACGATCACTATGCCCGATTTACGCCCCAACATGTACCACCCCACAG 
541  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CAAACCTTGGACATTGCTAGTGATACGGGCTAAATGCGGGGTTGTACATGGTGGGGTGTC 
 
 
PacI               PflMI 
GCAATCCTGGCCTTGTACCAACGTTGGTTTTATCTGTGTATAATAATTTAATTAACCCAT 
601  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CGTTAGGACCGGAACATGGTTGCAACCAAAATAGACACATATTATTAAATTAATTGGGTA 
 
 
              SpeI 
TTGGTGGCTCAACTAGTGCTATCCAAGTGACTGTAGAAACGCGACCTTCAGAAGATTTTG 
661  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AACCACCGAGTTGATCACGATAGGTTCACTGACATCTTTGCGCTGGAAGTCTTCTAAAAC 
 
 
              BclI 
AATTTGTGATGATCAGAGCCCCCTCCTCTAAAACCGTCGATTCCATAAGTCCAGCCGACT 
721  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TTAAACACTACTAGTCTCGGGGGAGGAGATTTTGGCAGCTAAGGTATTCAGGTCGGCTGA 
 
 
    ScaI 
TGCTGACAACACCAGTACTTACGGGGGTGGGTACTGATAATCGCTGGAATGGCGAGATCG 
781  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACGACTGTTGTGGTCATGAATGCCCCCACCCATGACTATTAGCGACCTTACCGCTCTAGC 
 
 
            AgeI        SmaI 
TAGGATTACAACCGGTCCCGGGCGGATTTAGCACTTGTAATCGCCACTGGAATCTAAATG 
841  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ATCCTAATGTTGGCCAGGGCCCGCCTAAATCGTGAACATTAGCGGTGACCTTAGATTTAC 
 
 
         PvuI                SacII 
GCAGCACTTTTGGCTGGTCGAGTCCCAGATTTGCGGCGATCGACCATGACCGCGGAAATG 
901  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CGTCGTGAAAACCGACCAGCTCAGGGTCTAAACGCCGCTAGCTGGTACTGGCGCCTTTAC 
 
 
CGAGTTACCCCGGCTCTAGCTCCTCGAACGTGCTAGAATTGTGGTACGCTTCAGCCGGTA 
961  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCTCAATGGGGCCGAGATCGAGGAGCTTGCACGATCTTAACACCATGCGAAGTCGGCCAT 
 
 
GTGCTGCGGACAACCCTATAAGTCAAATAGCTCCTGACGGCTTTCCTGATATGTCATTTG 
1021  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CACGACGCCTGTTGGGATATTCAGTTTATCGAGGACTGCCGAAAGGACTATACAGTAAAC 
 
 
TGCCCTTTTCGGGAACTACCGTTCCTACGGCAGGGTGGGTGGGATTCGGCGGCATTTGGA 
1081  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACGGGAAAAGCCCTTGATGGCAAGGATGCCGTCCCACCCACCCTAAGCCGCCGTAAACCT 
 
 
ACTCTAACAACGGCGCTCCGTTTGTCACAACGATGCAAGCATACGAACTGGGCTTCGCCA 
1141  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TGAGATTGTTGCCGCGAGGCAAACAGTGTTGCTACGTTCGTATGCTTGACCCGAAGCGGT 
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CGGGCGCTCCCTCGAACCCCCAACCGACGACCACTACCTCTGGTGCCCAAATTGTTGCGA 
1201  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCCCGCGAGGGAGCTTGGGGGTTGGCTGCTGGTGATGGAGACCACGGGTTTAACAACGCT 
 
 
            AgeI 
AAAGCATTTACGGCGTAGCGACCGGTATCAACCAAGCCGCTGCCGGCTTATTTGTTATGG 
1261  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TTTCGTAAATGCCGCATCGCTGGCCATAGTTGGTTCGGCGACGGCCGAATAAACAATACC 
 
 
CGAGTGGCGTGATTTCTACACCGAACAGTAGTGCGATAACGTACACTCCGCAACCGAACC 
1321  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GCTCACCGCACTAAAGATGTGGCTTGTCATCACGCTATTGCATGTGAGGCGTTGGCTTGG 
 
 
              HincII                             PvuII 
GCATCGTTAACGCACCTGGTACGCCCGCAGCTGCCCCAGTTGGCAAAAACACTCCAATCA 
1381  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CGTAGCAATTGCGTGGACCATGCGGGCGTCGACGGGGTCAACCGTTTTTGTGAGGTTAGT 
 
 
TGTTTGCCTCGGTGGTGCGTAGAACCGGAGACATTAACGCTGAAGCCGGTAGCGCCAACG 
1441  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
ACAAACGGAGCCACCACGCATCTTGGCCTCTGTAATTGCGACTTCGGCCATCGCGGTTGC 
 
 
               BstEII 
GGACACAATACGGCGCTGGCTCTCAACCGTTGCCGGTGACCGTTGGACTTTCATTGAACA 
1501  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CCTGTGTTATGCCGCGACCGAGAGTTGGCAACGGCCACTGGCAACCTGAAAGTAACTTGT 
 
 
ATTATAGTTCCGCATTGATGCCGGGCCAGTTTTTTGTCTGGCAATTGAACTTTGCATCTG 
1561  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
TAATATCAAGGCGTAACTACGGCCCGGTCAAAAAACAGACCGTTAACTTGAAACGTAGAC 
 
 
      BsaI                                      BspMI 
GTTTCATGGAATTGGGTCTCTCGGTGGATGGCTATTTTTATGCAGGTACAGGAGCCAGCG 
1621  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
CAAAGTACCTTAACCCAGAGAGCCACCTACCGATAAAAATACGTCCATGTCCTCGGTCGC 
 
 
CTACCTTAATTGATCTATCGGAACTGGTGGACATTCGTCCAGTTGGACCCCGGCCTTCTA 
1681  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GATGGAATTAACTAGATAGCCTTGACCACCTGTAAGCAGGTCAACCTGGGGCCGGAAGAT 
 
 
       KpnI                        BsiWI                EcoRI 
CATCGACTCTGGTTTATAATTTGGGCGGTACCACAAACGGGTTTTCGTACGTATAAGAAT 
1741  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
GTAGCTGAGACCAAATATTAAACCCGCCATGGTGTTTGCCCAAAAGCATGCATATTCTTA 
 
 
     HindIII 
TCAAGCTTCTGGGCCTCATGGGCCTTCCTTTCACTGCCCGCTTTCCAG 
1801  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
AGTTCGAAGACCCGGAGTACCCGGAAGGAAAGTGACGGGCGAAAGGTC
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